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Abstract 
Does surface neuromuscular electrical stimulation (sNMES) to the upper limb 
following acute stroke Improve outcome? 
Introduction: Upper limb impairment affects 85% of stroke patients, half of whom still 
experience problems three months later('-3). The literature is unclear about the effectiveness 
of upper limb rehabilitation strategies, and there is a need to identify interventions that will 
improve upper limb function and reduce the incidence of shoulder pain. Surface 
neuromuscular electrical stimulation (sNMES) has been proposed as a safe method of 
improving outcome after stroke but further research is needed to evaluate the effect of this 
(4.5) treatment on upper limb recovery and pain 
Aims: We have undertaken a randornised controlled trial to evaluate a programme of upper 
limb sNMES following acute stroke. 
Methods: Patients admitted within 10 days of acute stroke were assessed against the 
following eligibility criteria: new upper limb impairment (motor and/or sensory and/or 
neglect); medically stable; no cognitive/language impairments or previous upper limb 
problem likely to influence assessments; no contraindication to sNIVIES. Participants were 
randomised via an independent telephone randomisation service to receive a 4-week 
programme of upper limb sNIVIES (11 hour three times daily) or placebo in addition to stroke 
unit care. The active stimulator produced a shoulder shrug. Outcome measures were 
undertaken by a researcher who was blinded to the randomisation group. The primary 
outcome measure was the Action Research Arm Test (ARAT)(6,7) 3 months after stroke. 
Secondary outcome measures included upper limb pain, disability and health status. One 
hundred and sixty eight subjects were required for 80% power to detect a clinically 
significant difference in ARAT (8 points)(6,7). 
Results: There were 176 study participants. The groups were well matched at baseline. 
There was no difference in arm function between groups in terms of the primary outcome 
measure. The median ARAT (6,7) score at 3 months was 50.0 in the intervention group 
(n=79) and 55.5 in the control group (n=74) (p=0.068). There were however significant 
differences in outcomes in favour of the control group when using other measures to assess 
arm function (the grasp and gross subsections of the ARAT(6 . 7) , and the Frenchay Arm Test' 
(FAT)(8)). There was also a significant difference in favour of the control group when 
assessing impairment using the Arm subsection of the Motricity Index(g). There were no 
statistically significant differences between the groups at 3 months in terms of prevalence of 
upper limb pain, disability and global health status. No significant differences were seen 
between the groups at 4 weeks in any of the outcome measures. 
Secondary analysis revealed statistically significant differences in favour of the control group 
in those with more severe initial functional impairment. 
Subjects received 70% of intended stimulation or placebo with no significant difference 
between groups. 
Conclusions: A 4-week programme of sNMES to the shoulder does not improve functional 
outcome following acute stroke and may worsen arm function in certain stroke patients. 
'Routine' use of sNMES to the proximal upper limb after acute stroke cannot be 
recommended. 
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Chapter 1 Introduction 
1.1 Epidemiology 
Stroke is the third largest cause of death in the United Kingdom and is the commonest cause 
of severe adult disability(lo). Each year, 110 000 people in England and Wales have their 
first stroke, and 30 000 people have a recurrent stroke (11,12) . The prevalence of stroke and 
stroke-related disability rise with age (13,14) and the consequences to individuals and their 
families can be devastating(15,16). Stroke patients are major users of NHS and social services 
resources("). Stroke prevention and treatment is a national priority as addressed in the 
National Service Framework for Older People and the National Service Framework for 
(i 1,18) Coronary Heart Disease 
1.2 Recovery after stroke 
Movement depends upon multiple regions of the central nervous system, including the 
primary, supplementary and cingulate motor cortices, and premotor cortex. The subcortical 
and brainstern regions also play an important part. The sensorimotor regions of the central 
nervous system demonstrate activity-dependent plasticity which is seen both in normal 
learning and in response to cerebral injury(19). Plasticity, or cortical reorganisation, is defined 
as 'any enduring change in the cortical properties, either morphological or functional'(20). 
Reorganisation of the affected sensorimotor cortex occurs by a variety of mechanisms and is 
a major contributor to recovery after stroke. The specific neurological mechanisms that 
mediate the neuromuscular recovery process after a stroke are not completely understood. 
Substantial changes in neuronal circuits are seen adjacent or connected to the infarct, 
including dendritic and axonal sprouting, and stem cell responses. Dendritic sprouts also 
grow with normal learning and in both the contralesional and ipsilesional cortex in 
association with limb use in rodents (21,22) . Axonal sprouting occurs in response to a specific 
signal produced by ischaernic brain lesions. This sprouting after stroke occurs in both local 
and long distance connections and produces new projection patterns in the brain. It appears 
to play a role in functional recovery (23) . The stem cell response to cortical ischaernia results 
in proliferation, migration, and differentiation of new neurons into areas of damage adjacent 
to the stroke. Unlike axonal sprouting, there is no correlation between the post-stroke stem 
I 
cell response and functional outcome(19). Through these processes, adjacent brain remodels 
after stroke and creates entirely new systems of connections. 
Motor learning and re-learning occurs as a direct result of experience or practice i. e. activity- 
dependent plasticity. This occurs within cortical, subcortical and spinal levels of the 
neuroaxis. Repetitive exercise enhances or guides neuroplastic recovery processes after 
brain injury. The learning process is based on the constant plasticity of the nervous system, 
and requires afferent input to the central nervous system. The 'sensorimotor integration 
theory' postulates that the somatosensory cortex interacts extensively with the motor cortex 
during motor re-learning (24). Neural mechanisms in the cerebral cortex association areas 
integrate sensory and motor functions during the perception/action of executing voluntary 
purposeful movement. Animal studies have shown an enlargement of the motor cortical 
representation in monkeys subjected to rehabilitative training after experimental stroke in the 
motor cortex(2'). In addition, positron emission tomography (PET) and functional magnetic 
resonance imaging (fMRI) have been used to look at brain plasticity in relation to normal 
learning, and also at the reorganisation of functional representations in relation to recovery 
from cerebral injury e. g. stroke. The overuse or disuse of particular inputs has been shown 
to lead to an increase or decrease, respectively, of the corresponding cortical 
representations. 
1.3 The upper limb after stroke 
Patients with herniplegia often feel that therapy has concentrated upon mobility and 
discharge planning and that not enough attention has been paid to improving arm 
function (26). Upper limb impairment affects 85% of stroke patients, of whom 55-75% still 
experience problems 3-6 months laterý1-3). In contrast, around 80% of survivors will be able 
to walk again (27,28) . Poor upper limb function is an important adverse prognostic indicator for 
subjective well being(-") and is also associated with pain, particularly at the shoulder, which is 
reported by approximately 50-70% of patients at least once during the first six months after 
stroke (30.31) . Identifying effective programmes to improve upper limb function and reduce the 
frequency of shoulder pain remains a challenge for stroke rehabilitation services. 
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1.3.1. Shoulder pain 
Shoulder pain is a common complication of stroke and can result in limited functional use of 
the affected limb, compromised recovery, and delayed discharge from hospital. It has been 
shown to be a predictor of poor recovery of upper limb function following stroke (32) . The 
frequency of shoulder pain following stroke is reported to vary between 5 and 84%(33) . This 
variation probably reflects differences in study design and the difficulties in measuring and 
quantifying pain. 
The causes of shoulder pain following stroke are thought to be multifactorial. It appears that 
changes in anatomy which occur both in the flaccid and spastic stages following stroke may 
(33) contribute to pain through different mechanisms . In flaccid paralysis of 
the shoulder, 
weakness of the shoulder girdle muscles and gravitational pull tend to produce inferior 
subluxation(34). Also, weakness in the muscles effecting scapular and humeral rotation 
during elevation results in failure of the mechanisms which normally prevent impingement, 
increasing the risk of rotator cuff damage (35) . The weight of the unsupported arm may also 
cause traction damage to various nerves (36) - With the development of spasticity, 
supraspinatus tends to reduce inferior subluxation, although this may not occur if there has 
been permanent stretching or damage to the rotator CU035). Soft tissue damage from 
improper handling of the affected upper limb may contribute further to shoulder pain (37) . 
The incidence of pain is related to severity of weakness, and the likelihood of developing it 
increases over time. Abnormal upper limb sensation is also strongly predictive of the 
development of shoulder pain (38) . The association of subluxation and shoulder pain is 
complex and this is thought to be due to variations in measuring both subluxation and pain, 
and a failure to identify other causes of shoulder pain in study populations. It has been very 
difficult to identify cause and effeCt(39). 
The management of shoulder pain following stroke is often difficult because of the diverse 
and multifactorial aetiology of herniplegic shoulder pain (33,38,40). The use of slings and 
supports remains controversial (33,39) . Early passive movement has been shown to be 
beneficial in the prevention of immobility and soft tissue contracture (41 ). The evidence for the 
use of ES in treating and preventing hemiplegic shoulder pain will be discussed below. Oral 
analgesia has been shown to be of some benefit, as has the use of local injections e. g. 
nerve blocks, botulinurn toxin, although the use of local steroid injections is not 
recommended (33) . 
3 
1.4 Upper limb rehabilitation 
The World Health Organisation's International Classification of Impairment, Disability and 
Handicaps (WHO ICIDH) was published in 1980. This model of illness has 4 levels: 
pathology, impairment, disability and handicap (42) Pathology refers to the abnormal 
processes occurring within an organ or organ system, impairments are tile alrect 
consequences of the underlying pathology (i. e. symptoms and signs), disability is the 
functional consequence of any impairment, and handicap is the social consequence of the 
disease 
The above model has been updated by the World Health Organisation's International 
Classification of Functioning (WHO ICF)(43) published in 2001. The ICF describes illness in 
terms of impairments of body functions, impairments of body activities, activity limitations 
and participation restriction, environmental factors, and other contextual information. Both 
this model and the ICIDH provide frameworks within which the many aspects of ill health can 
be described. These models have been used to define rehabilitation. For example, Wade 
described rehabilitation as "a problem-solving and educational process aimed at reducing 
the disability and handicap experienced by someone as a result of a disease, always within 
the limitations imposed both by available resources and by the underlying disease"(44) . 
Epidemiological studies have shown that early physiotherapy and mobilisation after stroke is 
beneficial(45,46) 
. 
Three systematic reviews (45,47.48) suggested that early intensive stroke 
rehabilitation may be associated with enhanced and faster improvement of activities after 
stroke, and the intensity of repetitive training has been shown to facilitate motor recovery(49). 
There has, however, been some concern regarding early overuse after cerebral ischaemia in 
rodents, raised by experimental models(50). There is also animal data to suggest that, 
although early intensive intervention after ischaemia can improve functional outcome, it is 
accompanied by increased brain damage (51 ). This is thought to be due to increased 
glutamate release by damaged cells, but the relevance of these findings in humans is not 
known. In addition to the evidence surrounding greater intensity, repetitive training in upper 
limb rehabilitation, it is also clear that learning a skill requires feedback. Studies suggest 
(49,52) that task-orientated or task-specific practice is best for skills learning 
There are many interventions that aim to improve upper limb function following stroke but the 
literature is unclear about the effectiveness of many of them. Such interventions include 
intensive therapy programmes 
(48,49,5348), home based exercise programmes 
(57 - 58) 
, strategies 
to overcome non-use of the hemiplegic arm 
(52,59.60) 
, electromyographic biofeedback(61), and 
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electrical stimulation(- "). Intensive therapy programmes were shown to be beneficial in a 
study by Kwakkel(49), but not in studies by Lincoln(54) or Rodgers(55). Reviews of the literature 
have concluded that such programmes may be effective following stroke despite the fact that 
firm evidence of this is lacking(56). Home-based exercise programmes have been shown to 
be feasible but studies have not shown consistent benefits in terms of functional recoverY( 57, 
58). Strategies to overcome non-use of the affected upper limb, e. g. constraint therapy, have 
been shown to be of benefit in improving function, but they were small, single-centre studies 
(63) (52) and therefore prone to false-positive results . Also, in the study by van der Lee , the 
functional improvement was judged only to be of clinical benefit in those with sensory loss or 
neglect, and in Dromerick's study(59), the follow-up period was only 2 weeks and the 
improvement seen in function did not clearly translate into a benefit on ADLs. A 6-week 
programme of electromyographic biofeedback has been shown to improve upper limb 
function following stroke but this was not sustained 6 weeks after treatmenf, "). The 
evidence of the effect of ES on recovery following stroke will be discussed in more detail in 
Section 1.6. 
As the majority of functional recovery occurs within the first six months after stroke and is 
most rapid within the first few weeks - if concepts of neuroplasticity are accepted(114) - then 
the maximum opportunity to improve recovery is offered by early intervention. This may 
improve the rate of recovery even if the overall level achieved is no greater (48,56). Most 
studies that have assessed the clinical efficacy of these interventions have recruited patients 
several weeks or months after stroke. 
Another explanation for the lack of effectiveness of upper limb rehabilitation techniques 
might be the failure to target interventions at those who are likely to gain most benefit. 
Upper limb impairment following stroke is due to a variety of motor and sensory deficits and 
it therefore seems unlikely that one rehabilitation approach will be suitable for all. Studies 
have tended to use one intervention in a mixed impairment population, so potentially diluting 
any effect, or use a complex intervention (such as intensive therapy), which has not been 
well defined and is difficult to generalise. 
Attempts have been made to identify clinical features that will predict upper limb recovery so 
that interventions can be targeted appropriately. For example, studies have shown that the 
severity of initial upper limb motor impairment is a predictor of upper limb recovery (65) and, in 
addition, early proximal muscle activity is believed to indicate a good prognosis("). Trials 
can therefore be designed to identify individuals who may be more or less likely to benefit 
from the intervention under examination. 
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It has also been shown that shoulder pain is correlated with initial upper limb motor 
impairment and is as powerful for predicting motor recovery at 6 months as initial motor 
score (67). The relationship is complex as upper limb weakness may also be a risk factor for 
both poor recovery and shoulder pain but the interaction between them is unclear. 
1.5 Measurement of outcome of upper limb rehabilitation 
There are a variety of scales available for measuring outcomes of upper limb rehabilitation. 
Measurement is 'the use of a standard to quantify an observation' and should be 
9(44 distinguished from assessment which is 'the process of interpreting the measurement ). 
The British Society of Rehabilitation Medicine recognises that no single tool can be used in 
outcome measurement but, in selecting scales, they state that it is important to take into 
consideration what is to be measured (e. g. function, disability), in what type of problem (e. g. 
neurological, musculoskeletal), and in which particular setting (e. g. hospital, community)(68). 
It is also vital to choose scales that are well validated and reliable. A measurement is valid if 
it accurately describes the underlying phenomenon or disease, and reliable if the 
measurement error (i. e. the intra- and inter-observer variability) is minimal(69). Outcome 
measures chosen should be relevant to the rehabilitation intervention and sensitive i. e. able 
to differentiate within a patient group and identify meaningful differences in their abilities(19). 
They should also be simple to use, give results that are easily understood by others (44) and, 
if possible, widely used in the clinical setting. 
Measures of 'arm function' usually assess motor control, manual dexterity or performance in 
a series of tasks involving both proximal and distal abilities. Many of the tests used to 
assess arm function are in fact measures of impairment. Others relate to specific arm 
abilities (i. e. they look at focal disability) or general abilities that depend on use of the upper 
limb. 
The outcome measures discussed in further detail below are those most commonly used in 
studies of sNMES to the upper limb. Measures used in this study (indicated by an asterisk) 
assessed a variety of outcomes pertinent to stroke rehabilitation. They were chosen as they 
are valid, reliable, relevant to the population and intervention studied, and simple to use. 
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1.5.1 Impairment 
* Motricitv Index (Appendix 1.1) 
The Motricity Index is a simple measure of motor loss which was developed for use after 
stroke(g). It is a clinical assessment of muscle strength and is based on the Medical 
Research Council (MRC) grades of muscle power. In the arm, shoulder abduction, elbow 
flexion and pinch grip are assessed. In the leg, the assessment is of hip flexion, knee 
extension and ankle dorsiflexion. The Motricity Index is sensitive to changes seen in 
recovery after stroke, and its validity and reliability have been demonstrated in these 
(70) patients 
* Shoulder Shrug Test (Appendix 1.2)(71) 
This is assessed by asking subjects to 'shrug' their shoulder against resistance and is 
scored on a scale of 0 to 2. A score of 2 indicates full movement and strength against 
resistance, 1 reduced strength and movement, and 0 no movement at all. Ability to shrug 
the hemiplegic shoulder has been shown to be a good prognostic indicator for the recovery 
of hand movements after stroke (72) .' 
Brunnstrom Fuql-Mever (F-M) assessment (Appendix 1.3) 
This is a cumulative numerical scoring system which was designed to assess the 
development of motor function and balance in stroke patients. Although it is a general motor 
assessment scale, it has a section specific to the arm (73) . It has been shown to be a valid 
test in herniplegic stroke patients with good inter-rater reliability (74) but is time-consuming. 
Grip Strength (Appendix 1.4) 
This is a sensitive measure of recovery, and is useful prognostically after a stroke (75). It is 
measured by asking subjects to squeeze a hand-held dynamometer. 
Rivermead Motor Assessment(7') (Appendix 1.5) 
This is a widely used measure of motor function after stroke. The scale assesses both 
impairments and disabilities, but has proven reliability and validity in stroke patients. It is a 
long test to perform, but can be used more rapidly if the gross function section is assessed 
simply by asking (77) . 
*Star Cancellation Test of visuospatial impairment (Appendix 1.6) 
This is one of 6 pencil and paper tests from the Behavioural Inattention Test (711). The stimuli 
in the test are 52 large stars, 13 letters, and 10 short words, interspersed with 56 smaller 
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stars. Subjects are asked to mark all the small stars that they can see on the page. Two of 
the central small stars are used for demonstration, so the maximum score on this test is 54. 
(79,0 Its sensitivity as a measure of neglect in stroke patients has been proven " ). The 
presence/absence of visuospatial impairment is important in rehabilitation (its presence is 
associated with poor functional recovery). Visuospatial deficits may also be improved by 
rehabilitation techniques. 
Modified Bobath Assessment Chart(81- 82) (Appendix 1.7) 
This involves the use of a standardised chart to evaluate active movements. The tests are 
designed to give information about a subject's ability or inability to perform certain 
movements, and they can also be used to monitor progress. There are tests relating to the 
arm and shoulder girdle, and to the wrist and fingers. There are also sections for the 
evaluation of lower limb movements. The evaluations are performed with the subject in 
supine, sifting, and standing positions, and are divided into 3 grades depending on their 
degree of difficulty (grade 1 being the easiest). It has been shown to be reliable in 
hemiplegic patientS(83) , and it has been partially validated (i. e. its validity is based on the fact 
that stroke subjects move through apparent stages in recovery which make up the "Bobath" 
approach, rather than on a comparison with a known "gold standardn)(84). 
1.5.2 Disability 
1.5.2.1 Upper limb disability 
One approach to testing disability is to measure the subject's performance on one single 
skill. There are also a number of test batteries that have been developed to test different 
skills. 
Peg Tests (Appendix 1.8) 
There are various peg tests which involve timing the patient placing and/or removing a set 
number of pegs into holes. They are simple to perform and sensitive to changes at the 
upper level of performance, but not when the disability is severe. They are very good 
measures of manual dexterity, however they cannot detect loss of proximal strength and 
may be affected by cognitive and visuospatial problems. The Nine-hole peg test is probably 
the most simple to perform and is a valid and reliable test in stroke(70- 85). It has been used in 
a large randomised controlled trial of upper limb therapy after stroke (53) . 
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Box and Block Test (Appendix 1.9) 
This is a timed test of transferring blocks from one part of a box to another. It has been 
(136) shown to be both a reliable and valid test in elderly people . It has been used 
in stroke 
patients (87.88) and has also been used to study deterioration in those with multiple 
sclerosis (89) . 
*Frenchay Arm Test (FAT) 8) (Appendix 1.10) 
(2) The FAT is a test of arm function comprising 5 tasks. It is a valid and reliable test in stroke 
and assesses proximal control and dexterity. It is simple to perform but requires equipment, 
and although it is sensitive, patients do tend to either pass or fail all of the tests. It has been 
found to be closely correlated to the F-M score (74) . 
*Action Research Arm Test (ARAT)(6) (Appendix 1.11) 
This is an abbreviated form of test battery first devised in 1965(90) and assesses proximal 
and distal upper limb functional aCtiVity(6). Its validity and reliability have been proven in 
stroke patients(7). It consists of 19 tasks which are grouped into 4 components of arm 
function: grasp, grip, pinch grip and gross motor movements. Each task is awarded a score 
from 0 to 3 depending upon the speed and degree of completion. The maximum score is 57. 
The ARAT has been shown to be well correlated with the F-M score and takes less time to 
administer(91). 
1.5. Z2 Global disability 
This is measured in terms of physical interactions (personal, domestic and 'outside home' 
behaviour) and information transfer (communication, memory, orientation, social 
interaction)(44). 
Activities of Daily Living (ADLs) refer to the basic physical functions which underlie normal 
living. Measures of ADL should record a person's actual performance rather than their 
presumed potential ability. 'Extended'ADL scores are intended to cover other categories in 
addition to 'personal' AD Ls such as shopping and housework, although sometimes there is a 
degree of overlap and it can be difficult to ascertain what activities should come under the 
term'ADLs'and what should be classified as'EADLs'. 
*Barthel ADL Index (Appendix 1.12) 
The Barthel ADL Index includes the most common areas included within ADL scales, 
particularly covering continence which other scales OMit(92.93) . The original scoring of the 
index was 0-100 in 5 point increments (92) , 
but the most commonly used scoring now is 0 
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(dependent on all items) to 20 (independent)(94) which can always be multiplied up if 
percentage scores are desired. It consists of the following domains: bathing, stairs, 
dressing, mobility, transfer, feeding, toilet use, grooming, and continence. It does not 
however include any direct assessment of cognitive and communicative function. This index 
has been well validated and the score correlates with motor loss after stroke. A low score 
predicts a poor outcome after stroke. The score has also been shown to be reliable in a 
variety of settings, and it is very simple to use (94) . 
Rivermead ADL Test (Appendix 1.13) 
This is a simple ADL test which measures only domestic activities. It has 15 items split 
between 2 household domains, and is scored on a7 point scale. It was developed for use 
with stroke patients in a specialist rehabilitation centre and has been shown to be a reliable 
and valid test for stroke 
Functional Independence Measure (FIM) 
In the 1980s, the FIM was developed by a consortium from the American Congress of 
Rehabilitation and the American Academy of Physical Medicine and Rehabilitation (97). It 
measures 18 items over 6 different domains: self care, sphincter control, mobility, 
locomotion, communication, and social cognition. The individual is given a score of 1 to 7 on 
each item in each domain. A score of 7 is achieved if the individual is able to perform the 
task independently. It has been shown to be valid and reliable in a variety of patient groups, 
(98,99) including the elderly and those undergoing neurorehabilitation 
Functional Assessment Measure (FAM) 
The FAM was developed specifically for use in brain injury. It is to be used with the FIM 
(known as the FIM+FAM (Appendix 1.15))(100), adding a further 12 items to it which address 
cognitive and psychosocial issues. The FIM+FAM was developed to try to improve reliability 
(101) for these particular issues which tend to be more subjective and difficult to score 
Motor Assessment Scale (MAS) (Appendix 1.17) 
The MAS was designed to measure the functional capabilities of stroke patients and focuses 
mainly on disability. It consists of 8 different items representing 8 areas of motor function 
and one item relating to muscle tone on the affected side (102) . 
It is a long test to perform but 
has been shown to be reliable and valid in stroke patients (103) . 
The Modified Motor 
Assessment Scale (MMAS) is a shorter, more simplified version of the MAS. It was modified 
to increase the assessment's sensitivity to changes in patient status and has been shown to 
(104) be a reliable test in stroke patients 
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Health Assessment Questionnaire (HAQ) (Appendix 1.18) 
This questionnaire was designed for use in rheurnatological diseases(105), although much of it 
also applies to those with neurological disability. It is to be self-completed which may prove 
difficult in those with cognitive and communicative problems, more likely in neurological than 
in rheumatological disease. 
Frenchay Activities Index (FAI) (Appendix 1.16) 
This was initially designed for use in older people following stroke and has since been 
revised(106). It is a 15-item questionnaire which covers, domestic, social and leisure activities. 
It is clinically relevant and simple to use, and can be administered as a postal 
questionnalre(107). It has good construct validity, particularly in middle-aged and elderly 
(108,109) people, and is reliable for use in stroke patients 
*Nottin-qham EADL Index (Appendix 1.14) 
This is an extended ADL index consisting of 22 items split into 4 sections, each of which has 
been found to form a hierarchal scale in stroke patients("0). The sections are: mobility 
(indoor and outdoor), domestic tasks, kitchen tasks and leisure activities. It is simple to 
administer and can be used as a postal questionnaire. It has also been shown to be reliable 
and valid in patients with multiple sclerosis 
The Rankin Scale 
The Rankin Scale is a simple index with 5 categories but is insensitive, is often subjective, 
and measures impairment and disability as well as handicap (112) . It was developed in 1957 
on the basis of research on the prognosis of stroke patients. It measures independence in 
tasks rather than performance of them. The *Modified Rankin (Appendix 1.19) has 6 
categories (the additional category grades those with no disability) and was used in a study 
of stroke patients in 1988(l 13) . The authors of this study suggested that a reduction in the 
number of grades would improve its reliability but that this would be at the expense of its 
sensitivity. 
1.5.3 Quality of life 
Quality of life is hard to define which makes it very difficult to measure. In its original 
(114) 
meaning, it was related to subjectively perceived emotions of satisfaction and happiness 
Quality of life not only reflects subjects' health status but also how they perceive and react to 
(115) it, and to other non-medical aspects of their lives 
11 
In stroke research, 5 of the most commonly used instruments to measure quality of life are: 
*Nottinqham Health Profile(' 16) (Appendix 1.20) 
This consists of questions divided into 2 parts. The first part contains 38 items which 
measure subjective health in 6 domains; sleep, pain, emotion, energy, social isolation and 
mobility. The second part explores the impact of perceived health problems on 7 areas of 
everyday life; work, home maintenance, home life, sex life, interest and hobbies, social life 
and holidays. It uses weighted scores to give a scale of 0-100. It has been shown to be 
valid and reliable in a range of patient groups, and is a useful measure of quality of life after 
17) stroke(' . It has, however, been criticised for not including some areas that may 
impact on 
quality of life after stroke e. g. bladder issues, memory problems and financial difficulties. 
Short Form-36 (SF36)(118) (Appendix 1.21) 
This 36-item survey was developed in 1993 and was designed for self-ad ministration. From 
the 36 items, eight health profiles are derived from summarised scores. All the dimensions 
are independent of each other. It is widely used to measure health status after stroke but its 
(119) validity in this setting has not been proven 
Stroke SDecific Quality of Life Scale (SS_QOL)(120) (Appendix 1.22) 
This was devised to measure health related quality of life in stroke patients. The domains 
and items, developed from focused interviews with 34 stroke patients, are: energy, family 
roles, language, mobility, mood, personality, self-care, social roles, thinking, upper extremity 
function, vision, and work/productivity. Initial results regarding its reliability and validity have 
been encouraging but further studies in larger stroke populations are needed to assess this 
further. 
Stroke Impact Scale (SIS)(121) (Appendix 1.23) 
This is a self-report measure that includes 64 items and assesses 8 domains (strength, hand 
function, ADL, mobility, communication, emotion, memory and thinking, and participation in 
(121-123) activities). It has been shown to be both reliable and valid in stroke patients 
EuroQoL EQ-51) questionnaire (124) (Appendix 1.24) 
This is a generic measure of health status developed by the EuroQoL Group, an 
international research network established in 1987 by researchers from Finland, the 
Netherlands, Sweden and the United Kingdom. The questionnaire defines health in terms of 
5 domains; mobility, self-care, usual activities, pain or discomfort, and anxiety or depression. 
Each is subdivided into 3 categories which indicate whether the respondent has no problem, 
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a moderate problem or a severe problem. A higher score indicates a poorer quality of life. It 
(125,126) has been shown to be valid and reliable in a range of patient groups 
1.5.4 Upper limb pain 
*5-Point severitv scale and 0-10 numerical ratinq scale 
(127.128) (Appendix 1.25) 
Numerous scales are available for measuring pain. A simple descriptive scale can be used, 
such as the 5-point severity scale, which uses points based on verbal description (i. e. none, 
mild, moderate, severe, very severe). One of the limitations of this scale is its insensitivity in 
detecting relatively small changes. The sensitivity can be increased by using numerical 
rating scales (either 0-10 or 0-20). These 2 types of pain scales have been shown to be well 
(127) correlated 
Visual Analogue ScaleS(128) (Appendix 1.26) 
A Visual Analogue Scale (VAS) is a measurement instrument that tries to measure a 
characteristic or attitude that is believed to range over a continuum of values and cannot 
easily be directly measured e. g. the amount of pain that a patient feels. A VAS is usually a 
horizontal line, 100mm in length, with word descriptors at each end e. g. no pain and very 
severe pain. The patient marks on the line the point that they feel represents their 
perception of their current state. The VAS score is determined by measuring in millimetres 
from the left end of the line to the point where the patient marks. Visual analogue scales are 
used for the subjective measurement of pain, mood and health status after stroke. A study 
by Price et al, however, showed that many stroke patients are unable to successfully 
(129) complete such scales 
* Pain-free range of humeral lateral rotation(130,131) 
Some studies have assessed pain at the shoulder by measuring pain-free range of 
motion (130,132). The limitation of this method, however, is its lack of sensitivity to non- 
mechanical pain (e. g. central post-stroke pain) and concerns about other influences on 
range of movement (e. g. viscoelastic changes, muscle tone). 
1.5.5 Summary of upper limb rehabilitation 
e There are many interventions that aim to improve upper limb function following stroke but 
the literature is unclear about their effectiveness. 
As the majority of functional recovery occurs within the first six months after stroke, the 
maximum opportunity to improve recovery is offered by early intervention. 
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A variety of scales are available for measuring outcomes. In selecting scales, it is 
important to consider what is to be measured, in what type of problem, and in which 
particular setting. The chosen scales must also be valid, reliable, relevant to the 
rehabilitation intervention, and feasible to use. 
1.6 Electrical Stimulation (ES) 
Electrical stimulation (ES) is defined as using an electric current to excite nerve or muscle 
tissue. Research studies suggest that treating stroke patients with various forms of 
electrotherapeutic agents may stimulate lower motor neurons of the peripheral nerve, 
improve contractibility of type A and c muscle fibres, decrease tone (spasticity) and enhance 
sensory stimulation (133) . ES may also reduce pain by the gate control theoryý 
134) which is 
based on the fact that small diameter nerve fibres carry pain stimuli through a 'gate 
mechanism' but larger diameter nerve fibres going through the same gate can inhibit the 
transmission of the smaller nerves carrying the pain signal. It is thought that the 'pain gate' 
can be shut by stimulation of mechanoreceptors and by the release of endogenous opioids, 
both of which may occur as a result of ES application. 
Electrical stimulation may also provide afferent stimulation of the somatosensory cortex by 
augmented sensory feedback (appropriately timed sensory stimulation to trigger voluntary 
motor activity), and by proprioceptive afferent stimulation as a consequence of movement 
(135) and muscle activation mediated by electrical stimulation Therapeutic electrical 
stimulation (TES) aims to reduce motor impairment through motor re-learning. Repetitive 
movements induced by electrical stimulation may be important for motor re-learning in the 
same way that active repetitive movements are. However, other effects such as muscle 
strengthening and modulation of spasticity may also influence the motor re-learning process. 
A secondary advantage might be the correct alignment of articular surfaces which may be 
important in the prevention of pain and creating the right conditions for useful limb function. 
1.6.1 Types of ES 
Electrical Stimulation can be broadly divided into 2 groups: functional electrical stimulation 
(FES) and therapeutic electrical stimulation (TES). Liberson and colleagueS(136) defined FES 
as 'the use of electrical stimulation to produce muscle contractions that have a functional 
purpose, ' e. g. the stimulation of dorsiflexion to assist gait. TES is designed to have 
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therapeutic effects which persist after the stimulation is terminated. There is, however, a 
considerable amount of overlap between FES and TES i. e. although the main objective of 
FES is for a functional purpose, many applications of FES are associated with long-term 
therapeutic effects. In addition, TES may produce muscle contractions as with FES, but the 
main aim of TES is for therapeutic effect rather than functional purposes. 
The main application of electrical stimulation for the upper limb following stroke is TES. It 
has been proposed as a safe method of improving upper limb outcome by enhancing 
shoulder joint alignment, muscle strengthening, analgesia, and modification of visuospatial 
deficits (82,137-141 ). TES can be classified into 4 different methods: 
1. Neuromuscular electrical stimulation (NMES) 
2. EMG-triggered electrical stimulation (EMG-stim) 
3. Positional feedback stimulation training (PFST) 
4. Transcutaneous electrical nerve stimulation (TENS) 
Each of these methods are applied by different devices and can be set to different 
stimulation parameters to determine the type of reaction provoked by the stimulation. TENS 
produces continuous or burst stimulation and there is no ramp-up or ramp-down time. The 
other three methods produce cyclic stimulation and the ramp-up, ramp-down and duty cycle 
can be adjusted independently. 
Patients receive NMES passively whereas they are actively involved in EMG-stim and PFST. 
NMES is used on innervated muscle to recruit motor units and increase the strength of the 
muscle, decrease spasticity through reciprocal innervation, improve range of motion, and 
improve muscle endurance by increasing aerobic capacity of the muscle. EMG-stim 
facilitates patterned, repetitive, volitionally initiated exercises of the herniparetic limb and 
provides cutaneous, proprioceptive, and electrical stimulation feedback with each attempted 
movement. The electrical stimulation is initiated voluntarily by EMG signals from the target 
muscle, rather than applied passively by the stimulato r(142). The technique may be used with 
stroke subjects who can voluntarily generate electromyographic signals in their paretic 
muscles, but who are unable to generate sufficient muscle contraction for adequate exercise 
or functional movements. Theoretically, the basis for EMG-stim is that alternative motor 
pathways can be recruited and activated to assist the stroke-damaged efferent pathways. 
In PFST, positional feedback and electrical stimulation are combined to facilitate 
movemed143) . The onset of electrical stimulation occurs with each voluntary effort and 
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causes muscle contraction and completion of full joint motion. Through the use of audio and 
visual displays, the subject is provided with sensitive and immediate sensory feedback of 
joint motion, a means of comparing their joint position with established goals for motion, and 
positive reinforcement of goal attainment. 
TENS was originally used for the treatment of pain by evoking a sensory reaction without 
muscle contraction. However, muscle contraction can be produced with TENS in addition to 
a sensory reaction by adjusting the stimulation parameters (62) - 
1.6.2 History of ES 
The first clinical application of ES was reported by Liberson and colleagues in 196 1(136) . 
They reported a series of case studies using a peroneal stimulator to activate the ankle 
dorsiflexors; during ambulation in 7 hemiplegic patients with gait difficulties due to foot drop 
and equinovarus. The stimulator was activated when the foot was lifted off the ground. The 
authors found improvements in ankle dorsiflexion and eversion during the swing phase of 
gait. The application of ES on the upper limb was first performed by Long and Masciarelli 
who created an electrophysiologic splint for the hand in 1963 in patients with spinal cord 
injUry(144). In 1973, the first commercially available FES unit for finger extension in 
(145) hemiplegic subjects became available 
During the 1970s, there were further reports about the use of ES in herniplegic subjects 
although the majority of these evaluated the ES technology rather than testing the efficacy of 
(146,147) the stimulation 
In the late 1970s, the use of FES to produce ambulation in subjects with spinal cord injury 
was reported (148) , and virtually all of the technological improvements in ES 
in the 1980s were 
in patients with spinal cord injury. 
During the 1990s, there was increased interest in the use of ES in herniplegic subjects. 
Much more work was done on the use of ES for the lower limbs (most commonly dorsiflexion 
assistance during ambulation (149.150) ) than for the upper extremities. The first study utilising 
an experimental design to evaluate the efficacy of FES in improving gait was undertaken by 
Bogotaj et al in 1995(151). Twenty herniplegic patients within 1 year of stroke were randomly 
assigned to one of two groups. All received conventional therapy for 6 weeks but one group 
received FES during the first 3 weeks, and the other during the last 3 weeks of therapy. 
Outcomes were in terms of gait performance and motor impairment (Fugl-Meyer score (73) ). 
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The authors report greater improvements when patients received FES plus conventional 
therapy rather than conventional therapy alone, but it is unclear whether these results were 
statistically significant, so they must be interpreted with caution. 
1.6.3 The sNMES regime 
Previous trials have used different sNIVIES regimes (Table 3) and there has been no 
published review of this to date to provide guidance on which regimes are most effective 
clinically. It is possible that failure of sNIVIES to produce clinical benefit in certain trials may 
be because of the regime used rather than the sNIVIES itself. 
1.6.4 Side effects of sNMES 
Surface NMES has been well-tolerated in previous trials. Most trials have reported no 
dropouts (Tables 1& 2) and very few side effects from the stimulators. The most common 
reported side effect is pain at the application site. 
1.6.5 Therapeutic applications of ES to the upper limb in stroke subjects 
ES has been proposed as a safe method of improving outcome following stroke via 
mechanisms such as muscle strengthening, improvement in joint alignment (in particular 
treatment/prevention of shoulder subluxation), analgesia, modification of visuospatial 
deficits, and psychological benefit due to sensory feedback(5,62) . The two commonest 
techniques used in this clinical setting are TENS and NMES. Studies to evaluate the use of 
ES to the upper limb in stroke patients have looked at its effect to the shoulder, wrist and 
fingers on a variety of outcome measures such as impairment, function, shoulder 
subluxation and pain. 
The randomised controlled trials (RCTs) of ES in stroke patients are discussed in detail 
below. The search strategy is detailed in Appendix 3.1. 
1.6.6 Randomised controlled trials (RCTs) of electrical stimulation (ES) in 
stroke subjects 
Studies have looked at the effect of electrical stimulation on motor performance, function, 
shoulder subluxation, pain, spasticity and neglect. There is a mixture of evidence about the 
effectiveness of any form of electrical stimulation, however it appears that more benefit 
occurs when muscle contraction is induced(62- 82,132,133,152) (Table 3). 
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The methodological quality of these studies is variable. Many only recruited small numbers 
of subjects, and some did not adequately report the population screened, the randomisation 
method, or the presence/absence of blinding (Tables 1& 2). The Scottish Intercollegiate 
Guidelines Network (SIGN) methodology checklist for RCTS (Appendix 3.2) was used to 
assess methodological quality. Power calculations are not included in this checklist, and are 
in fact rare in rehabilitation studies. Many such studies are exploratory, and a small sample 
but with a very significant finding could be important. However, it must be noted that it is 
often difficult to interpret and generalise the findings of such small studies. 
1.6.6.1 ES to the upper limb for motorlfunctional recoverY 
Few studies have looked at motor and functional recovery following electrical stimulation to 
the shoulder after stroke. 
In 1994, Faghri et al looked at the effects of functional electrical stimulation (FES) on 
shoulder subluxation, arm function and recovery, and shoulder pain in hemiplegic stroke 
subjeCtS(82) . They undertook an RCT of 26 subjects with shoulder muscle flaccid ity/paralysis 
due to stroke but the authors do not state where these were recruited from (i. e. whether they 
were in-patients or 6ut-patients). They excluded those with a permanent pacemaker, but it 
was unclear whether there were any other exclusion criteria, for example, subjects with 
previous shoulder problems. It is also unclear how many were screened for entry into the 
study. 
Thirteen of the participants were randomised to the treatment group and 13 to the control 
group. The randomisation method is not stated. Those in the treatment group were given 6 
weeks of FES to the shoulder (posterior deltoid and supraspinatus) for 1.5-6 hrs per day. It 
is unclear how much treatment was actually received and there was no sham treatment for 
the control group. 
Participants were assessed at baseline in terms of arm function (using the shoulder and arm 
function subsection of the modified Bobath assessment chart(81)), arm muscle tone (0-4 
53) grading)(' , posterior deltoid muscle electromyographic (EMG) activity, upper arm girth, 
shoulder lateral range of motion (SLROM)(130,131) for assessment of pain in the involved 
shoulder, and shoulder subluxation (x-rays of both shoulders). These assessments were 
repeated at 6 and 12 weeks and it is unclear whether or not they were blinded. 
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At baseline, the subjects were well matched in terms of sex, age, time post-stroke and side 
of impairment. The mean (+/-SD) time post-stroke was 16+/-5 days in the intervention group 
and 17+/-4 days in the control group. The majority of subjects had left sided impairments 
(this may be due to receptive problems in patients with right sided impairments but this is not 
discussed in the paper, and receptive dysphasia was not given as an exclusion criterion). 
The authors assumed that the number of current infarcts was similar between groups as the 
patients were 'randomly assigned'. There were no significant differences between groups in 
terms of the baseline upper limb assessments, although no results are given for initial upper 
arm girth. 
At 6 weeks, the intervention group had increased arm function, tone, and EMG activity which 
was statistically significantly higher than the control group. Both groups showed 
improvements in these measures from baseline to 6 weeks, but these changes were not 
statistically significant in either group. The 12-week outcomes for function, tone and EMG 
activity are not reported. At 6 and 12 weeks, there were statistically significant increases in 
SLROM (both absolute values and when compared with baseline) for patients in the 
intervention group compared with controls. An increase in the SLROM was interpreted to 
mean that patients had less pain in the shoulder. There was less subluxation (when 
compared with baseline) in the intervention group at both 6 and 12 weeks compared with 
controls. However, this difference was only statistically significant at 6 weeks. 
The authors concluded that FES can reduce shoulder subluxation after a stroke and may 
result in faster recovery of arm function. They suggest that the ES treatment may have 
resulted in faster recovery of shoulder function by preventing the disuse atrophy that may 
occur during the flaccid stage of recovery. However, the reduced subluxation in the 
intervention group was only statistically significantly different from the control group at 6 
weeks; this significant difference was no longer present at 12 weeks. Also, the improvement 
in arm function seen at 6 weeks was not significantly greater than improvements seen in the 
control group, and the 12-week outcomes for arm function are not reported. The authors 
also reported that FES can reduce pain at the affected shoulder. However, it is important to 
note that shoulder pain at baseline is not assessed in this study. 
Other studies have looked at recovery following stimulation of the wrist and finger extensors 
in the paretic arm post-stroke. 
In 1979, Bowman et al(143) undertook a randomised controlled study of positional feedback 
stimulation training (PFST). The aim of the study was to compare a group of hemiplegic 
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subjects with poor wrist extensor control receiving PFST and conventional therapy with a 
similar group of subjects receiving only a conventional therapeutic programme. Subjects 
were recruited between 3 weeks and 4 months post-stroke (embolic or thrombotic) and had 
a minimum of 5 degrees and maximum of 30 degrees of active extension at the wrist. They 
had to have sufficient cognition to follow instructions and give informed consent. It is unclear 
where subjects were recruited from or how many were screened. Randomisation was by the 
flip of a coin, 15 into the intervention group and 15 controls. Those in the intervention group 
received PFST for 30 minutes twice daily, 5 times per week for a total period of 4 weeks. 
There was no sham treatment for those in the control group. 
Baseline evaluations were undertaken, and then blinded outcomes performed weekly until 
the end of the 4 week treatment period. Average maximal isometric wrist extension was 
measured with the wrist positioned in 30 degrees of flexion and then in 30 degrees of 
extension (mean of 3 efforts). An electrical goniometer was used to measure voluntary 
patterned and selective ranges of motion (ROM) at the wrist. In addition to these 2 
evaluations, the intervention group were tested weekly with the PFST equipment to 
determine the patient's ability to extend isotonically against incremental resistances (using 4 
resistance levels). 
There were no significant differences between the groups at baseline in terms of the above 
evaluations. No baseline demographics or clinical features were given, however, so it is not 
possible to comment on whether the subjects in each group were similar. For subjects in the 
treatment group, there were increases in isometric wrist extension (both in flexion and 
extension) over the period of the study. Statistically significant differences were seen in the 
2 nd , 3rd and 4th weeks when the wrist was positioned in 30 degrees of flexion, and the 3 
rd and 
4th weeks when the wrist was in 30 degrees of extension. For ROM, the authors report that 
the groups were 'essentially equal' at baseline but do not give results for this. The average 
change in active extension ROM in the treatment group in the 2 nd 3 rd and 4 th weeks was 
higher when compared with controls, and this difference was statistically significant in the 
2 nd , 3rd and 4th weeks. When testing those in the intervention group against resistance, 
subjects were able to extend against a statistically significantly greater resistance at the end 
of the treatment program compared with prior to treatment. 
The authors state that they felt that establishing performance goals helped patient 
motivation. They also point out that the PFST equipment in this study was designed to 
operate automatically, allowing the therapist to oversee the treatment without constantly 
being present. 
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In 1998, Chae et al performed a RCT to assess the efficacy of neuromuscular stimulation 
(NMES) in enhancing motor and functional recovery of the upper limb in acute stroke 
patients(154). They state that the design was influenced by the review by Glanz et al (1996)(4) 
which concluded that further blinded research with longer follow-up periods was needed to 
look at electrical stimulation in post-stroke rehabilitation. 
Subjects admitted to an acute inpatient rehabilitation service within 4 weeks of stroke were 
screened for inclusion into Chae's study. It is unclear how many subjects were screened, 
but a total of 46 patients were recruited. Only those with moderate/severe upper limb 
paresis were included (Fugl-Meyer (F-M) score (73) <44) and there were other exclusion 
criteria. The participants were randomised to the treatment or control group by a computer- 
generated random number table. 
There were a large number of drop outs (n=17) either because they could not tolerate the 
stimulation (n=8), did not finish the treatment protocol and declined further treatment (n=5), 
were medically unstable (n=3), or were found not to have had a stroke (n=l). There was 
one further drop out in the control group because it was not possible to achieve cutaneous 
stimulation without muscle activation in this particular subject. Therefore only 28 subjects 
completed the study-14 in the treatment group and 14 in the control group. Of the 18 
subjects who dropped out of the study after randomisation, 11 were in the treatment group 
and 7 in the control group. Those in the treatment group received NMES for I hour per day 
for a total of 15 sessions. The NMES produced full wrist and finger extension in the 
treatment group. Those in the control group were given a cutaneous stimulator. 
It is of note that only those who completed the treatment were included in the baseline and 
outcome analyses (i. e. the authors did not use an intention-to-treat analysis). Assessments 
were undertaken at baseline, and blinded outcomes after treatment, at 4 weeks and at 12 
weeks. Motor function was assessed with the F-M score (73) and upper extremity disability 
assessed with the self-care component of the Functional Independence Measure (FI M)(97) 
(which is not specific to the upper limb). 
At baseline, the 28 subjects who completed the study were well matched in terms of sex, 
age, past medical history, and side of herniparesis. The mean (+/-SD) time of stroke onset 
to treatment was 13.6 (+/- 7.1) days in the treatment group and 17.8 (+/- 5.9) days in the 
control group. All subjects in the treatment group had non-haemorrhagic strokes, whilst 3 of 
those in the control group had haemorrhagic strokes (it is unclear whether these were 
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primary intracerebral haemorrhages or haernorrhagic infarcts). This difference was not 
statistically significant. There were more cortical strokes and more anterior circulation 
strokes in the control group compared to the intervention group, but again, this difference 
was not statistically significant. 
At baseline, there were lower motor scores (i. e. upper limb F-M scores) in the control group. 
This may have confounded the results, but the difference did not reach statistical 
significance. It is not stated whether these are mean or median scores. outcomes used 
were gains in the F-M and FIM scores after the 15-day treatment period and at the follow up 
periods (4 weeks and 12 weeks). There were greater motor improvements for the treatment 
group compared to the control group at 15 days, 4 weeks and 12 weeks. These differences 
are reported to be statistically significant but it must be noted that the 95% confidence 
intervals are very wide (16.2,0.0 at 4 weeks; 18.9, -0.2 at 12 weeks). The differences in the 
FIM gain scores between groups were not statistically significant at any of the follow up 
periods. 
The authors concluded that, whilst an improvement was seen in motor recovery, this did not 
translate into a functional benefit. They acknowledged the large number of dropouts, mainly 
due to pain from the stimulator (8 out of the 18,7 of whom were in the treatment group). 
They suggested that their results should be interpreted with caution and that future studies 
should use a functional outcome measure that is specific to the arm and more sensitive to 
the degree of arm herniparesis. 
In 1998, Sonde et al looked at the effect of low-frequency transcutaneous electrical nerve 
(155) 
stimulation (low-TENS) for treatment of the post-stroke paretic arm 
They undertook a RCT of 44 patients with a paretic arm (F-M score (73) 0-50) due to a first- 
ever stroke occurring within the previous 6-12 months. It is unclear where subjects were 
recruited from, and how many patients were screened in total. No exclusion criteria were 
given. Subjects were randomised by the random number generator method. 
All subjects in the treatment group received stimulation of the wrist extensors, and some also 
had additional stimulation at the elbow and shoulder (although it is not clear who actually 
received this additional stimulation). The low-TENS treatment was given for 60 minutes, five 
times per week, for 3 months. There was no sham treatment for the control group. 
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Outcome measures (unblinded) were performed at the end of the treatment period and 
consisted of motor function (F-M score)(73), spasticity (Modified Ashworth Scale 
(156)), 
pain 
(Visual Analogue Scale 0_1 00(128)) , and Activities of Daily Living (ADLs) (Barthel ADL 
Index (92) ). 
Twenty six subjects were randomised to the treatment group and 18 to the control group. 
Mean (SID) time since stroke was 9.1 (2.2) months in the treatment group and 8.3 (2.1) in the 
control group. Subjects were well-matched at baseline in terms of age and side of paresis. 
There were more males in the treatment group (19 compared to 8 controls) but this 
difference was reported as being non-significant. The authors did not report Ashworth 
scores at baseline, and it was also unclear which of the participants actually had pain at the 
start of the study. Of note, the mean baseline Barthel scores indicated more severe 
disability in the control group (69.2 +/- 16.6) compared to the intervention group (29.6 +/- 13) 
and this difference reached statistical significance (p=0.03). 
Improvement in motor function was seen in the treatment group as assessed by the change 
in F-M score from the start to the end of the study. The improvement was statistically 
significantly greater than that in the control group. The improvement in motor function in the 
treatment group was also greater in those less severely affected, and in those with the 
shortest post-stroke time. There was no effect of the low-TENS on pain, spasticity or ADLs. 
It must be stressed, however, that this study was uncontrolled, the description of stimulation 
received is unclear, and outcome assessments were unblinded. The positive results 
reported in this study must therefore be interpreted with caution. 
Sonde et al performed a three-year follow-up study on this cohort(157) to assess whether the 
low-TENS treatment resulted in long-term improvements in motor function, spasticity or 
ADLs- Twenty eight (18 treatment and 10 controls) out of the original 44 subjects were 
available for this re-assessment. It is unclear why the remaining 16 could not be followed- 
up. The motor performance (F-M score (73) ) of the affected arm of subjects in both groups 
had deteriorated. This decline was greatest in less severely affected subjects in the 
treatment group, where the F-M score was statistically significantly lower at 3 years 
compared with the score at the end of the treatment period. There was a slight increase in 
spasticity (modified Ashworth score (156)) in both groups but this was not statistically 
significant. The average ADL scores (Barthel ADL IndeX(92) ) decreased in both groups and 
this was statistically significant in the control group. However, the changes in motor 
performance, spasticity and ADL scores were not actually compared between the groups. 
The authors concluded that low-TENS treatment started 6-12 months after stroke does not 
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affect arm motor function 3 years after completion of treatment. They also concluded that 
low-TENS treatment may result in maintained ADL-scores at 3 year follow-up. Again, these 
results must be interpreted with caution in view of the original flaws in study design. 
In 1998, Francisco et al(158) performed a single-blind randomised pilot study of EMG-triggered 
electrical stimulation to assess its effect on the arm function of acute stroke subjects. First 
ever stroke subjects, within 6 weeks of stroke onset, were screened against strict criteria for 
entry into the study. It is unclear where they were recruited from, or how many were 
screened. Inclusion criteria were given as: non haemorrhagic lesion on CT or MRI brain 
scan, a detectable surface EIVIG signal from the extensor carpi radialis of the hemiparetic 
arm, and volitional wrist extension in synergy or isolation with muscle grade of less than 3/5. 
It is unclear whether subjects with a 'normal' brain scan were excluded from the study on the 
basis of these criteria. Subjects were excluded if they had previous neurological co- 
morbidity that impaired strength in the affected upper limb, if they were on medications which 
impaired neuromuscular performance (e. g. antispasmodics, antiepileptics), if they had an 
insensate affected forearm, if they had a permanent pacemaker, or if they were pregnant. 
These strict inclusion and exclusion criteria obviously limited recruitment to this study and 
this was acknowledged by the authors. 
Sixteen eligible subjects were randomised by a computer-generated random number table. 
Seven of these dropped out due to medical instability. Of the remaining 9 subjects, 4 were 
in the intervention group and 5 in the control group. No information is given regarding the 
randomisation groups of the dropouts, and the baseline and outcome data only relates to the 
9 who completed the study. Participants in the intervention group received twice daily EMG- 
triggered electrical stimulation (30 minutes per session) to the forearm extensors (surface 
electrodes were placed on extensor carp! radialis) 5 times per week for the duration of their 
inpatient stay. There was no sham treatment for those in the control group, but they were 
given 2 additional 30-minute individual therapy sessions per day. 
Blinded outcomes were performed at discharge from hospital (i. e. at the end of the ES 
treatment) and consisted of the F-M(73) and Fl M(97) Scores. 
The results showed a significant difference in the distribution of lesion laterality between the 
2 groups at baseline (all 5 of the control subjects had left hemisphere lesions compared with 
only 1 of the 4 in the intervention group). The subjects were otherwise well matched at 
baseline in terms of age, sex, time from stroke onset to admission, and baseline F-M and 
FIM scores. 
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Outcomes at discharge were looked at in terms of 'gain' in scores. Those in the treatment 
group showed statistically significantly greater gains in the upper limb F-M scores and FIM 
scores than controls. The authors concluded that EMG-stimulation has the potential for 
enhancing upper limb motor recovery within 6 weeks of stroke onset, and that this enhanced 
recovery appeared to translate into functional recovery. However, the numbers in the study 
were small and the length of treatment (and timing of the outcome assessments) was based 
on length of stay (which was slightly longer in the treatment group than controls, but this 
difference did not reach statistical significance). The dropouts were not included in any of 
the analyses. Also, it is difficult to see how widely applicable these results are, as it appears 
that EMG-triggered stimulation can only really be used in a very select group of acute stroke 
subjects. 
In 1999, Powell et al undertook an RCT to look at the effects of electrical stimulation (ES) of 
the wrist extensors on impairment of wrist function and on upper-limb disability in subjects 
undergoing rehabilitation after acute stroke. (152) 
Subjects admitted consecutively, with Medical Research Council (MRC) power of wrist 
extension grade 4/5 or worse, were screened for entry into the study. A total of 60 were 
recruited but it is unclear how many were actually screened. Recruited subjects were all 2-4 
weeks post-stroke, exclusions were given and all had a CT head scan. 
Randomisation was by computer-generated random numbers held in sealed envelopes and 
30 were recruited to each group. ES was given for 3 half-hour periods daily for 8 weeks to 
stimulate wrist and finger extension in the treatment group. No sham treatment was given 
for the control group. Compliance with treatment was recorded in a patient diary. 
Blinded outcomes were undertaken at 4,8,20, and 32 weeks. These looked at impairment 
(using a purpose-built device to measure the isometric strength of wrist extension and the 
active and passive ranges of motion at the wrist); and disability (Action Research Arm Test 
(ARAT)('), grip strength (75) and the 9-hole peg test(70,85)). Other outcomes were spasticity 
(modified Ashworth scale (156)), visual inattention (star cancellation test(78)), disability (Barthel 
ADL score (92) ), and global handicap (Rankin score (112) ). 
Participants were recruited a mean (SD) of 23.9 (7.7) days post-stroke in the treatment 
group, and 22.9 (5.5) days in the control group. The groups were well-matched at baseline 
9 in terms of sex, age, abbreviated mental test score (AMT)(15 ), side of hemiparesis and 
stroke subtype. Forty eight subjects of the total of 60 completed the study. Dropouts were 
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due to death (n=3), further neurological events (n=3), and patients declining follow-up (n=6). 
Of these 12 dropouts, 5 were in the ES group and 7 were controls. The ES was not 
associated with any significant local discomfort. 
Outcomes were assessed in terms of change from baseline. The authors compared the 
baseline data with those after treatment (i. e. at 8 weeks) and at the end of the follow-up 
period (i. e. 32 weeks). They do not report their outcomes at 4 weeks and 20 weeks and it is 
unclear why this is the case. They showed a statistically significant increase in isometric 
strength of wrist extensors (at a wrist angle of 0 degrees extension) at both 8 weeks and 32 
weeks in the treatment group when compared with controls. ES also reduced upper limb 
disability, as assessed by the grasp and grip subscores in the ARAT(6) at week 8, but the 
differences between treatment and control were no longer statistically significant at the end 
of follow-up (i. e. at 32 weeks). There were however no statistically significant differences 
seen, between treatment and control groups, in change in resting wrist angle, range of 
passive extension, hand grip strength, 9-hole peg test, star cancellation and Ashworth, 
Barthel and Rankin scores, from weeks 0 to 8 or weeks 0 to 32. It is questionable how 
informative the 9-hole peg test was because many subjects were unable to insert any pegs. 
Nineteen subjects showed good compliance with the treatment, 3 missed occasional 
sessions and 5 showed poor compliance although the reasons for this in the latter group 
were not stated. 
The authors concluded that cyclic ES of the wrist extensors enhances motor recovery and 
reduces upper-limb disability, although the reduction in disability is not maintained after the 
treatment is stopped. However, it must be noted that the only statistically significant results 
were seen in strength of wrist extension (at 8 and 32 weeks) and in 2 of the 4 subgroups of 
the ARAT(6) (at 8 weeks only). They suggested that larger scale studies were needed with 
use of a sham treatment for the control group. 
In 2000, Cauraugh et al(88) undertook a randomised trial of electromyography (EMG) - 
triggered NMES. The aim of the study was to determine its effect on the wrist and finger 
extension muscles in individuals who had had a stroke more than 1 year previously. They 
used a modified crossover design, i. e. control patients received the EMG after the treatment 
period was complete. It is unclear where subjects were recruited from. Subjects had to be 
able to voluntarily extend the wrist 20 degrees against gravity from a 90 degrees flexion 
position. Subjects were excluded if they had more than a 75% motor recovery, if there was 
a history of 'previous neurological deficit' and/or if they were already enrolled in rehabilitation 
treatment. 
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A total of 11 subjects were included in the study -7 in the treatment group and 4 controls. 
The authors did not state how they were randomised. Those in the treatment group received 
two 60-minute sessions of EMG-triggered NMES to the wrist and finger extensors 3 times 
per week for 2 weeks. There was no sham treatment for the control subjects. 
The outcome assessments consisted of the Box and Block TeSt(87), Motor Assessment 
Scale (102) , F-M SCOre(73) , reaction time and sustained muscle contraction. 
The same 
instrument was used for both the reaction time and sustained muscle contraction tasks: a 25 
lb load cell measured the amount of force generated during the isometric wrist extension 
movements. For the reaction time, subjects were instructed to respond as quickly as 
possible to the onset of an auditory stimulus by initiating the wrist and finger muscles for an 
isometric contraction against the platform of the load cell. For the sustained muscle 
contraction, subjects were instructed to gradually increase their wrist/finger extension force 
to a maximal isometric contraction and hold that level for 5 seconds. All of the assessments 
were undertaken at baseline and then repeated after the 2-week treatment period. It is 
unclear whether or not these outcomes at 2 weeks were blinded. 
The mean age, mean time after stroke, and side of lesion were reported for the 11 subjects 
but it is not possible to say whether treatment and control groups were similar. No other 
baseline demographics or clinical features were reported. For the Box and Block test, the 
treatment group increased the number of blocks moved, whereas the control group 
maintained the same level of performance for both test sessions. This increase seen in the 
intervention group reached statistical significance. In the treatment group, there was an 
improvement in sustained force impulses observed during the isometric contraction task, and 
this improvement reached statistical significance. No statistically significant results were 
seen with the MAS, F-M score and reaction times. 
The authors concluded that there were improvements in functional motor abilities with EMG- 
stim treatment. However, it should be noted that a very small number of subjects were 
recruited and there were flaws in the study design. 
In 2003, Popovic et al(160), performed a single-blinded randomised study to evaluate the 
effects of functional electrical therapy (FET) on the paretic upper limbs of acute stroke 
subjects. They describe the difference between FET and other forms of electrical 
stimulation, stating that FET 'combines intensive voluntary activation of proximal muscles 
and patterned multichannel electrical stimulation of distal muscles providing grasp and 
release functions in the paretic hand'. 
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They considered 41 acute herniplegic subjects for entry into the study but only 28 subjects 
participated. The authors did not state where the subjects were recruited from. Inclusion 
criteria included first ischaemic or haemorrhagic stroke (confirmed by MRI or CT scanning) 
between 2 weeks and 6 months previously, ability to give informed consent, and ability to 
understand how to apply the electrical stimulation. Exclusion criteria were given. 
Subjects were divided into a lower functioning group (LFG) and higher functioning group 
(HFG) based on their ability to voluntarily extend the wrist and fingers against gravity. A 
random generator was used to select 28 subjects for the study, 16 from the HFG and 12 
from the LFG. Subjects were then randomised into a FET and a control group using a 
random generator. Therefore, the subjects were assigned to 4 groups: FET HFG, control 
HFG, FET LFG, and control LFG. All subjects participated in 30 minute treatment sessions 
for a period of 3 weeks. These sessions were either exercise with stimulation (FET group) 
or exercise only (control group). The authors report that these sessions were given daily as 
the subjects were in-patients. They also state that subjects in the FET groups occasionally 
missed FET sessions but never more than 2 days in a row. 
The subjects were assessed at the start of the study, and then blinded outcomes undertaken 
after the 3-week treatment period, and at 6,13 and 26 weeks. The outcome measures were 
the Upper Extremity Functioning Test (UEF7)(161) (Appendix 1.27), Drawing Test (DT) 
(Appendix 1.28)(162) , modified Ashworth scale 
(156) (Appendix 1.29), and Reduced Upper 
Extremity Motor Activity Log (RUE/MAL) questionnaire (163) (Appendix 1.30). 
At baseline, data for the 28 subjects was given for age, time between stroke onset and study 
entry, paretic side, and stroke type. The time between stroke onset and study entry was 
similar between groups. However, it is unclear whether there were any statistically 
significant differences between groups in terms of the remaining baseline data. 
There were no statistically significant differences between intervention and control groups at 
baseline for both the HFG subjects and LFG subjects in the UEFT, DT, Ashworth scale, and 
RUE/MAL questionnaire. 
Differences in absolute outcome were analysed between intervention and control subjects, in 
each of the HFG and LFG groups. In the UEFT, significant differences were seen between 
intervention and control subjects at all of the outcome assessment times. In the DT, 
statistically significant differences were seen at all outcome times except after treatment (Le. 
at 3 weeks) in the LFG. The assessment of spasticity using the modified Ashworth scale 
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was only performed at the start and end of the study. The muscle tone was decreased in all 
subjects at the end of the study, but the only statistically significant result was seen in the 
HFG when comparing intervention with control at 26 weeks. The RUE/MAL questionnaire 
was also only performed at the start and end of the study. The authors reported statistically 
significant differences between intervention and control groups at 26 weeks in both the HFG 
and LFG. They also reported significant differences between groups in the change from 
baseline to 26 weeks. It is of note that at baseline, those in the HFG had higher scores than 
those in the LFG and these were even higher in the FET HFG than in the control HFG group. 
These differences were not commented on by the authors, and it is unclear whether they 
were statistically significant. 
The authors concluded that the FET treatment promoted functional recovery (as measured 
by the UEFT and DT) and reduced spasticity. The most significant differences were seen in 
the HFG, indicating greater effects of FET in subjects who were less limited in terms of 
functioning and movement at the start of the study. The authors stated that the RUENAL 
results indicated that the FET was received well by herniplegic subjects. However, there 
were differences at baseline which were not discussed in the paper and it is of note that, with 
the exception of the modified Ashworth scale, the outcome measures used were not well- 
recognised scales with proven validity and reliability. Also, this was a small study so results 
should be interpreted with caution. 
Other studies have looked at the effects of electrical stimulation to both the upper and lower 
limbs following stroke. 
In 2001, Johansson et al undertook a multi-centre RCT to study the effects of acupuncture 
and transcutaneous electrical nerve stimulation on functional outcome and quality of life after 
(164) 
stroke 
One hundred and fifty subjects, within 5 to 10 days of acute stroke, were recruited from 
medical and neurological centres in Sweden although the number of patients actually 
screened is not stated. All patients had moderate/severe disability (measured by Barthel 
ADL IndeX(92), 9-hole peg teSt(85) or 1 Om walk(165)) and exclusions were given. 
Subjects were randomised with the use of closed envelopes, and stratified by centre to 1 of 
3 groups: acupuncture; sensory stimulation with high-intensity low-frequency transcutaneous 
electrical nerve stimulation (TENS) that induces muscle contractions; and low-intensity high 
frequency electrostimulation (control group). Forty eight subjects were randomised to the 
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acupuncture group, 51 to the TENS group and 51 to the control group. Each treatment 
session was 30 minutes and took place twice weekly for ten weeks (total of 20 sessions). 
Treatment was given to both the paretic upper limb and lower limb simultaneously. It is 
unclear whether any stimulation was given at the shoulder. All subjects received usual 
therapy irrespective of randomisation group. 
Blinded outcomes, performed at 3 months and 12 months, consisted of ADI-s (Barthel ADL 
IndeX(92)), overall motor function (Rivermead Mobility Index( ... )), fine motor function (9-hole 
peg test("), walking ability (10m walk(161)), and quality of life (Nottingham Health Profile 
Questionnaire(' 16) ). Twelve participants had dropped out of the study at the 3-month follow 
up, and a further 12 at the 12-month follow-up. Therefore, a total of 126 (84%) subjects 
remained in the study at the 12-month follow-up, and the reasons for withdrawal were given. 
Only one subject dropped out of the study due to an adverse reaction from the treatment and 
he/she was in the TENS group. 
The subjects were well-matched at baseline in both groups in terms of age, sex distribution, 
medical history and CT findings. There were no significant differences between the groups 
at baseline in any of the above stated outcome measures. Although the authors stated that 
subjects were recruited within 5-10 days, they did not report the mean or median time post- 
stroke for the patients recruited. 
Outcomes were reported as actual measures at 3 and 12 months and were compared 
between groups. No statistically significant differences were seen between the groups in 
overall or fine motor function, walking ability or ADI-s at 3 and 12 months. Quality of life was 
also similar in all groups at follow-up. . 
The authors concluded that their data did not support the hypothesis that TENS or 
acupuncture after stroke is beneficial in patients with moderate or severe hemiparesis. They 
also stated that although their study was the largest of its kind to date, it was still small. 
They suggested that the study may not have been adequately controlled as those in the 
control group received a degree of sensory stimulus. They stated that, on the basis of the 
results, these treatments could not be recommended as standard in the subacute phase for 
subjects with moderate or severe stroke. 
In 2002, Peurala et al looked at whether cutaneous electrical stimulation has a role in the 
enhancement of sensorimotor function in chronic stroke(167) . Their study was performed with 
59 patients with herniparesis (the degree of motor impairment was not specified) due to 
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chronic stroke (mean time to stroke 3.3 years (range 7 months - 14 years)). Subjects were 
recruited to the study during their 'yearly inpatient intensive rehabilitation period'. It is 
unclear what this period of rehabilitation entailed as no further details are given in the paper. 
The numbers in each group were unequal: 32 had active treatment in the paretic hand and 
19 in the paretic foot; 8 had sham treatment in the hand but none had sham treatment in the 
foot. The randomisation method was not described. Subjects received twice daily 
treatment sessions of 20 minutes for 3 weeks. 
Blinded outcomes were undertaken after the 3-week treatment period. The outcome 
measures included the Modified Motor Assessment Scale (MMAS)('04), 'paretic limb function 
test', limb sensory function (measured by Somatosensory Evoked Potentials (SEPs) and a 
Visual Analogue Scale (128) ) and 10 metre walking speed(165). Not all measurements were 
available on all subjects and the authors did not give reasons as to why this was the case. 
The 'paretic limb function test' is not a validated test of function. It was described by the 
authors as a clinical evaluation, assessed by picking up a pencil, all fingers extension, pinch, 
and wrist extension. Scores were given after treatment depending on whether the patient's 
performance was better, worse or the same as prior to treatment. It is not clear exactly how 
this was judged. 
At baseline, the age and sex distribution were reported for the total 59 subjects, but not for 
the individual groups. No other baseline demographics were given. Baseline MMAS, limb 
sensory function and 10m walk speed results were reported for each group but it was not 
stated whether there were any statistically significant differences between them. No losses 
to follow up were reported. 
In this study, the number of sessions actually given was stated -a mean of 21.6 +/- 6 
sessions. However, they did not report whether there were any differences between the 
groups in terms of treatment received. It is also of note that it was intended that subjects 
received a total of 42 sessions, so the mean number actually received was less than half of 
that intended. They report that the mean (SID) number of individual physiotherapy sessions 
received by the subjects was 10.4 (3) over the 3 week period and, again, this information 
was not given for the individual groups. 
The authors reported improved 10m walk speed in the hand treatment group, and improved 
WAS and sensory function in both treatment groups compared with baseline. The 
difference was statistically significant for the WAS in foot-stimulated patients, and for the 
10m walk and sensory function in the hand-stimulated patients. The authors concluded that 
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cutaneous stimulation may improve the motor and sensory function of the paretic limb even 
years after stroke, but did acknowledge the small numbers (particularly in the control group) 
and that'no real randomisation was done throughout the project. ' 
1.6.6.2 Summary of studies of ES to the upper limb for motorlfunctional 
recovery 
These ten studies are summarised in Tables 1 and 3. There is marked heterogeneity in 
terms of study size, the intervention studied and outcome measures chosen, which makes 
comparisons difficult. There is evidence that ES improves motor recovery but it is unclear 
whether this translates into improved upper limb function and subsequently a beneficial 
effect on ADLs (154.155) . The studies by Fransisco, Powell, 
Cauraugh and Popovic (88.152,158,160) 
which suggested that the ES improved function have limitations in their study design (see 
Tables I and 3). For example, Fransisco's study (158) was small in number, did not analyse 
dropouts and had variable treatment periods and outcome assessment times. The studies 
by Peurala, Johansson, Faghd and Chae (82,154.164,167) showed no benefit of ES on upper limb 
function. Faghri's studyý 82) showed a beneficial effect of ES on upper limb pain and shoulder 
subluxation. 
There is also a suggestion that any beneficial effects of ES are not maintained after 
(82,152) treatment is stopped 
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1.6.6.3 ES to the upper limb for shoulder subluxation and shoulder pain 
In 1990, Leandri et al undertook an RCT to evaluate the effectiveness of high-intensity TENS 
vs. low-intensity TENS vs. placebo for the treatment of herniplegic shoulder pain (132) . They 
recruited 60 subjects (20 in each group) with ischaernic stroke (mean 12 weeks after stroke). 
It is unclear where subjects were recruited from and how many were screened. All of the 
subjects had 'motor impairment' but could stand and walk with assistance, and all had 
shoulder pain. Those with polyarthritis, bony disorders, and 'overt psychological 
disturbances' were excluded. 
Subjects were randomised to receive either high intensity TENS, low intensity TENS or 
placebo for a 4-week period. The randomisation method is not described. Electrodes were 
placed on painful areas and treatment sessions were given 3 times weekly for the 4-week 
period (i. e. a total of 12 sessions). The actual duration of these sessions was not stated. 
Blinded outcomes undertaken after treatment and 1 month after that assessed 4 passive 
131) range of movements (PROMs) at the shouldePO, 
The baseline characteristics of all subjects were similar with no significant differences 
between groups in terms of age, gender, time since stroke onset, side of paresis and 
number with shoulder subluxation. Baseline PROMs at the shoulder were also similar 
between groups. 
The outcome measure was expressed as 'improvement' in PROMS. There was a 
statistically significant improvement in PROMS for subjects in the high intensity TENS group. 
Subjective reports of pain were also better in this group. There was some improvement in 
PROMS in the other 2 groups but these did not reach statistical significance. 
In 1999, Linn et al looked at whether electrical stimulation (ES) can prevent shoulder 
(133) subluxation after stroke 
This was an RCT of 40 subjects recruited within 48 hrs of admission to an acute stroke unit. 
Exclusions were given and subjects were randomised by the use of opaque sealed 
envelopes (20 to the intervention group and 20 controls). 
28 sessions per week (each session lasting 0.5-1 hour) of ES (to supraspinatus and posterior 
deltoid) were given to the treatment group for a total period of 4 weeks. No sham treatment 
was given to the control group. All subjects completed the study although 2 subjects 
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couldn't have x-rays at the end of the study period as they were unable to travel to the x-ray 
department. 
Blinded outcomes undertaken at 4 weeks and 3 months, were shoulder subluxation (x-ray 
appearances), pain (pain-free range of passive lateral rotation using a clinical gonlometer(130. 
131) ), motor function (upper arm section of the Motor Assessment Scale (102) ) and upper arm 
girth. 
There were no significant differences between the groups at baseline in terms of age, 
gender distribution, affected side, stroke classification, shoulder subluxation, pain, motor 
function and upper arm girth. The time from stroke onset is not reported, although it is 
stated that subjects were recruited within 48 hours of admission. 
There was greater subluxation in the control group at 4 weeks compared to the treatment 
group, although this difference did not reach statistical significance. This difference was not 
maintained after the withdrawal of treatment (i. e. at the 3-month assessment). There were 
no statistically significant differences in change in motor score, lateral rotation, pain and arm 
girth between groups over the total study period (i. e. up to 3 months). 
The authors concluded that subluxation was prevented during the ES treatment but then 
relapsed after the treatment was stopped. 
In 1999, Kobayashi et al also looked at therapeutic electrical stimulation (TES) for the 
reduction of shoulder subluxation(169). They also aimed to identify which of the 2 major 
muscles, supraspinatus or middle deltoid, was more effective in improving subluxation and 
shoulder function. 
Twenty four subjects with clinically suspected shoulder subluxation due to chronic stroke 
were identified from a rehabilitation unit. Seventeen of these, who showed downward 
shoulder subluxation on a stress x-ray test, were recruited. Exclusion criteria were given. 
There was no true randomisation method. Subjects were randomly assigned to an S group 
(who received TES to the supraspinatus muscle) and aD group (who received TES to the 
middle-deltoid muscle). Subjects who refused electrical stimulation or who were not able to 
undergo the continuous TES treatment were assigned to the control group. 
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The treatment groups received TIES for 15 minutes twice daily for a period of 6 weeks. 
There was no sham treatment for the control group. The effect of TIES of each muscle on 
shoulder subluxation during treatment was confirmed using x-ray. 
Outcome assessments were undertaken at 6 weeks and it is unclear whether or not these 
were blinded. These were to assess shoulder subluxation, maximal voluntary abduction 
force of the shoulder joint and EMGs of each muscle, shoulder pain, and muscle tone of the 
pectoralis major. To assess subluxation, x-rays were taken while patients were in a seated 
position, during a no-stress and a stress test. During the no-stress test, subjects kept their 
arm in a relaxed position, and during the stress test, a 3.5kg weight band was placed around 
the distal part of the upper arm. The maximum abduction force of the shoulder and EMG 
recordings were taken while the subject performed three 4-second trials of maximum 
abduction in a seated position. During this test, subjects were restrained by straps around 
the trunk to limit elevation, rotation of the scapula, and lateral flexion of the trunk. Shoulder 
pain was evaluated using a visual analogue scale (128) during the movement of voluntary 
abduction. Pectoralis major muscle tone was assessed using the modified Ashworth 
Scale 
Six subjects were assigned to the S group, 6 to the D group, and 5 to the control group. The 
time of stroke to randomisation was very different in each group (mean 60.3 weeks in S, 
95.0 weeks in D and 190.2 weeks in the control group). Baseline demographics were similar 
between the groups. Patients in the D group were older than those in the S and control 
groups (mean age 69.3 years compared with 59.3 and 53.2 respectively) although it is not 
reported whether this difference reached statistical significance. No statistically significant 
differences were seen in the degree of subluxation and maximum abduction force between 
the 3 groups before the TIES was given. 
In the stress test, there was decreased subluxation in the treatment groups compared to 
controls (which was statistically significant in the D group) after 6 weeks. No statistically 
significant results were seen in the no-stress test. There was an increased mean abduction 
force in the treatment groups compared to controls, which again reached statistical 
significance in the D group. Increased EMG activity was seen in both treatment groups but 
the EMG results for the control group are not reported. Seven subjects had pain at baseline, 
3 in the S group, 3 in the D group and one in the control group. Four of the 6 in the TES 
groups experienced as much as a 50% reduction in pain relief following the TIES treatment. 
Muscle tone was assessed in terms of change from baseline, and muscle tone did not 
decrease in any of the subjects when assessed at 6 weeks. 
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The authors concluded that TES treatment reduces shoulder subluxation and also results in 
an increase in force of contraction and EMG activity of affected shoulder muscles, and a 
decrease in pain. A comparison of the TES effects of the 2 muscles showed a tendency for 
deltoid muscle stimulation to be more effective in increasing muscle force. They state that 
these results thus indicate an improvement in shoulder function by the TES treatment, 
despite the fact that function is not actually assessed. The limitations of the study were that 
there were large differences in time from stroke onset between the groups. The 
randomisation method was questionable. The authors suggest that the efficacy of TES in 
preventing subluxation should be evaluated for long term use of TES treatment from the 
early recovery stage. 
A study by Chantraine et al in 1999(170) was performed to determine the effect of electrical 
stimulation on subluxation and shoulder pain in herniplegic subjects. One hundred and 
twenty patients were included from a total of 256 herniplegic subjects followed as inpatients 
or outpatients at the University Hospital of Geneva. Exclusions were given. Not all were 
Stroke subjects: there were 92 with cerebral thrombosis, 9 with cerebral haemorrhage, and 
19 with brain injury. All were within 2-4 weeks of diagnosis, and all had a subluxed and 
painful herniplegic shoulder. 
Subjects were alternately assigned to either the treatment or control group (i. e. there was no 
randomisation). Those in the treatment group received ES for 5 weeks; 130 minutes in the 
first week, then increasing throughout subsequent weeks. This ES was given to the 
shoulder but the authors do not report to which muscles it was applied. There was no sham 
treatment for the control group. Subjects were assessed at baseline and then outcomes 
Were undertaken at 1,3,6,12, and 24 months. It is unclear whether or not these 
assessments were blinded. Shoulder pain was assessed using a Visual Analogue Scale (128) 
and by recording the presence or absence of pain during active and passive movement of 
the shoulde r(130,131). Shoulder subluxation was assessed radiologically. Function was 
assessed by asking subjects to perform an antepulsion and abduction of their hemiplegic 
arm. Recovery of motor function was defined as the ability to raise the arm actively to 60 
degrees of antepulsion and to 40 degrees of abduction. 
The authors state that the groups were similar at baseline but only data regarding age and 
side of herniplegia is given. It is of note that subjects in this study were very young (mean 
52.7 years in the treatment group and 52.3 years in the control group). The authors report 
improvement in pain, subluxation, and motor function in the ES group which was maximal at 
6 months, and conclude that their work confirms that of other studies showing the beneficial 
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effect of ES on pain and subluxation in hemiplegic subjects. However, they do not use a 
validated tool to assess function, and it is difficult to generalise these findings in view of the 
limitations already described. 
In 2000, Wang et al(171) undertook an RCT to assess the effectiveness of a functional 
electrical stimulation (FES) programme on acute and chronic shoulder subluxation. Thirty 
two stroke subjects (16 men and 16 women) were recruited from rehabilitation inpatient and 
outpatient departments. It is unclear how many were screened. All participants had to 
demonstrate a minimum of 9.5mm of acromiohumeral distance in their affected shoulder. 
Those with a history of shoulder pain, traumatic lesions to the shoulder joint, limited 
functional range of shoulder motion, or reflex sympathetic dystrophy syndrome were 
excluded. 
Participants were placed into 2 groups: the short duration (herniplegia onset within 21 days) 
and the long duration (herniplegia onset more than 365 days previously) groups. Sixteen 
subjects were in each of these groups. The participants were then randomised to either a 
treatment or a control subgroup (n=8 in each) but it is unclear how this randomisation was 
done. Those in the treatment group received 6 weeks of FES to posterior deltoid and 
supraspinatus, followed by 6 weeks of routine therapy, followed by a further 6 weeks of FES. 
The FES was given 5 times weekly but the duration of these sessions is not stated. There 
was no sham treatment for the control group. 
The outcome was the degree of shoulder subluxation on X-ray. This was assessed at 6 
weeks, 12 weeks, and 18 weeks i. e. after both courses of the FES, and after the 6 weeks of 
routine therapy. It is unclear whether or not these outcomes were blinded. 
In the short duration group, the treatment and control subgroups were similar at baseline. 
There were statistically significant decreases in subluxation (compared with baseline) in the 
treatment group after both courses of FES, but this was not maintained during the period of 
routine therapy. In the long duration group, the treatment and control subgroups were 
similar at baseline. Of note, the degree of subluxation in all of these subjects was 
statistically significantly greater at baseline compared with those in the short duration group. 
No statistically significant differences in degree of subluxation were seen in either subgroup 
of the long duration group at any of the outcome times. 
In conclusion, this study demonstrated the benefit of ES in reducing subluxation in acute 
hemiplegic subjects, but this benefit was not maintained once the stimulation course ended. 
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It must be noted that this study was very small, and did not report the randomisation method. 
There was no sham treatment for controls, and it was unclear whether or not outcome 
assessments were blinded. 
1.6.6.4 Summary of studies of ES to the upper limb for shoulder subluxation 
and shoulder pain 
These five studies are summarised in Tables 2 and 3. Again, there is marked heterogeneity 
in terms of study size, the intervention studied and outcome measures chosen, which makes 
comparisons difficult. There is evidence of the benefit of ES in reducing shoulder 
subluxation and shoulder pain from these studies (132.133.169-171) . 
However, it is unclear 
whether this benefit translates into an improvement in motor function and ADLs, and there is 
also a suggestion that benefits seen are not maintained after the treatment is discontinued. 
1.6.6.5 Other RCTs of ES to the upper limb 
In 1998, Tekeoglu et al(172) performed a randomised controlled trial of 60 stroke subjects to 
look at the effect of transcutaneous electrical nerve stimulation (TENS) on Activities of Daily 
Living (ADLs). Subjects were between 30 and 240 days post stroke and all were in-patients 
of a university clinical research programme for hemiplegia after stroke. 
All stroke subjects had a herniparesis, and the diagnosis had been determined by 'physical 
and laboratory examination including CT and blood screen. ' Subjects had to be able to 
stand and walk with assisted if necessary, and give informed consent for participation in the 
study. No exclusions were given (e. g. previous neurological deficit). 
Participants were randomised to one of 2 groups (30 patients in each group) by block 
randomisation. Subjects in the treatment group received 8 weeks TENS treatment to the 
elbow and calf for half an hour per day, 5 days per week (Monday to Friday) i. e. a total of 40 
sessions. The sensory threshold was determined by the intensity of stimulation which was 
gradually increased to the 'bearable level'. Subjects in the control group received a sham 
stimulator. All subjects in the study received the same type of exercise programme each 
morning in addition to either active TENS or placebo TENS. 
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Blinded outcomes were undertaken at 8 weeks (i. e. after treatment). The Barthel lndeX(92) 
was used to assess ADI-s. Spasticity was also measured using the Modified Ashworth 
(156) Scale 
Baseline characteristics were similar between the 2 groups in terms of age, gender 
distribution, days post-stroke, side of herniparesis, and presence or absence of shoulder 
pain. However the baseline Barthel scores indicate that patients in the treatment group 
were initially much more dependent than controls, and this was statistically significant. 
At 8 weeks, an improvement in ADI-s was seen in both groups, but it was more marked (and 
reached statistical significance in the treatment group. There was a statistically significant 
reduction in spasticity in both groups at 8 weeks in both upper and lower limbs. 
The TENS treatment therefore had a positive effect on ADLs but none on spasticity. 
However, those in the treatment group were more dependent at baseline which may have 
confounded the results. As the subjects were recruited from a research programme, it is 
difficult to generalise these results. 
Also in 1998, Hesse et al(l 73) performed a double-blind randomised controlled trial of 
botulinum toxin and electrical stimulation in the treatment of upper limb flexor spasticity after 
stroke. Twenty four subjects between 6 and 11 months after stroke (mean 7.45 months) 
were recruited to the study. All were outpatients from a neurological rehabilitation clinic. All 
had severe upper limb flexor spasticity (at least grade 3 on the Modified Ashworth Scale (156) ) 
and a non-functional affected upper limb with no possibility of any selective movement. 
Exclusion criteria were given. Subjects were randomised to one of 4 treatment groups 
although the method used was unclear. The 4 groups were: botulinum toxin (botox) and 
electrical stimulation (n=6), botulinum toxin only (n=6), placebo and electrical stimulation 
(n=6), and placebo (n=6) only. The botox was to biceps, brachialis and the finger flexors. 
The electrical stimulation was to the arm and forearm for 30 minutes three times daily during 
the 3 days following the botox injection. There was no sham treatment for the placebo 
group. 
Blinded outcomes were undertaken at 2,6 and 12 weeks after treatment to assess muscle 
tone (Modified Ashworth Scale (156) ), limb position at rest, and difficulties encountered by the 
subject and/or observed by the caregiver with three ADI-s. 
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No baseline demographics or clinical features were reported. The authors conclude that 
electrical stimulation enhances the effectiveness of botox in treating spasticity. However, 
there were no differences across the groups for the Ashworth scores of the elbow, wrist and 
finger joints. The only statistically significant result seen was with regard to the facilitation of 
hand hygiene (daily activity cleaning the palm) when the combined treatment of ES and 
botox was superior to placebo and ES, and placebo alone. However, it was not statistically 
significantly better than treatment with ES and placebo. 
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1.6.6.6 Published reviews of the RCTs 
A number of published systematic reviews and meta-analysis of the randomised trials 
suggest that the evidence regarding the effectiveness of ES to the upper limb following acute 
stroke remains inconclusive (Table 4). None of these papers are re-analysis of primary data. 
The search strategy is detailed in Appendix 3.1. 
The meta-analysis published by Glanz et al in 1996(4) looked at 4 RCTs- They commented 
that there was inadequate documentation of the randomisation process and/or blinding in 
these trials. The trials looked at ES to different joints (2 ankle (174,175) 91 
knee (176)9 and 1 
wriSt(143) ) and the data from both upper limb and lower limb joints is combined in this meta- 
analysis. They concluded that ES appears to improve muscle strength recovery after stroke 
but it was unclear whether this reflected a clinical benefit as well. They recommended that 
future studies should be blinded and sham-controlled. 
In 1997, Binder-MacLeod et al published a review paper of FES(139). They gave a historical 
overview of FES and its applications and then described studies that looked at its clinical 
efficacy in both the upper and lower limbs. They concluded that although studies had 
suggested that FES may have the potential for improving the gait of hemiplegic patients and 
for reducing shoulder subluxation in such patients, further clinical studies were needed. The 
authors stated that they felt that FES might become a more common clinical tool in the 
treatment of the herniplegic patient in the future. 
Chae and Yu published a critical review in 2000 of neuromuscular electrical stimulation in 
hemiplegia (177) 
. They reviewed the efficacy of NMES in facilitating post-stroke motor re- 
learning and in reducing shoulder subluxation and pain. They then reviewed the 
development of upper and lower extremity neuroprostheses and their efficacy in reducing 
physical impairment and disability. 
Six trials of cyclic NIVIES for motor relearning were identified, 3 upper limb(' 52,154 155) and 3 
lower limb(5'- 174.175) trials. All of the 6 studies had small sample sizes. In the upper limb 
studies, all reported improved outcomes in motor impairment with the NIVIES treatment. 
However, in the studies by Powell and Sonde, there was no sham treatment for the control 
group, and the groups had unequal treatment intensities. It is thus difficult to say whether 
benefits seen in these studies were from the NMES or from increased treatment intensity, 
and placebo effects could not be ruled out in the absence of a sham treatment. Only the 
study by Powell reported number of patients screened. In Chae's study, there was a 
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significant drop-out rate and the authors failed to use an intention-to-treat analysis. All of the 
upper limb studies evaluated disability, but only the study by Powell showed benefit with 
NMES, however this was not maintained after the treatment was stopped. Five controlled 
trials of EMG-stim or PFST for motor relearning were identified, 3 upper limb (143,158,178) and 2 
lower limb (176.179) trials. Of the 3 upper limb studies, one used matched controls (i. e. it did 
not use a randomised controlled design (178) ). Again, the studies were reported as showing 
positive effects of stimulation on motor impairment but there were numerous flaws in study 
design. No longer term follow up was undertaken in either of the upper limb randomised 
trials (143.158) and sample sizes were small in all of the studies. None of the 3 upper limb 
studies had a sham treatment for controls, and Bowman's study did not report their 
randomisation method. 
Despite all of these limitations to the above studies, the authors of this review concluded that 
the evidence suggested that NMES enhances motor relearning in hemiplegia. They did, 
however, propose that future studies should be large, multi-centre, placebo-controlled, 
randomised clinical trials. They stressed that the studies should clearly define the study 
population and described the total number of patients screened in order to enable 
generalisability of findings. They stated the importance of identifying optimal stimulation 
parameters, and also suggested that stimulation techniques should be refined to maximise 
compliance and clinical outcomes. 
This critical review then discussed 4 randomised trials of NMES for shoulder dysfunction in 
herniplegia (82,133,138,170). Baker and Parker evaluated the NMES as a treatment, Linn as 
prevention, and Faghri evaluated it for both treatment and prevention. All studies 
demonstrated a reduction in shoulder subluxation, at least in the short term, but the effects 
on pain were inconsistent. There were methodical differences between studies. 
Chantraine's was the largest study but not all subjects had hemiplegia secondary to stroke. 
In addition, this study was not randomised, did not provide adequate baseline data, and was 
not blinded. Although Faghri's study looked at both treatment and prevention, shoulder pain 
and subluxation were not inclusion criteria. Linn's study showed a trend towards the benefit 
of NMES which was not statistically significant. The authors of the review hypothesised that 
this may have been because of small numbers, or inadequate stimulation dosing. 
Again, the authors concluded that future studies were needed to address the methodological 
limitations of previous studies. The final section of this review discussed NMES as a motor 
neuroprosthesis in herniplegia which will not be discussed in detail here. 
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A review in 2001 by Burridge et al(135) described in detail the theories behind motor re- 
learning following acute stroke and the evidence for the effect of ES on this re-learning 
process. They described the review by Chae and Yu in 2000 and commented on the 
methodological flaws in many of the published studies prior to the year 2000. The trials by 
Sonde, Chae and Powell(152,154.155) were then discussed in detail as their methodology was 
more 'robust'. The conclusions of these studies were that motor control improved with 
stimulation, but the authors of this review made the points that benefits were not sustained 
after treatment was discontinued, and that a reduction in impairment did not translate into an 
improvement in everyday activities. Finally, the use of EMG-triggered stimulation was 
discussed. The authors felt that putting the stimulation under the control of the patient may 
have been a more effective way (compared with cyclic ES) of improving motor re-learning, 
especially if the movement produced was a task-orientated one. They described 2 
studies (158.178) which showed positive results. 
The authors concluded that ES would be widely used in the future but that there needed to 
be an improved understanding its interaction with the central nervous system, and sound 
clinical evidence for its effectiveness. The authors concluded that, in order to achieve these 
goals, further trials were needed. These trials must be large, randomised and controlled, 
using rigorous methodology, and appropriate outcome measures. 
In 2001, a Cochrane review of electrical stimulation to the upper limb after stroke found 
significant benefits for range of pain-free humeral lateral rotation and glenohumeral 
subluxation (5) . There was no improvement in patients' reports of shoulder pain, although 
this 
(129) 
may have been due to inconsistencies in the use of pain rating scales by stroke patients 
There was no overall improvement in upper limb function, although significant benefit was 
reported from two of the four studies included in the meta-analysis (82,155) . It was uncertain 
whether the overall effect on recovery did not reach statistical significance because of the 
absence of any true benefit, or whether this was due to the large variation in study design 
and outcome measures used, and small numbers of study participants. The largest trial 
which investigated the effects of electrical stimulation on upper limb recovery found an 
impressive beneficial effect, but was not included in the analysis as a small percentage of 
study subjects had hemiparesis due to head injury rather than stroke(170) . The Cochrane 
Review concluded that there was an urgent need for adequately sized randomised controlled 
trials to investigate the effects of electrical stimulation on upper limb recovery and shoulder 
pain after stroke. 
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Chae and Yu published a further review of ES in 2002("0). This reviewed the same literature 
as the review of 2000, except that the study by Cauraugh (88) was added to the section about 
the use of EMG-stirn for motor relearning in herniplegia. The conclusions drawn were as 
already discussed and the need for future trials was again stated. There was more detail in 
this paper regarding refining electrical stimulation techniques i. e. the use of percutaneous 
ES rather than surface ES. 
A review by Yu and Chae, also published in 2002(1'31), discussed ES specifically for shoulder 
dysfunction. The studies by Baker, Faghri, Chantraine, and Linn (82,133,138,170) were 
discussed. In addition, studies by Kobayashi and Wang (169,171) were reviewed. The authors 
again reported in detail the methodical limitations of all of the studies, but concluded that ES 
reduces subluxation and may improve shoulder range of motion, enhance upper limb motor 
recovery, and reduce pain. The rest of the review discussed intramuscular NMES as an 
alternative therapy that is less painful and easier to apply than sNMES(182). They reported a 
pilot study to investigate the effects of intramuscular NMES(1"3) which demonstrated its 
feasibility although they acknowledged that further research was needed to evaluate its 
efficacy. 
A meta-analysis was undertaken by Ada et al in 2002(184). The primary purpose of this was 
to examine the efficacy of surface ES, which produced a motor response in supraspinatus 
and posterior deltoid, in both preventing and reducing subluxation at the shoulder. The 
secondary purpose was to examine the efficacy of surface ES in improving function of the 
shoulder both early (defined as within 2 months) or late (more than 2 months) after stroke. 
They reviewed the trials by Baker, Faghri, Kobayashi, Linn and Wang (82,133,138,169) , all of 
which looked at ES to supraspinatus and posterior deltoid as an adjunct to conventional 
therapy. The methodological quality of each was assessed using the PEDro scale (185) . They 
noted that the methods of assessing outcomes were similar for subluxation but more varied 
for function and pain. 
By pooling data from these trials, they stated that early ES plus conventional therapy was 
superior in reducing subluxation to conventional therapy alone. This was not the case for 
late ES however. In order to compare the effect of ES on function, outcome scores were 
converted to a percentage, and a random effects model used. This enabled pooling of this 
data and the results showed that early (but not late) ES was beneficial. In preventing pain 
(measured using a goniometer), there was no evidence that early ES was beneficial, but late 
ES may have been. 
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In summary, they concluded that there was evidence to support the efficacy of early ES (as 
an adjunct to conventional therapy) for preventing shoulder subluxation and for increasing 
upper limb function, and of late ES in reducing pain. They therefore recommended that 
stroke patients with a score of less than 4 on item 6 of the MAS("') early after stroke should 
receive ES to the shoulder. They acknowledged that their findings with regard to subluxation 
were similar to those stated in the Cochrane review (5) but that their results regarding pain 
were conflicting with this review. They suggested that this may be because the Cochrane 
review included trials where ES produced a sensory response as well as a motor one. They 
also pointed out that the trial by Wang et al(171 ) had unusually small standard deviations, and 
if this trial was removed from the meta-analysis, there was no evidence of a beneficial effect 
of ES on function (in keeping with the Cochrane review). 
A systematic review of TES was undertaken by de Kroon and colleagues in 2002C6'). Their 
objective was to assess the available evidence on the effect of TES of the affected upper 
extremity in improving motor control and functional abilities after stroke. They focussed 
specifically on TES rather than FES and identified 6 RCTs which met their criteria for 
selection. All of these trials looked at ES of the arm and wrist and 3 looked at patients in the 
acute phase after stroke (152,154,158). There were large differences between the trials in terms 
of time to randomisation, ES regime used and outcome measures. All of the studies looked 
at motor recovery but only 2 actually assessed functional abilities (88,152) . 
In two of the 
studies, a post-hoc subgroup analysis was undertaken to compare those less severely 
affected with those more severely affected. One study reported a significantly better effect 
on motor control in the less severely affected group than the more severely affected 
(155) 
, and 
the other reported a significant effect on functional abilities in the less severely affected 
group but no effect in the whole group (152) . De Kroon and colleagues concluded 
that there 
was evidence for a probable positive effect of TES on motor recovery, but none yet for a 
beneficial effect on function. 
A further review by Chae in 2003(1 86) looked at the same studies as were discussed in 
2002(181) and there was again detail regarding intramuscular ES as described above. 
Handy et al undertook a meta-analysis in 2003(87) . The purpose was to examine 
the 
effectiveness of ES for stroke patients in reducing shoulder subluxation, increasing range of 
motion of the shoulder, reducing pain, and improving functional use of the upper extremity. 
They recognised the paucity of RCTs of treatment and prevention of shoulder pain in stroke 
patients, and acknowledged that the measurement of pain is subjective. They reviewed the 
studies by Chantraine, Faghri, Cauraugh, Wang and Linn (82,133,170,171.188). They concluded 
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that there was evidence that ES produced a beneficial effect on range of motion, pain, upper 
extremity function, and subluxation, but acknowledged that their meta-analysis was limited 
by the small number of studies. 
A further meta-analysis by Bolton et al in 2004(189) assessed the effect of EMG-triggered 
neuromuscular stimulation on hand and arm function. They acknowledged that the different 
performance outcomes made it difficult to pool multiple studies for a robust comparison. In 
this meta-analysis, outcomes were looked at in terms of function and impairment. They 
looked at studies by Kraft, Hummelsheim, Francisco, Cauraugh, and Cauraugh & Kim (88,158. 
178,188.190) 
. It is important to note that the studies by Kraft and by Hummelsheim were not 
randomised controlled trials. 
A large mean effect size was seen when pooling data from these studies which indicated a 
significantly positive influence of EMG-triggered NMES on motor recovery outcome 
measures. However, the authors acknowledged that the quality of the 5 studies was 
variable but they chose to include them all as there were so few. 
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double-blind and sham- 
controlled. 
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1.7 Summary of introduction 
* Upper limb impairment affects the majority of stroke survivors, and over half of these still 
experience problems 6 months later. 
" The effectiveness of many upper limb rehabilitation interventions is unclear. 
"A variety of scales are available for measuring outcome in upper limb rehabilitation and it 
is important that ones chosen are valid, reliable, and relevant to the intervention and 
study population. 
" Electrical stimulation (ES) has been proposed as a safe method of improving outcome 
after stroke but the evidence for its effectiveness is unclear. The literature suggests that 
ES is effective in reducing subluxation following stroke and may have a beneficial effect 
on upper limb impairment and pain. However, the evidence is lacking that this is 
translated into clinical benefit i. e. an improvement in upper limb function and pain. 
" Previous studies of ES to the upper limb following stroke have methodological 
limitations. Many have recruited small numbers of subjects, have failed to use a secure 
randomisation method, have not used sham treatments for controls and/or have not used 
blinded, validated and reliable outcome measures. The setting for these studies has not 
always been in stroke units. 
" It is currently unclear what an ES programme should include (i. e. the amount and 
intensity of stimulation). 
Reviews of the literature have suggested that there is a need for larger, randomised 
controlled trials with robust methodology. 
Studies have suggested that subjects with a greater severity of upper limb weakness 
gain more benefit from ES treatment. However, evidence of benefit for other subgroups 
is lacking, so subjects with all levels of upper limb impairment should be included in 
future studies. 
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Chapter 2 Aims and Objectives 
2.1 Alm 
To evaluate a four week programme of surface neuromuscular electrical stimulation 
(sNMES) for subjects with upper limb impairment following acute stroke. 
2.2 Objectives 
To compare the upper limb function and impairment of stroke subjects who receive a 
programme of surface neuromuscular electrical stimulation (sNMES) to the upper limb 
(the intervention group) with those receiving placebo (the control group) at the end of a 
four week intervention period and three months after stroke. 
To compare the prevalence of post-stroke upper limb pain between the intervention and 
control group at the end of a four week intervention period and three months after 
stroke. 
To compare disability and global health status of the intervention and control group at 
three months after stroke. 
To seek the experiences and views of subjects about sNMES. 
Stroke patients wish to regain useful upper limb movement, so the primary outcome 
measure chosen for this study was upper limb function. Previous studies have looked at the 
effect of ES on subluxation, motor recovery and pain, and although there is evidence of the 
beneficial effect of ES on these, it is not clear whether this translates into improved 
functional recovery. The timings of assessments were chosen to coincide with the end of 
the treatment period and to look at longer term effects. Three and six months are widely 
used time points for measuring outcomes in stroke research. Three months was selected to 
enable comparisons with other studies, and to enable the research to be undertaken within 
the timescale available for an MD thesis. 
Although there is evidence that ES is beneficial in improving joint alignment (i. e. reducing or 
preventing subluxation) and reducing spaStiCity)(5,62), these outcomes were not measured in 
this study. There is often confusion when trying to define subluxation (33) , and 
its 
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measurement is unreliable and often of no new clinical significance 
ý181). There is no 
(156) 
validated measure of upper limb spasticity other than at the elbow 
At the 3-month assessment, participants were asked whether or not they had experienced 
symptoms from the ES, and to give their views on which stimulator they thought they had 
received. 
There was one pre-planned subgroup analysis in this study. This was to look at the 
outcomes of participants with mild/moderate upper limb function (ARAT>O) and those with 
severe functional impairment (ARAT=O) at the initial assessment. There is evidence that the 
severity of initial upper limb motor impairment is a predictor of upper limb recovery (3.65) , and 
there is also some evidence that ES is more beneficial in stroke patients with a milder 
degree of upper limb impairment(' 55) . 
Some of the outcome assessments were undertaken immediately after the intervention 
period and at 3 months (i. e. measures of impairment, function and pain), whereas others 
(disability and global health status) were only undertaken at 3 months. This was because 
outcomes such as impairment and pain were expected to be affected early after treatment 
whereas disability would be later effect. The difference in timings of outcome assessments 
therefore reflects this. A number of study participants were also likely to still be in hospital at 
the 4-week assessment so measurement of E-ADLs would not be possible. 
2.3 Compliance with treatment 
Previous studies of electrical stimulation have described the participants' intended amount of 
stimulation but only two (152.167) reported the amount of stimulation actually received. In a 
RCT, the treatment received by randomisation groups should differ only in receipt of the 
intervention. In this study, the amount of sNMES or sham given was recorded by the use of 
diaries (Chapter 6). 
2.4 Inter-observer study 
We undertook an inter-observer study to look at the inter-observer reliability of our outcome 
measures. We wanted to ensure that there was good reliability, i. e. minimal inter-observer 
variability, between the 2 nurses undertaking the blinded outcome assessments, and 
between the research fellow (CC) undertaking the initial assessments and these nurses 
(Chapter 7). 
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Chapter 3 Methods 
3.1 Design 
A two-centre pragmatic randomised controlled trial 
3.2 Study Design 
The design of the study is shown in Figure 1. 
Figure 1: Study Design 
Identify all patients admitted to the stroke wards at North Tyneside General Hospital and Wansbeck I 
General Hospital with acute stroke. 
I 
Assess eligibility 
I Obtain consent I 
Conduct baseline assessment 
RANDOMISE 
Intervention group Control group 
4-week blinded outcome assessments 
3-month blinded outcome assessments 
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The study design was in place prior to the appointment of the research fellow (CC). An 
application for a Teaching and Research Fellowship was made to Northumbria Healthcare 
NHS Trust in order for the study to be undertaken. This application was accepted and CC 
was appointed this post to start on 1s' November 2001. 
The research fellow (CC) wrote applications for ethical and Trust approval, wrote 
applications for funding to Remedi (successful) and PPP Healthcare (unsuccessful), 
designed study protocols for the day-to-day running of the project, developed assessment 
questionnaires, organised training in the delivery of sNMES, and held launch meetings for 
clinical staff before recruitment commenced. 
3.3 Intervention 
This comprised a standard programme of surface neuromuscular electrical stimulation 
(sNMES) to the upper limb commencing within 10 days of stroke onset. The following 
regimen was chosen as it has been used in previous trials and is widely used in clinical 
practice. Two surface electrodes placed over supraspinatus and posterior deltoid on the 
stroke affected side were used (Figure 2). 
Figure 2: Positioning of electrodes 
w 
The basic stimulation frequency was 30 Hz. The stimulator on time and the stimulator off 
time were 15 seconds with a3 seconds ramp up and 3 seconds ramp down time. The 
intervention group received a level of stimulation that was increased until a comfortable 
visible contraction of the shoulder muscles was clearly seen during each "on" period. 
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The 'sham' stimulator was identical to this intervention stimulator but an internal 
disconnection prevented any current from being delivered. It was applied in the same way, 
and the settings adjusted to a mid-point. 
In addition to their other rehabilitation needs, participants received a four-week programme 
of sNMES which was delivered outwith their individualised therapy sessions. On the first day 
participants received 30 minutes of sNMES and the duration of treatment was increased 
over the first week according to a study protocol until 3x1 hour treatment sessions per day 
were achieved, which was then administered daily for the next three weeks. Stroke unit 
therapists and nursing staff were trained in the technique so that it could be delivered seven 
days per week. Where possible, participants who left hospital before the end of the four- 
week intervention period continued to receive sNMES in their own homes. Training was 
given to participants, carers and support workers to enable them to use the equipment and 
members of the study team were available to deal with any queries or issues that arose. 
3.4 Primary outcome measure 
Upper limb function - Action Research Arm Test (ARAT) (6,7) at 3 months after stroke 
(Figure 3). This was chosen because it is a robust test, with proven validity and 
reliability in stroke patients, which assesses different components of arm function. 
Figure 3: Action Research Arm Test 
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3.5 Secondary outcome measures 
These were undertaken at the end of the four-week intervention period and three months 
after stroke. 
" Upper limb pain - 5-point severity scale and 0-10 numerical rating scale 
(127,128) 
" Pain free range of humeral lateral rotation 
(130,131) (degrees). 
" Impairment - Motricity Index(9); Star Cancellation Test of visuospatial impairment(79,80) 
" Upper limb function - ARAT (4 weeks)(8.7) ; Frenchay Arm Test (FAT)(") 
" Disability - Nottingham Extended Activities of Daily Living (E-ADL) Index (3 months 
only)('10) 
" Global health status - Nottingham Health Profile (NHP) (3 months only)("') 
" Experience and views of participants about sNMES - patients were asked which 
stimulator they thought they had received. They were also asked to comment on 
whether or not they had experienced symptoms from the sNMES, and were asked in 
general how they found the stimulator. 
3.6 Calculation of sample size 
A difference of 8 points on the ARAT score (6,7) was defined as clinically significant. This 
difference of 8 represented an improvement of 2 points on all 4 subtests of the ARAV", 7). 1n 
practice, this is the difference between not being able to do a subtest and then to partially 
complete it, or being able to partially do a subtest and then complete it fully. This clinical 
definition has not been used in previous studies. Using variance and effect size from 
previous studies we initially calculated that 180 subjects were needed to achieve a 90% 
chance (power 0.9) of detecting this 8 point difference (0.25 standard deviations) between 
mean ARATO . 7) scores in the intervention group and the control group (two tailed alpha 
=0.05). This sample size would also produce a 90% chance (power 0.9) of detecting a 0.5 
point difference (0.54 standard deviations) between mean FAT scores(8) (two tailed alpha 
=0.05). Allowing for 9% attrition of subjects (as experienced in previous studies) we planned 
to recruit 198 subjects. Eight hundred acute stroke patients are admitted to North Tyneside 
(NTGH) and Wansbeck General Hospitals (WGH) each year. Using the stroke register we 
estimated that 12 patients per month would be eligible to participate and that recruitment 
would be complete in 17 months. 
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Recalculation of power was undertaken at the end of December 2002 as recruitment rates 
were lower than predicted. To give an 80% chance (power 0.8) of detecting the above 
differences in mean ARAT(-') and FAT scores(), taking into account our actual attrition rate 
of 8%, we calculated that we would need to recruit a total of 168 patients. 
3.7 Ethical and Trust approval 
Permission to carry out the study was obtained from Newcastle and North Tyneside Joint 
Ethics Committee, Northumberland Ethics Committee (Appendix 2.11) and Northumbria 
Healthcare NHS Trust. The project was registered in accordance with the Data Protection 
Act. 
North Tyneside and Wansbeck are district general hospitals within Northumbria Healthcare 
NHS Trust. Approximately 800 patients with acute stroke are admitted to these 2 hospitals 
each year. Patient populations and stroke management at these 2 sites are typical of 
hospitals throughout the UK. Both hospitals have an acute stroke unit. NTGH has a stroke 
rehabilitation ward on the acute hospital site. Stroke patients at WGH are rehabilitated 
initially on the acute stroke ward, and then transferred to one of 4 community hospitals 
(based at Morpeth, Blyth, Alnwick and Berwick) for further stroke rehabilitation. 
3.8 Case ascertainment 
All patients admitted to the stroke wards at NTGH and WGH were identified by regular (twice 
weekly at each site) contact with the wards. 
3.9 Eligibility criteria 
All patients admitted to the stroke wards at NTGH and WGH within 10 days of acute stroke 
were assessed against the following eligibility criteria: 
Residence 
Usual residence in North Tyneside (NTGH patients) or in the catchment area for 
Morpeth Cottage Hospital (or Blyth Cottage Hospital from 1/7/02) (WGH patients). 
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Patients living in the catchment area for Berwick and Alnwick Infirmary were excluded 
for logistical reasons. 
Pre-morbid features 
" No other diagnosis likely to significantly interfere with rehabilitation. 
" Pre-stroke Oxford Handicap Scale (195) score < 4. 
" No previous major upper limb problem (stroke-affected side) likely to influence 
assessments i. e. an upper limb amputation/atresia, significant upper limb impairment 
from previous stroke, diagnosis of frozen shoulder, dislocation or fracture of the upper 
limb within 1 month. 
No regular analgesia specifically for the upper limb (stroke-affected side). 
No reason to preclude electrical stimulation (e. g. the presence of a permanent 
pacemaker or implantable defibrillator, a history of previous life-threatening cardiac 
arrhythmias, the presence of a metallic shoulder implantation on the stroke-affected 
side). 
Clinical 
0 Medically stable. 
" Patient opens eyes spontaneously or to speech (i. e. Glasgow Coma Scale(196) > 4). 
" No cognitive or language impairment likely to influence assessments 
" Evidence of upper limb weakness/drift and/or finger-nose incoordination and/or star 
cancellation fail. 
Reasons for non-eligibility were recorded on a standard proforma. 
We aimed to recruit patients with a wide range of upper limb impairments. All participants 
were required to have evidence of upper limb weakness/drift and/or finger-nose in- 
coordination and/or visual inattention. There is a wide variation in professionals' views as to 
who should be given sNMES and, in clinical practice, it is given to patients with a range of 
deficits. We also recruited patients with different stroke subtypes as there is no rationale to 
believe that stroke subtype (i. e. the vascular territory affected) can determine the effects of 
sNMES. 
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3.10 Assessment of eligibility 
Patients on the stroke wards were screened by a ward doctor using the eligibility criteria 
(Appendices 2.2 and 2.3). All eligible subjects were given a patient information leaflet 
(Appendix 2.4). The research fellow (CC) checked the names of those subjects screened 
against the names in the ward admission book to ensure that all new stroke admissions had 
been screened (Appendix 2.5). 
3.11 Consent 
The research fellow (CC) discussed the study with all eligible subjects to ensure that they 
had had time to consider the contents of the information sheet and that it had been clearly 
understood. The research fellow (CC) also answered any questions and confirmed eligibility 
prior to seeking written consent (Appendix 2.6). 
3.12 Initial assessment 
This was undertaken by the research fellow (CC) for all eligible subjects who had given 
written consent (Appendix 2.7). It consisted of demographic details, handedness, other 
relevant co-morbidity, new neurological impairment('97) , stroke subtype(198), and the CT head 
scan result. 
The research fellow then completed the following assessments for each participant: 
" Oxford Handicap Scale (OHS)(195) 
" Pain scale (pre and post-stroke)(127,128) 
" Nottingham E-ADL Index (pre-stroke)('10) 
" Abbreviated Mental Test Score (159) 
" Sheffield Aphasia Screening Test for acquired language disorders(199) 
*Motricity Index(9) 
*Frenchay Arm Test (FAT)(8) 
*Action Research Arm Test (ARAT)(6,7) 
Shoulder Shrug Test(7') 
National Institute of Health Stroke Scale (197) 
*Star Cancellation Test(7", 80) 
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Measurement of passive and active range of pain-free humeral external rotation (130,131) 
Basic testing of sharp-dull and hot-cold discrimination (to identify subjects at risk of 
central post-stroke pain in the upper limb)(200) 
Measurement of upper arm girth(133) 
*Inability to perform these assessments was scored as zero. 
The completed initial assessment forms were returned to the project secretary for entry onto 
a database designed specifically for the study. An information letter was sent out to the 
participant's general practitioner when the initial assessment details were entered onto the 
database (Appendices 2.8 and 2.9). 
3.13 Seven-day assessment 
At seven days after stroke, nursing staff were asked to complete the Barthel Activities of 
Daily Living (ADL) index(") to measure disability (Appendix 2.10). 
3.14 Randomisation 
All eligible subjects were randomised using a central independent telephone computerised 
service based at the University of Newcastle upon Tyne. Participants were stratified by 
severity of upper limb weakness according to the FAT(8) (scores 0,1 vs. scores 2-5). 
Participants were randomised to either the intervention or control group. There were no 
crossovers between groups. 
All of the sNMES boxes had a serial number inside the battery compartment. All the boxes 
were also labelled on the outside with another number (1,2,3 etc. ) which was known as the 
'box number'. A list was kept at the University detailing each box (its box number and serial 
number), whether it was intervention or placebo and whether it was located at NTGH or 
WGH. 
The research fellow (CC) telephoned the database manager who entered the name, FAT 
score(8) and subject location (NTGH or WGH) onto a database which was set up to randomly 
allocate participants to either the intervention group or the control group in blocks of eight, 
i. e. for every eight subjects entered into the study, four were in the intervention group and 
four were in the control group. 
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Once the participant had been randomised, the database manager informed the research 
fellow (CC) of the randomisation group, participant study number and box number. The 
research fellow (CC) recorded this box number and study number in the participant's stroke 
pathway, and collected this box from the ward. The randomisation group was not recorded. 
A blank white sticker was used to label the box with the participant's name and date of birth. 
A yellow sticker (Appendix 2.11) was placed on the inside back cover of their medical notes 
to clearly indicate that they were participating in the study. 
The research fellow (CC) then prescribed the sNMES on the participant's drug kardex. The 
research fellow (CC) set up the sNMES equipment on the participant with a member of 
stroke unit staff to ensure that it was done correctly. The sNMES was then commenced 
according to the study protocol. 
3.15 Applying and using sNMES 
Training was given to specific stroke unit nurses in applying and using the sNMES 
equipment (Appendix 2.12). 
The two sites for the electrodes were supraspinatus and deltoid on the stroke-affected upper 
limb. These sites were marked on the arm with a waterproof pen to aid future treatment 
sessions prior to putting the electrodes in position. The wires were then attached to the 
electrodes (red to the top electrode, black to the bottom) and to the box. Initially, the box 
mode was set to 'continuous' (mode 2) before setting the intensity level. 
The intensity knob was turned up slowly until muscle movement was seen at the shoulder. 
Once muscle movement was seen, the intensity knob was not turned up any further and the 
intensity level was noted. It was turned up slowly to enable subjects to become accustomed 
to any symptoms that they might experience, and to ensure that the level was not set higher 
than that required to produce movement at the shoulder. The intensity level remained 
approximately the same throughout treatment sessions. In the placebo group, the 
equipment was identical to that of the intervention group but an internal disconnection 
prevented any current from being delivered. In this case, no shoulder movement was seen 
and the intensity level was set at level 5. 
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The box mode was then changed directly over to 'alternate' (i. e. to deliver an intermittent 
current) (mode 3) and the equipment left in place for the duration of the treatment session. 
The protocol for the timing of the sNMES was the same in both the intervention group and 
the placebo/control group and is as follows: 
Day 1 Half an hour twice daily (morning and evening) 
Day 2 Half an hour twice daily (morning and evening) 
Day 3 Half an hour three times daily (morning, lunch and evening) 
Day 4 Half an hour three times daily (morning, lunch and evening) 
Day 5 1 hour in the morning, 1 hour at lunchtime, half an hour in the 
evening 
Day 6 1 hour in the morning, 1 hour at lunchtime, half an hour in the 
evening 
Day 7 onwards 1 hour three times daily (morning, lunch and evening) 
A timer was provided with each box which was used to time each session and was a 
reminder to stroke unit staff to turn off the equipment once the treatment session was 
complete. 
If subjects were to be discharged within the four-week treatment period, the participant 
and/or relative/carer was trained to apply the sNMES prior to the participant's discharge so 
that the sNMES could continue at home. 
At the start of the study, participants planned for discharge during the course of sNMES 
were asked to perform the ARAT(6 . 7) . Those achieving a maximum score were 
discharged 
home without the sNMES. The primary outcome measure was the ARAT and it was 
therefore decided that those achieving a maximum score on this test pre-discharge were not 
required to continue the sNMES at home. However, it was not practical to perform a pre- 
discharge ARAT on all participants due to be discharged and so it was decided in July 2002 
(6 months after the start of recruitment) to discharge all participants with the sNMES 
equipment unless there was another reason not to do so. 
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3.16 Recording sNMES 
The research fellow (CC) prescribed the sNMES treatment sessions on the participant's drug 
kardex and stroke unit staff signed for this treatment each time it was given. 
In addition, each participant was given a study diary (Appendix 2.13). The participant's 
name, study number, box number and sNMES intensity level were all documented in the 
diary by the research fellow (CC). The diary contained clear instructions for the timings of 
the sNMES treatment sessions as detailed above. For each treatment session, stroke unit 
staff ensured that participants were given the same sNMES box by checking that the box 
number corresponded to that recorded in the participant's diary. 
The treatment sessions were recorded in the diary by documenting the start and finish times. 
The diary was also used to record reasons for non-receipt of treatment and for staff to record 
comments about any difficulties encountered. 
Patients received a programme of therapy in addition to the sNMES sessions which was 
individualised and delivered by the multi-disciplinary team. We did not attempt to 
standardise the type and amount of therapy received as this would have been inappropriate. 
We believe that the amount and type of therapy received by patients is similar across sites; 
this was not formally recorded as it would have been difficult and time consuming to do 
accurately with the resources available. 
3.17 Staff training and use of sNIVIES 
Stroke unit staff at NTGH, WGH, Morpeth Cottage, and Blyth Community Hospitals were 
trained in applying and using sNMES. Newsletters were mailed out every 4 to 6 months to 
inform staff of the progress of the study (Appendix 2.14). Two lunchtime meetings were also 
held in each hospital during the first 6 months of the study to provide further training in the 
use of the sNMES equipment, and to answer any staff concerns or questions. The research 
fellow (CC) visited the wards on a weekly basis to ensure that the application of sNMES was 
correct, to provide individual staff training and to answer any questions. 
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3.18 Follow-up assessments 
A research nurse who was "blind" to the randomisation group undertook follow-up 
assessments at the completion of the four-week sNMES programme (Appendix 2.15) and 
three months after stroke (Appendix 2.16). The research fellow trained the research nurses 
to perform the assessments prior to the start of the study. Assessments took place in the 
hospital if the participant was an in-patient or if the participant had been discharged but was 
well enough to travel and happy to do so. Transport was provided. Participants who did not 
wish to or who were unable to travel to hospital were assessed in their own home. 
Before contacting the participant, the research nurse obtained the following details for each 
participant by reviewing the medical notes: 
0 Whether the participant was still alive 
Participant's date of death (if applicable) 
Whether the participant was discharged following their stroke 
Date of discharge (if applicable) 
Details of readmission to hospital (if applicable) 
Current contact address 
0 Current contact telephone number 
Details of any treatment interventions given for the upper limb (e. g. oral analgesia, 
steroid injection etc. ) 
0 New medical problems or new upper limb problems. 
3.18.1 Four-week assessments 
The four-week assessment was undertaken after completion of the course of sNMES i. e. on 
day 29 (+ 7 days after this i. e. up to day 35) after randomisation. As participants were 
recruited within 10 days of stroke, this assessment was performed up to 45 days after 
stroke. It was a face to face interview and assessment of upper limb function by a blinded 
research nurse and consisted of the following: 
0 Pain scale 
(127,128) 
Oxford Handicap Scale (195) 
Barthel ADL indeX(92) 
0 Star Cancellation Test("- 80) 
Motricity Index(g) 
Shoulder Shrug TeSt(71) 
Frenchay Arm Test(8) 
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Action Research Arm TeSt(6'7) 
Measurement of humeral lateral rotation 
(130,131) 
and upper arm girth 
(133) 
Reasons for non-completion of the assessment were recorded. At the 4-week assessment, 
the diary was collected and the sNMES equipment returned to its original ward. 
3.18.2 Three-month assessments 
The three-month assessment was undertaken on day 90 (+/- 7 days before or after this i. e. 
between day 83 and 97) after stroke. It was a face to face interview and assessment of 
upper limb function by a blinded research nurse and consisted of the following: 
Pain scale 
(127,128) 
Oxford Handicap Scale (195) 
Barthel ADL IndeX(92) 
Nottingham E-ADL Index(110) 
Star Cancellation TeSt(79,80) 
Motricity Index(9) 
Shoulder Shrug Test(71) 
Frenchay Arm Test(8) 
Action Research Arm TeSt(6,7) 
Measurement of humeral external rotation 
(130,131) 
and upper arm girth('33) 
Participant's views regarding sNMES 
In addition to the above, details of whether the participant was still receiving physiotherapy 
was recorded. Following the assessment, the participant was asked to complete the 
(116) Nottingham Health Profile (NHP) Questionnaire 
Reasons for non-completion of the assessment and/or questionnaire were recorded. 
3.19 Staffing and Organisation 
The project team consisted of the lead investigator (HR), the research fellow (CC), three 
consultant physicians with a specialist interest in stroke medicine, an engineer with expertise 
in the electrical stimulators, a project secretary, a database manager, and a project 
secretary. The project team met monthly to review progress and discuss issues arising. 
There was a research agenda at each meeting and minutes were kept. CC produced 
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progress reports and study updates for these meetings. A Gantt chart (Appendix 2.17) 
based upon project milestones was developed for project monitoring. 
The research fellow (CC) was responsible for the day to day running of the project. As 
discussed in this chapter, CC identified eligible subjects, sought consent, undertook the 
initial assessments, and was responsible for training ward nursing staff and ensuring that the 
sNMES was given as per protocol. CC held regular update meetings for clinical staff. The 
nursing staff administered the sNMES and completed the diaries to indicate treatment 
sessions given or reasons for non-receipt of treatment. Two 'blinded' research nurses, 
trained by CC, collected the outcome data at 4 weeks and 3 months. A database was 
developed by the database manager/statistical advisor and data entry was undertaken by 
the project secretary. The study database generated appointment dates and facilitated 
project management. CC supervised the data entry and analysis. 
3.20 Database and data quality checks 
All information from the initial assessments, diaries, 4-week and 3-month assessments was 
entered on to the database which was specifically designed for the study. Data was 
checked for quality and completeness on a regular basis. The database manager and 
project secretary ensured that data collection was complete. Any data discrepancies were 
identified at project meetings and data subsequently cleaned and re-entered if necessary. 
Outcomes of intervention and control groups were not compared until the final 3-month 
assessment had been completed. 
3.21 Data analysis 
The study was analysed on an intention to treat basis using SPSS. Comparative analyses of 
most of the non-parametric data were made using the Mann-Whitney U Test. For the 
analysis of data with only a few categories, a chi square test was used. The significance 
level was p=0.05. There was one pre-planned subgroup analysis: participants with 
mild/moderate upper limb functional impairment (ARAT(e . 7) score > 0) were compared with 
those with severe functional impairment (ARAT (6,7) score =0). 
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Chapter 4 Randomised Controlled Trial Results 
4.1 Recruitment 
Between Vt January 2002 and 29th February 2004,1627 subjects were admitted to the 
stroke wards at NTGH and WGH with a diagnosis of possible stroke. A total of one hundred 
and seventy six subjects participated in the study. Figure 4 shows the study profile. 
Based on stroke admission rates and data from previous studies, we initially anticipated that 
we would recruit 12 subjects per month over a 17-month period. However our initial 
recruitment rate was 7 per month. At the start of the study, subjects admitted to WGH who 
were resident in the catchment area for Blyth Community Hospital, Alnwick Infirmary and 
Berwick Infirmary were excluded for logistical reasons. Since the recruitment rate was lower 
than predicted, the study was expanded at the start of July 2002 to include those subjects 
resident in the catchment area for Blyth Community Hospital. At the end of 2002, the actual 
recruitment rate had remained low, so the predicted recruitment rate was adjusted to 7 per 
month and the recruitment period extended to a total of 26 months (Figure 5). 
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Figure 4: Study Profile 
1627 admissions to North Tyneside General Hospital or 
Wansbeck General Hospital with a diagnosis of possible stroke 
207 had not had an acute stroke 




1 194 eligible to parUcipate I 
1 16 eligible but refused consent I 
1 178 randomised I 
2 vvithdrawn after randomisation as final 
diagnosis was not stroke 
I 
1 176 study participants I 
90 randomised to intervenbon group 
6 died 
I refused follow up 
10 
lost to follow up 
I 
83 completed 4-week assessment 
3 died 
0 refused follow up 
10 
lost to follow up 
I 
80 completed 3-month assessment 
86 randomised to control group 
2 died 
0 refused follow u 
2 unable to contact 
82 completed 4-week assessment 
7 died 
1 refused follow up 
II 
lost to follow up 
I 
75 completed 3-month assessment 
* 4-week assessment was not completed for 2 of the control subjects but 3-month 
assessment was completed for both 
79 









Jan Feb Ma 
2002 2002 200 
12 76 
12 12 12 
mulat" 12 19 25 
c unnult- 12 24 36 
4.2 Reasons for exclusion 
ýAJAW 200 
Preftled 











One thousand two hundred and twenty six subjects with acute stroke were excluded as they 
did not meet the eligibility criteria. The commonest reasons for exclusion were no upper limb 
deficit (28%), living outside the area (19%), not within 10 days of stroke (12%), and receptive 
dysphasia (9%) (Table 5). Sixteen eligible subjects declined to take part in the study. 
Table 5: Main reasons for exclusion (n=1226) 
343 (28%) had no upper limb deficit 
241 (19%) lived outside the area 
154 (12%) were not within 10 days of stroke 
106 (9%) had a significant receptive dysphasia 
70 (6%) were medically unstable 
58 (5%) scored >3 on the pre-stroke Oxford Handicap Scale 
51 (4%) were discharged home prior to screening 
49 (4%) had previous upper limb impairment 
40 (3%) had a significant cognitive deficit 
34 (3%) had another diagnosis likely to interfere with rehabilitation 
31 (2%) scored <5 on the Glasgow Coma Scale 
22 (2%) died prior to screening 
10 (1 %) had a permanent pacemaker/implantable defibrillator 
10 (1 %) other e. g. participation in another research trial 
5 (< 1 %) had a diagnosis of recent shoulder fracture/dislocation (stroke-affected side) 
2 (<1 %) were taking regular analgesia for the upper limb (stroke-affected side) 
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4.3 Initial Assessment 
4.3.1 Baseline characteristics and upper limb assessment 
One hundred and seventy eight subjects were randomised but two were withdrawn 
immediately after randomisation as their final diagnosis was not stroke. Therefore, 176 
subjects participated in the study, 90 randomised to the intervention group and 86 to the 
control group (Figure 4). The median time from stroke to randomisation was 5 days [lQR 4- 
7] for the intervention group and 4 days [IQR 3-7] for the control group. 
Table 6: Demographics and pre-stroke characteristics (n=176) 
Intervention (n= Control (n=86) 
Sex -n Male 42(46.7%) 
47(54.7%) 
Female 48 (53.3%ý_ _ 
39 (45.3%) 
Median JIQR] age (years) All 75.5 [64-81] 73.5 [65.8-79] 
Male 73.5 [62.3-82] 71 [63-761 
Female 77 [64.3-80-81 76 [69-821 
Oxford Handicap Scale"W") (pre-stroke) -n (%) 
0- no symptoms 43(48%) 36(42%) 
I- few symptoms, not interfering with daily life 11(12%) 15(17%) 
2- symptoms changing life, can look after self 32(36%) 27(31%) 
3- symptoms changing life, need some help to 4(4%) 8(9%) 
look after self 
Nottingham E-ADO"") lndex(pre-stroke)-median 
[IQR] 
Mobility 5 [5-61 5 [3.8-6] 
Kitchen 5 [5-51 5 [4-51 
Domestic 3 [2-41 3 [2-4] 
Leisure 4 [2-4] 3 [2-4] 
Total 17JL15-181 16 (12.8-181 
Previous stroke -n 
___ 17(19%) 15(17%) 
Previous stroke affecting same side -n (%) 7(4%) 
12(14%) 
The demographics and pre-stroke characteristics are shown in Table 6. There was a higher 
percentage of females in the intervention group but this difference was not statistically 
significant. Randomisation groups were well matched for age, pre-stroke handicap and 
Extended Activities of Daily Living (measured by the Oxford Handicap Scale (195) and 
Nottingham E-ADL(110) Index respectively). The scores in the mobility subsection of the 
Nottingham E-ADL Index were higher in the intervention group compared to controls, but this 
difference did not reach statistical significance. 
Stroke type and impairment is shown in Table 7. One hundred and sixty four (93%) strokes 
were due to cerebral infarction. In terms of stroke subtype, the participants were well- 
matched between groups. More participants had left sided impairment in both randomisation 
groups because many right sided strokes were excluded due to the presence of receptive 
dysphasia. A greater number of participants in the intervention group had visuospatial 
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deficits at baseline compared With those in the control group although this difference did not 
reach statistical significance. There were no statistically significant differences between the 
groups in terms of stroke severity (National Institute of Health Stroke Scale (197), Barthel ADL 
IndeX(92)), visuospatial impairment (Star Cancellation Test(79)), cognition (Abbreviated Mental 
Test Score(159)) and aphasia (Sheffield Aphasia Screening Test("'). 
Table 7: Stroke type and impairment (n=176) 
Intervention (n=90) Control (n=86) 
Stroke type -n Infarct 86(96%) 78(91%) 
Haemorrhage 4(4%) 8(9%) 
Stroke subtypet"'ul -n (%) 
Total anterior circulation stroke 29(32%) 24(28%) 
Partial anterior circulation stroke 23(26%) 23(27%) 
Lacunar stroke 36(40%) 37(43%) 
Posterior circulation stroke 2(2%) 2(2%) 
Unilateral weakness affecting face -n (%) 66(73%) 62(72%) Unilateral weakness affecting arm/hand 89(99%) 84(98%) 
Unilateral weakness affecting leg/foot 86(96%) 80(93%) 
Sensory deficit affecting face 15(17%) 14(16%) 
Sensory deficit affecting arm/hand 40(44%) 41(48%) 
Sensory deficit affecting leg/foot 38(42%) 38(44%) 
Dysphasia 12(13%) 19(22%) 
Homonymous hemlanopla 30(33%) 28(33%) 
Visuospatial disorder 45(50%) 30(35%) 
Brainstem1cerebellar signs 2(2%) 3(3%) 
Other deficit 0(0%) 1 (1%) 
Side of upper limb impairment -n (%) Right 31(34%) 33(38%) 
Left 59(66%) 53(62%) 
National Institute of Health Stroke Scale""' 
Median [IORI 8.5 [6-121 9 [5-12.31 
Star Cancellation Test'""u) fail (Score <=51)-n (%) 38(42%) 31(36%) 
Sheffield Aphasia Screening Test' median [IQR] 
Age <59 (n=28) 19 [19-19.8] 19 [18-191 
Age 60-69 (n=32) 19 [18-201 19 [17.5-20] 
Age 70+ (n=1 16) 18 [15-191 17 [14-191 
Abbreviated Mental Test Score""' - median [IQRj - 
9 [8-101 9 [7.8-10 
Barthel ADL Index"T 7-days after stroke - median [IQR] 8 [4-14.81 10 [5.8-1 
In the initial upper limb assessment (Table 8), as discussed above, there were more 
participants with left sided upper limb impairment in both randomisation groups. Six 
participants (7%) in the control group reported pain pre-stroke compared with two (2%) in the 
intervention group but this difference was not statistically significant. The prevalence of 
upper limb pain following stroke at the initial assessment was similar between groups. The 
participants were well matched in terms of baseline upper limb impairment and disability 
(Motricity Index(g), Shoulder Shrug Test(71), Frenchay Arm Test(8), and Action Research Arm 
Test (ARAT)(6 . 7)) . Although many participants had reasonable upper limb muscle strength 
(arm Motricity Index(9) median scores of 57.5 in the intervention group, 60.5 in controls), 
most had no useful upper limb function (indicated by scores of 0 on the ARAVO , 7) and 
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Frenchay Arm Test(8)). There was no difference in terms of the presence of cerebellar signs 
and sensory symptoms between randomisation groups. 
Table 8: Initial upper limb assessment (affected side) (n=1 76) 
Intervention (n--90) Control (n=86) 
Handedness -n Right 82(91%) 78(91%) Left 7(8%) 6(7%) 
Ambidextrous 1 (1 %) (I %) 
Uncertain 0(0%) 0%) 
Current stroke affecting dominant hand-n(%) Yes 32(36%) 32(37%) 
No 58(64%) 54(63%) 
Side of upper limb impairment -n (%) Right 31(34%) 33(38%) Left 59(66%) 53(62%) 
Upper limb pre-stroke pain -n 2(2%) 6(7%) 
Upper limb post-stroke pain -n (%) 21(23%) 22(26%) 
Motricity Index"" (Scale of 1-100) 
median [IQR] 
Arm 57.5 [12-77] 60.5 [14.3 -77] 
Leg 70 [43-84] 70 [43-841 
Total 61.3 (36-82.41 63.3 [36.4-78.11 
Shoulder Shrug Ted median[IQRI 1 [1-21 
-n (%) 
0= no movement 16(18%) 14(16%) 
1= reduced movement 49(54%) 52(61%) 
2= normal movement 25(28%) 20(23%) 
Frenchay Arm Ted") median [IQR1 0.510-41 0 [0-41 
Action Research Arm Test (ARAT)t'5* 7- n=89 n=83 
(Scale 1-57) median[IQR] 
Total 0 [045.51 3 [047] 
Grasp 0 [0-151 0 [0-16] 
Grip 0 [0-10.51 0 [0-10] 
Pinch 0 [0-121 0 [0-12] 
Gross 0 [0-91 3 [0-91 
Number (%) of those with baseline ARAT =0 45(51%) 39(47%) 
Number (%) of those with baseline ARAT >0 44(49%) 44(53%) 
National Institute for Health Stroke Scale' best motor n=90 n=86 
arm -n (%) 
0- no drift 6(7%) 8(9%) 
1- drift after brief hold 36(40%) 37(43%) 
2- cannot resist gravity 15(17%) 12(14%) 
3- no effort against gravity 33(37%) 29(34%) 
Cerebellar signs -n (%) 2(2%) 3(3 
% ý 
Sensory symptoms -n (%) 41(46%) 41 8-16 
* ARAT performed in 154 participants (76 intervention, 76 controls); 20 subjects (13 intervention, 7 controls) were 
unable to sit and therefore scored 0. The ARAT was not performed In 4 participants (I intervention-felt 
unwell/dizzy. 3 controls-2 subjects unavailable; ARAT table unavailable for one subject). 
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4.4 Follow up assessments 
4.4.1 Four-week outcomes 
One hundred and sixty five participants completed the four-week assessments: 83 in the 
intervention group and 82 in the control group. Eight participants died prior to the 4-week 
assessment (Table 9), and one (in the intervention group) refused follow up although was 
alive and in private residence at the time that this assessment was due. We were unable to 
contact two participants within the timescale of the 4-week assessment. Both of these 
participants however completed the assessments at 3 months. 
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According to the study protocol, the 4-week assessment was to be done between days 29 
and 36 after randomisation. Participants in the intervention group were seen a median of 32 
days (range 27 to 43), and those in the control group a median of 31 days (range 26 to 42) 
after randomisation (Figure 6). 
There were no statistically significant differences between the groups in terms of current 
residence. More participants in the control group had been readmitted to hospital prior to the 
4-week review than those in the intervention group but this difference was not statistically 
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significant. The prevalence of new upper limb problems (stroke-affected side) was similar 
between groups (Table 9). 
Table 9: 4-week mortality, placement and dependence 
Intervention Control P value 
(n=90) (n=86) 
Dead -n (%) 6(7%) 2(2%) 0.279 
Institutionalised (nursing home/ n=84 n=84 
residential home/hospital) 42(50%) 35(42%) 0.353 
Oxford Handicap Scale (OHS)(195) n=83 n=82 
median [10R] 3 [2-5] 3 [2-5] 0.721 
Barthel ADL lndeX(92) n=83 n=82 
median [IQR] 14 [9-18] 15 [6-191 0.952 
Dead or dependent (OHS(' 95)3-5) n=89 n=84 
62(70%) 62(74%) 0.663 
Dead or dependent (Barthel(92) n=89 n=84 
.r . 
ig/2o)(201) 
69(78%) 60(71%) 0.456 
n=90 n=86 
Dead or Institutionalised 48(53%) 37(43%) 0.223 
n=83 n-82 
Readmission to hospital -n 2(2%) 5(6%) 0.277 
Recurrent stroke* 1 (1%) 10%) 1.000 
New upper limb problems -n (%)** 3(4%) 2(2%) 1.000 
(affected side) I 
um not report new upper orno proDiems resuiting trom tneir recurrent stroKe. 
New upper limb problems all secondary to new trauma 
There were no statistically significant differences between the groups in any of the upper 
limb outcome measures at 4 weeks i. e. upper limb impairment and disability (ARAT score(6), 
FAT score(8), Motricity Index(), Shoulder Shrug Testc7l), and Star Cancellation Test (79)), and 
upper arm girth(133) (Table 10). The pain assessment was similar between groups in terms of 
presence of pain in the affected upper limb, severity of pain (127,128), pain-free range of 
humeral lateral rotation (130,131) , and the number of participants receiving analgesia or other 
interventions for upper limb pain since their stroke (Table 11). 
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Table 10: 4-week upper limb outcome measures (affected side) 
Intervention Control P value 
(n=83) (n=82) 
ARAV"' n=81 n=82 
median [lQRj 
Total 45.0 [0-57] 45.510-571 0.888 
Grasp 15 [0-18] 12 [0-181 0.853 
Grip 12 [0-12] 12 [0-12] 0.523 
Pinch 12 [0-18] 11.5 [0-18] 0.818 
Gross 9 [0-91 9 [0-91 0.885 
FAV) n=83 n=82 
median VQRI 4 [0-51 4 [0-51 0.923 
Motricityýý) Index n=83 n=81 
median [IQR] 
Arm 77 [40-100] 81 [53-1001 0.574 
Leg 76 [62-100] 84 [58.5-1001 0.940 
Total 80 [52.5-931 77 [62.5-961 0.850 
Shoulder Shrug Tesf n=83 n=81 
median [lQR] 2 [1-2] 2 [1-2] 0.183 
n (%) - 0= no movement 16(19%) 11(14%) 0.409 
1= reduced movement 25(30%) 21(26%) 
2= normal movement 42(51%) 49 (61%) 
Upper arm girth"4ý1 in cm n=78 n=79 
median PQRI 31 [28-341 32130-341 0.353 
Star Cancellation Testt'ý n=83 n=82 
no. (%) failed 27(33%) 28(34%) 0.870 
* ARAT performed in 143 participants (73 intervention, 70 controls); 20 participants (8 intervention, 12 controls) 
were unable to sit and therefore scored 0. The ARAT was not performed in 2 participants (intervention group) -1 
barrier nursed, I ARAT table unavailable. 
Table 11: 4-week upper limb pain (affected side) 
Intervention Control P value 
(n=83) (n=82) 
Li-p-per limb paW"'-'ý"') -n (%) 22(27%) 26(32%) 0.462 if pain, median [IQR] 
5 point severity scale 3 [2-3.31 3 [2-4] 0.227 
0-10 numerical rating scale 5 [3-7.31 5 1`3.8-81 1 0.770 




Passive* n=80 n=79 
90 [77-100] 90 [72-102] 0.901 
Actve** n=81 n=77 
72.0 [20-95.51 70 [42.5- 5 0.614 
Taking regular painkillers for upper limb n=83 n=82 
ain -n (%) 18(22%) 18(22% 1.000 
Other interventions for upper limb pain n=83 n=82 
since stroke -n (%) 
None 62(75%) 63(77%) 0.856 
oral analgesia 21(25%) 17(21%) 0.580 
Steroid injection 0(0%) 0(0%) - 
TENS 2(2%) 0(0%) 0.497 
Botulinum toxin 0(0%) 0(0%) 
Other (amitryptiline) 0(0%) 1 (1%) 0.497 
One participant (intervention group) not assessed as barrier nursed. Missing data for 5 participants (2 
Intervention and 3 controls). 
** Two participants (control group) unable to understand and one (intervention group) barrier nursed therefore not 
assessed. Missing data for 4 participants (I intervention and 3 controls). 
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4.4.2 Three-month outcomes 
One hundred and fifty five participants completed the 3-month assessment, 80 in the 
intervention group and 75 in the control group. Ten participants died between the 4-week 
and 3-month assessment (Figure 4). Eighteen participants (9 intervention and 9 controls) 
died during the 3-month study period (Table 12). One participant in the control group, in 
private residence at the time that the 3-month assessment was due, refused follow up at 3 
months. Another participant in the control group was lost to follow up. They were alive and 
in private residence at the time that the 3-month assessment was due but we were unable to 
contact them. 
According the study protocol, the 3-month assessment was to be done between days 83 and 
97 post stroke. Participants in the intervention group were seen a median of 92 days (range 
82 to 131), and those in the control group a median of 93 days (range 84 to 116) after 
randomisation (Figure 7). 
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The majority of participants were in private residences at the time of the 3-month 
assessment, and there were no statistically significant differences between the groups in 
terms of current residence. The length of initial hospital stay was longer in the intervention 
group than the control group but this difference did not reach statistical significance. The 
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readmission rates since the 4-week assessment were similar between groups. The 
prevalence of new upper limb problems (stroke-affected side) was also similar between 
groups. There was no significant difference between groups in the number of participants 
still receiving physiotherapy at 3 months (Table 12). 
Table 12: 3-month mortality, placement, dependence, and physiotherapy 
Intervention Control P value 
(n=90) (n=86) 
Dead -n 9(10%) 900%) 0.883 
Institutionalised (nursing homelresidential n=81 n=77 
home/hospital) 21(26%) 17(22%) 0.704 
Oxford Handicap Scale (OHS)ý'ý'01 n (%) n=80 n=75 
median FlQR1 3 [2-41 3 [2-41 0.997 
Barthel ADL indexý') n=80 n=75 
median PORI 17.5 [11.3-201 17 [14-201 0.692 
n=89 n=84 
Dead or dependent (OHS(' 95) 3-5) 62(70%) 59(70%) 0.934 
n=89 n=84 
Dead or dependent (Barthel(92) <19/20ý 201) 60(67%) 55(65%) 0.913 
n=90 n=86 
Dead or Institutionalised 30(33%) 26(30%) 0.780 
Length of initial hospital stay (days) n=90 n=86 
median PQRI 35.5 [17-58.61 24.5 [12-63.31 0.131 
Readmission to hospital since 4 week n=80 n=75 
assessment -n (%) 5(6%) 5(7%) 1.000 
Readmission to hospital since stroke n=80 n=75 
n 7(9%) 8(11%) 0.895 
n=80 n=75 
Recurrent stroke 0(0%) (1%) 0.484 
New upper limb problems (since 4 week n=80 n=75 
assessment)* -n (%) (affected side) 2(3%) 3(4%) 0.674 
Still receiving physiotherapy at 3 months n=86 n=85 
nM 33(43.4%) 25(35.2%) 0.205 
- in tutj intervention group, one was aue to a trozen snoulaer and trie otrier to a swonen nana or unKnown 
aetiology. In the control group, one was due to trauma, one to arthritis, and one to recurrent stroke. 
The primary outcome measure was arm function as measured by the ARAT(' J) at 3 months 
after stroke (Table 13). Those in the control group achieved higher total scores than those in 
the intervention group (medians of 55.5 and 50.0 respectively) but this did not reach 
statistical significance. However, significant differences were seen in the grasp and gross 
subsections of the ARAT (6,7) , the controls achieving higher scores than the intervention 
group. The median [IQR] grasp score was 18 [12-18] in the control group and 12 [0-18] in 
the intervention group, and the median [IQR] gross score was 9 [9-9] in the control group 
and 9 [0-9] in the intervention group (p values of 0.014 and 0.015 respectively) (Table 13). 
Clinically, a difference of 3 on the ARAT(6 J) reflects not being able to do a subtest and then 
to fully complete it. 
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Table 13: 3-month upper limb outcome measures (affected side) 
Intervention Control P value 
n=79 n=74 
median [IOR] 
Total 50.0 [0-57] 55.5 [38.3-571 0.068 
Grasp 12 [0-181 18 [12-18] 0.014 
Grip 12 [0-12] 12 [8.8-12] 0.071 
Pinch 15 [0-18] 18 [8.5-18] 0.155 
Gross 9 [0-91 9 [9-91 0.015 
FAV") n=80 n=75 
median [IOR] 4 [0.3-51 5 [3.0-51 0.014 
MotriciWý') Index n=79 n=74 
median [IQR] 
Arm 84 [56-100] 93 [77-1001 0.025 
Leg 92 [70-100] 86 [76-100] 0.948 
Total 88 [66-1001 89 [76.5-1001 0.248 
Shoulder Shrug Tesf n=79 n=74 
median [IQR] 2 [1-2] 2 [1-2] 0.108 
n (%) 
0 (no movement) 9(11%) 5(7%) 0.273 
1 (reduced movement) 23(29%) 16(22%) 
2 (normal) 47( 0%) 53(72%) 
Upper arm girth""' in cm n=79 n=75 
median [IQR 32 [28-351 32 [30-351 0.105 
Star Cancellation Tesf", t5u) I n=80 n=75 
number (%) of subjects failed 25(31%) 18(24%1 n-371 
* ARAT performed in 153 participants (74 intervention, 70 controls); 9 participants (5 Intervention, 4 controls) 
unable to sit = score 0; not performed in 2 participants (11 intervention, I control) as the ARAT Table was 
unavailable. 
For the other measures of upper limb impairment and disability, the control group achieved 
higher scores on the FAT(8) and the Arm subsection of the Motricity Index(9) and these 
differences were statistically significant (Table 13). The median [IQR] FAT score was 5 [3.0- 
5] in the control group and 4 [0.3-5] in the intervention group, and the median [IQR] Arm 
Motricity Index score was 93 [77-100] in the control group and 84 [56-100] in the intervention 
group (p values of 0.014 and 0.025 respectively). Clinically, an improvement of 1 on the 
FAT(8) indicates being able to complete one of the 5 subtests that previously could not be 
done. 
There were no statistically significant differences between the groups for the remaining 
upper limb outcome measures i. e. Shoulder Shrug Test(71), upper arm girth(133) and Star 
Cancellation Test(7') (Table 13). When assessing visuospatial impairment using the Star 
Cancellation Test(7'), a greater percentage of participants failed this test in the intervention 
group compared to the controls but this was not statistically significant. 
There were no statistically significant differences between groups in the upper limb pain 
assessment at 3 months (Table 14). 
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Table 14: 3-month upper limb pain (affected side) 
Intervention (n=80) Control (n=75) P value 
Upper limb painý'z'---"01 n (%) 37(46%) 34(45%) 03 
If pain, median [lQR] 
5 point severity scale 3 [1-3] 3 [2-3] 0.429 
0-10 numerical ratinq scale 6 [3.5-81 7 [5-81 0.651 
Taking regular painkillers for UL 
pain-n (%) 25(31%) 19(25%) 0.477 
Humeral lateral rotation - range of 
pain free movemenel'- 131) 
median [IQR] 
Passive 90 [70-110] 89 [70-100] 0.924 
Active 80 [40-951 80 [50-961 0.650 
Other interventions for upper limb 
pain since stroke -n (%) None - 58(73%) 55(73%) 1.000 
Oral analgesia 22(28%) 19(25%) 0.856 
Steroid injection 0(0%) 0(0%) - TENS 0(0%) 0(0%) 
Botulinum toxin 0(0%) 0(0%) - Other 10%) 1 (1%) 1.000 
Assessment of disability using the Nottingham EADL Index('10), and global health status 
using the Nottingham Health Profile(' 16) showed no statistically significant differences 
between the groups at 3 months (Table 15). Although the median energy level and pain 
scores were higher in the control group than the intervention group, the inter-quartile ranges 
and distributions were similar between groups and the p values are therefore not statistically 
significant. 
Table 15: 3-month disability and global health status 
Intervention Control P value 
Nottingham-EADO"') Index n=80 n=74 
median [IQR] 
Mobility 1 [0-5] 2 [0-5] 0.209 
Kitchen 3 [1-5] 3.5 [0-5] 0.807 
Domestic 1 [0-2] 1 [0-31 0.566 
Leisure 2 [1-3] 2 [1-3) 0.551 
Total 8 [2-151 8.5 [2-151 0.515 
Nottingham Health Profile "67 median [IQR] n=76 n=71 
Energy level 39.2 [24-1001 60.8 [24-100] 0.998 
Pain 10.2 [0-37.41 18.7 [0-38.2] 0.673 
Emotional reactions 18.3 [0-56.0] 17.6 V. 1-40.61 0.756 
Sleep 34.6 [0-77.61 12.6 [0-50.4] 0.063 
Social Isolation 0.0 [0-41.21 0 [0-34.5] 0.793 
physical abilities 44.3 [13.5-57.2] 43.9 [11.6-57.3] 0.988 
Mean of subscales 31.2 [10.4-52.1] 28.1 [15.7-48.2] 0.577 
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4AZ 1 Participantsviews about sNMES 
In rehabilitation studies, it can be difficult to blind participants and assessors to treatment 
group allocation. Many previous studies did not use a sham treatment for control 
participants as we have in this study. In addition, many have not reported whether outcome 
assessors were blinded to treatment group allocation. 
We were initially concerned that control participants in this study would be aware that they 
were receiving 'sham' treatment but this has not been the case. In the intervention group, 
when participants were asked (at 3 months) which stimulator they had been given, 71% 
thought that they had been given the 'real' stimulator, 1% the 'dummy' stimulator and 28% 
were uncertain. In the placebo group, 20% thought that they had been given the 'real' 
stimulator, 24% the 'dummy' stimulator and 55% were uncertain (Table 16). That is, the 
percentage of those participants correctly identifying the type of stimulator was 71% in the 
intervention group and 24% in the control group. Overall, 49% of participants correctly 
identified their stimulator. Many more participants in the control group than the intervention 
group were uncertain about which type of stimulator they had received. This may have been 
because most of the controls did not experience any symptoms from their stimulator. 
Table 16: Experience and views of participants about sNMES 
Participants' views about sNMES Intervention (n=80) Control (n=74) P value 
Correct about type of stimulator received - 
n (%) 57(71%) 18(24%) <0.001 
Incorrect about type of stimulator received 
-n (%) I (I %) 15(20%) <0.001 
Unsure about type of stimulator received - 
n (%) 22(28%) 41(55%) <0.001 
Symptoms from the stimulator e. g. tingling 
-nN 68(85%) 15(20%) <0.001 
Pain from the stimulator -n (%) 14(18%) 10%) 0.002 
In the intervention group, 85% of participants experienced symptoms from the stimulator, 
and 18% attributed upper limb pain to the stimulator. In contrast, 23% of participants in the 
control group reported experiencing symptoms from the stimulator and 1% experienced pain 
(Table 16). 
Participants were also asked to give general comments regarding their experience of the 
sNMES. In 67% of cases, comments were positive or neutral. In 22%, the comments were 
negative, and 11 % of participants made no comment. In the intervention group, 59% were 
positive/neutral, 30% negative, and 11% made no comment. This was compared with 
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percentages of 75%, 15% and I I% respectively in the control group. Positive comments 
included "felt like a massage when the machine was on"; "felt more relaxed when the 
machine was on"; "lovely - relaxing". Neutral comments included "no bother"; "can't 
remember having it on"; "felt nothing at all - no problem". Negative comments included 
"uncomfortable at times"; did not like feeling tied down to machine"; "did not like it - got in 
the way of her clothes". 
Previous studies of upper limb sNMES which used a sham stimulator did not ask participants 
to comment on treatment group allocation or to give views regarding the stimulator. 
4.5 Summary of RCT results 
There was no statistically significant difference in arm function between groups for the 
primary outcome measure (total ARAT (6,7) score at 3 months after stroke). 
There were, however, significant differences in outcomes in favour of the control group 
when using other measures to assess arm function at 3 months (the grasp and gross 
subsections of the ARAT(6 7) , and the FAT(8)). 
" There was also a significant difference in favour of the control group when measuring 
upper limb impairment at 3 months using the Arm Motricity Index(9). 
" These results were surprising and the reasons unclear. 
" There were no statistically significant differences between the randomisation groups at 4 
weeks. 
* There were no statistically significant differences between the randomisation groups at 
baseline, in particular stroke subtype, cognition, pain and visuospatial deficit. 
e We undertook a post-hoc exploratory analysis to try to explain the differences seen 
between randomisation groups at 3 months. 
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Chapter 5 Subgroup and Secondaty Analyses 
The main randomised controlled trial results (Chapter 4) found no statistically significant 
difference in arm function between the randomisation groups for the primary outcome 
measure. However, significant differences were seen at 3 months in favour of the control 
group when using other measures to assess arm function. No statistically significant 
differences were seen between groups at 4 weeks. 
There were no obvious confounding factors to explain these results at 3 months in favour of 
the control group. The randomisation groups were similar at baseline, in particular, stroke 
subtype, pain and visuospatial deficit. More participants in the control group (n=9) dropped 
out between 4 weeks and 3 months compared with participants in the intervention group 
(n=3) (Figure 4). We analysed these dropouts in terms of their demographics and 4-week 
outcome measures to see if there were any differences between groups which may have 
confounded the results. Four-week outcome measurements for these participants are 
shown in Table 17. If the dropouts in the control group were more impaired at 4 weeks than 
those in the intervention group, this could have explained, at least in part, why the control 
group achieved better scoires at 3 months in the measures of function and impairment. 
However, this was not the case and the controls were in fact less impaired at 4 weeks than 
those in the intervention group (Table 17). 
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Table 17: 4-week outcomes for participants who dropped out of the study 
between 4 weeks and 3 months 
Intervention (n=3) Control (n=9) 
Sex -n Male 1(33%) 3(33%) 
Female 2(67%) 6(67%) 
Median [IQR] age (years) All 77 [76-*] 72 [69.5-81.5] 
Male 76 r] 75 [72-*] 
Female 78.5 [77-ý*] 71 [68-80.8] 
Institutionalised (nursing home/ residential 
home/hospital) -n (%) 3(100%) 8(89%) 
Oxford Handicap Scale (OHS)(195) 
Score 3 0(0%) 3(33%) 
Score 5 3(100%) 6(67%) 
Barthel ADL Index (92) 
median [IQR] 2 [0-*] 2 [0-17.5] 
Recurrent stroke 0(0%) 0(0%) 
ARAT(6,7) median [IQR] 
Total 0.0 [0-0] 0 [0-22.5] 
Grasp 0.0 [0-0] 0 [0-6] 
Grip 0.0 [0-0] 0 [0-6] 
Pinch 0.0 [0-0] 0 [0-6] 
Gross 0.0 [0-0] 0 [0-4.5] 
FAVO) 
median [IQR] 0 [0-0] 0 [0-2.5] 
Motricity Index(g) n=3 n=8 
median [IQR] 
Arm 1 [1-*] 54.5 [12-84] 
Leg 1 [1-*] 71.5 [44.3-90] 
Total 1 [1-*] 67.8 [29.5-83.9] 
Shoulder Shrug TeSt(71) n=3 n=8 
median [IQR] 0 [0-0] 1 [0.3-2] 
Star Cancellation TeSe79.80) 
no. (%) failed 3(100%) 9(100%) 
Upper limb pain 
(127,128,130,131) 
n (%) 1(33%) 3(33%) 
If pain, median [IQR] 
5 point severity scale 2 3 [2-*] 
0-10 numerical rating scale 9 5 [1-*] 
- uname to caicuiate aue to sman numners 
There was one pre-planned subgroup analysis to look at the outcomes of participants with 
mild/moderate upper limb function (ARAT>O) and those with severe functional impairment 
(ARAT=O) at the initial assessment. There is evidence that the severity of initial upper limb 
motor impairment is a predictor of upper limb recovery (3.65). There is also evidence that ES 
is more beneficial in stroke patients with a milder degree of upper limb impairment(155). 
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5.1 Outcomes according to initial arm function 
5.1.1 Outcomes at 4 weeks, according to initial arm function 
There were no statistically significant differences between the groups for mortality, 
placement or dependency (measured by the OHS(195) and Barthel ADL Index (92) ) at 4 weeks 
when the outcomes were analysed according to initial arm function (ARAT=O vs. ARAT>O) 
(Table 18). 
Table 18: 4-week mortality, placement and dependency, according to initial 
arm function 
Intervention Control P Intervention Control P 
value value 
ARAT=O ARAT=O ARAT>O ARAT>O 
n=45 n=39 n=44 n=44 
Dead n (0/6) 6(13%) 2(5%) 0.275 
Institutionalised n=39 n=37 n=44 n=44 
(NH/RH/hospital) n(%) 31(79%) 26(70%) 0.508 10(23%) 9(20%) 1.000 
Dependent (Barthe1<1 9/20) n=39 n=37 n=43 n=42 
n(%) 37(95%) 34(92%) 0.671 25(58%) 21(50%) , 
0.592 
OHV"4'0' n=39 n=37 n=43 n=42 
median [IQRI 5 [3-51 5 [3-51 0.551 2 [2-41 3 [2-31 0.469 
Barthel ADL lndexý" n=39 n=37 n=43 n=42 
median [1QRj 9 [4-131 6 [2.5-15.51 0.617 18 [15-201 18 [14-181 0.477 
Table 19: 4-week affected upper limb outcomes, according to initial arm 
function 
Intervention Control P value Intervention Control P value 
ARAT=O ARAT=O ARAT>O ARAT>O 
n=39 n=37 n=43 n=42 
ARAV'5") n=37 n=37 n=43 n=42 
median [IOR] 0 [0-20.5] 0 [043] 0.917 57 [48-57] 53.5 [44.8-57] 0.200 
Grasp 0 [0-71 0 [0-121 0.702 18 [18-181 18 [12-18] 0.054 
Grip 0 [04.51 0 [0-12] 0.555 12 [12-12] 12 [12-121 0.937 
Pinch 0 [0-1.5] 0 [0-8.5] 0.520 18 [12-18] 18 [10.3-18] 0.547 
Gross 010-91 0 [0-91 0.844 9 [9-91 9 [9-91 0.417 
FAT"') n=39 n=37 n=43 n=42 
median [IQR1 
- 
0 [0-21 0 [0-2.51 0.602 5 [4-51 5 [4-51 0.197 
Motricityýý') hd ex n=39 n=36 n=43 n=42 
median [IQRI 
Arm 40 [1-77] 53 [29.3-77] 0.348 93 [84-100] 93 [77-100] 0.807 
Leg 76 [34-841 62 [34.3-84] 0996 92 [76-1001 92 [70-1001 0.664 
Total 57 [22-781 64.5 [30-761 0.702 68 [81.5-1001 92 [76.9-1001 0.768 
Star cancellation n=39 n=37 n=43 n=42 tesf7g, 8()) fail 
n(%) 19(49%) 0.258 7(16%) 5(12%) 0.757 
Shoulder Shrug n=39 n=36 n=43 n=42 TesP) median IIQRI 
- 
1 [0-11 110-21 0.401 2[1-21 212-21 0. 
Upper arm girth"" n=36 n=35 n=42 n=41 in cm median [IQRI 29 [26.3-321 31 [30-341 0.091 
1 
32 [29-35.6 33 [29.5-341 0.798 
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No statistically significant differences between the groups were seen in any of the upper limb 
outcome measures when the 4-week outcomes were analysed according to initial arm 
function i. e. upper limb impairment and disability (ARAT(3 . 7) , FAT(8), Motricity Index(9), Star 
Cancellation Test(79- 80), and Shoulder Shrug Test(71)), and upper arm girth(133) (Table 19). 
There were also no significant differences between groups for the affected upper limb pain 
assessment('27- 128.130,131) at 4 weeks, according to initial arm function (Table 20). 
Table 20: 4-week upper limb pain (affected side)(127 1 
12', "0 ' 131) 
, according to initial arm function 
Intervention Control p 
value 
Intervention Control p 
value 
ARAT=O ARAT=O ARAT>O ARAT>O 
Pain n=39 n=37 n=43 n=42 
Affected side -n 17(44%) 16(43%) 0.841 5(12%) 10(24%) 0.235 
If Pain n=17 n=16 n=5 n=10 
Severity scale - median 3 [1.5-3.51 3[2-4] 0.402 3 [2.5-3.5] 3.5 [2-4] 0.679 [1QR] 
Numerical rating scale - 
median jlQR] 5 [3.5-8] 5 [2.5-81 0.901 5 [2-6.5] 6 [4.5-7.3] 0.371 
Humeral lateral rotation 
- median [IQR] 
Passive n=37 n=34 n=43 n=42 
82 [63.5-94.5] 84.5 [60-97] 0.403 95 [82-110] 90 [79-110] 0.334 
Active n=37 n=32 n=43 n=42 
An rn-7, i 
5.1.2 Outcomes at 3 months according to initial arm function 
There were no statistically significant differences between the groups for mortality, 
placement and dependency (measured by the OHS("', 5) and Barthel ADL IndeX(92)) at 3 
months when participants were analysed according to initial arm function (Table 21). 
Table 21: 3-month mortality, placement and dependency, according to initial 
arm function 
Intervention Control P value Intervention Control P value 
ARAT=O ARAT=O ARAT>O ARAT>O 
n=45 n=39 n=44 n=44 
Dead n 8(18%) 7(18%) 0.791 0(0%) 2(5%) 0.494 
Institutionalised n=37 n=32 n=44 n=42 (NH/RH/hospital) n (%) 19(51%) 13(41%) 0.516 2(5%) 4(9%) 0.428 
Dependent (Barthel n=37 n=30 n=43 n=42 
<1 9/20) n(%) 31(84%) 23(77%) 0.452 20(47%) 21(50%) 0.829 
OHS n=37 n=30 n=43 n=42 
median j1QRJ 4 [3-51 4 [3-51 0.974 2 [1-31 3 [2-31 0.358 
Barthel ADL inde)Ou"' n=37 n=30 n=43 n=42 
median FIQRJ 14 [7-181 14.5 [5-18.51 , 0.815 19117-201 18.5 [16-201 1 0.465 
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In those participants scoring 0 on the ARAT(6 . 7) at baseline, differences were seen between 
the groups in favour of the control group for the assessment of arm function. The median 
total ARAT(6- 7) score at 3 months was greater in the control group than the intervention 
group but this difference did not reach statistical significance. There were, however, 
statistically significant differences in favour of the control group in the grasp and gross 
subsections of the ARAT(6 . 7) (Table 22). 
For the other measures of upper limb impairment and disability, there were again differences 
in favour of the control group when analysing participants who scored 0 on the ARAT(6- 7) at 
the initial assessment. The control group achieved higher scores on the FAT(') and the Arm 
Motricity Index(g), and the difference in the Arm Motricity Index scores reached statistical 
significance. 
In the ARAT=O group, no other statistically significant differences were seen for the other 
7 (71) upper limb outcome measures i. e. the Star Cancellation Test( 9,80), Shoulder Shrug Test 
and upper arm girth(133) (Table 22). 
Table 22: 3-month upper limb outcomes (affected side), according to initial 
ARAT(6,7) score 
Intervention Control P value Intervention Control P value 
ARAT=O ARAT=O ARAT>O ARAT>O 
ARAV6,7F- - n=37 n=30 n=42 n=41 
median [IQR] 
Total 0 [0-33.5] 34.5 [0-541 0.057 57 [51-571 57 [52.5-57] 0.690 
Grasp 0 [0-6] 11 [0-18] 0.049 18 [17.3-181 18 [18-18] 0.201 
Grip 0 [0-12] 9.5 [0-12] 0.124 12 [12-12) 12 [12-121 0.673 
Pinch 0 [0-6] 3 [0-17.31 0.179 18 [16.5-181 18 [16-18] 0.963 
Gross 0 ro-91 910-91 0.034 919-91 9 [9-91 0.444 
FAT"' n=37 n=30 n=43 n=42 
med! 29 IQR LU 0.010-3.51 3 [0-4.31 0.086 5 [4-51 5 [4-51 0.134 
MotriciVý'J n=36 n=29 n=43 n=42 
Index 
median [IQR] 
km 53 [15-77] 77 [35-93] 0.039 100[85-1001 100[86-100] 0.544 
Leg 73 [48.8-921 76 [41-85] 0.899 100[92-100] 100[81-100] 0.792 
Total 67 r44-76.51 76.5r4l. 5-86.51 0.204 100[88-1001 1001`84.8-11001 0.938 
Star n=37 n=30 n=43 n=42 
cancellation 
test(79"10) fail 
n (%) 15(41%) 15(50%) 0.469 10 (23%) 3(7%) 0.068 
Shoulder Shrug n=36 n=29 n=43 n=42 Tese7l) 
median [IQRI 1 [0.3-21 2 [1-21 2.115 2 1`2-21 2 r2- 1 0.858 
Upper arm n=36 n=30 
t t_ 
n=43 n=42 
girth(133) in cm 
. median 
[IQRI 
, 29 [26.3-331 30 [29-35.31 0.087 32 [29-361 1 33 [31-351 1 0.543 1 
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No statistically significant differences between the groups were seen on any of the upper 
limb outcome measures for participants who scored more than 0 on the ARATO' 
7) at the 
initial assessment (Table 22). 
There were no statistically significant differences In the affected upper limb pain 
assessmene"'7- 121ý IM. 131) at 3 months when this was analysed according to initial arm 
function (Table 23). 
Table 23: 3-month upper limb pain (affected side) 
(127,128,130,131). according to 













n=37 n=30 n=43 n=42 
Affected side - n(0/9) 23(62%) 19(63%) 1.000 14(33%) 14(33%) 
1.000 
If Pain n-23 n=19 n=14 n=14 Severity scale - 
median [10R] 2 [1.31 3 [2-31 0.220 3 [2-3-31 312-3.31 0.839 
Numerical rating scale 
- median [IQRI 6 [3-91 7 [5-81 0.557 6 [3.5-7.31 513.5-7.31 0.874 
Humeral lateral n=37 n=30 n=43 n=42 
rotation - median [IQR] 
Passive 70 [52-951 82.5 [64.8-941 0.340 95 [86-1101 92180-1001 0.131 
Active______ L So 110-82.51 62.5 tO-86.31 1 0.765 85 0-1001 82163.8-1001 0.478 
Table 24: Disability and global health status, according to Initial ann function 




- - ARAT=O ARAT=O ARAT>O 
ARAT>O 
Notti nFtý; m ; --ý-L n-37 n=30 n=43 n=41 Incle)PO) 
median [10111 Mobility 











Domestic 0 [0-0.51 010-1.3] 0.569 1 [1-5] 111,3.51 0.773 Leisure 
T t 1 [0-21 1 [0-2.3 I 0.638 3 
[2-41 3 [2-31 0.874 
al o 5-71 210 2 [0-131 0.959 11.0 t8-18.01 12 [7.5-16.51 0.717 NHP . n=33 n-29 - n=43 n=41 median [IQRI Energy level 60.8[24-1001 60.8[24-63.21 0.554 36.8124-1001 60.8124-1001 0.376 Pain 
Emotional i 
22.9[0-60A] 20.510-521 0.865 g[O-34.61 14.8[0-37.51 
16A 3 5 43 1 
0.347 
0 636 react ons Sleep 27.3[7.1-61.81 21[7.2-49.7] 0.461 16.8[0-45.81 [ . - . 1 . 308 Social Isol ti 
49.6112.6-77.61 12-610-55.31 0.142 22.4[0-77.61 12.6[0-34.3] 
44 
0. 









0[0- . 11 34.5111.2. . 0.481 
Total 40.7[20.5-59 81 
64.61 




Assessment of disability using the Nottingham EADL Index("O), and global health status 
using the Nottingham Health Profile (NHP)(116) showed no statistically significant differences 
between the groups at 3 months when the results were analysed according to initial arm 
function (Table 24). 
5.2 Further exploratory analyses 
Further exploratory analyses were undertaken. As the results of our single pre-planned 
subgroup analysis showed that the negative effect of sNMES was only seen in those with 
initially severe upper limb impairment, we chose other subgroups which were measures of 
stroke severity: the presence or absence of shoulder weakness at baseline (measured by 
the Shoulder Shrug Test(71)), the NIHSS(197), and the stroke subtype (TACS/PACS vs. 
LACS/POCS)(198). 
We also hypothesised that the side of deficit may be of importance. Those with the non- 
dominant arm affected and/or those with visuospatial deficit (seen more commonly in right 
hemisphere strokes) may have been more susceptible to any negative effects of sNMES. 
Those with sensory deficits may also have been more susceptible. 
1. Other measures of stroke severity 
e Initial Shoulder Shrug Test(71) (score 0 vs. score 1 or 2) as there is evidence that the 
presence of a shoulder shrug following stroke is a good prognostic indicator for 
recovery of hand movement(72). 
National Institute of Health Stroke Scale (binary split of initial NIHSS score Le. 0-9 vs. 
>/=10)(197) 
Stroke subtype (TACS/PACS vs. LACS/POCS)(198) 
2. Side of upper limb impairment (left versus right) 
3. Dominant hand versus non-dominant hand affected 
4. Presence/absence of visuospatial deficit at baseline 
5. Presence/absence of sensory loss at baseline 
Change from baseline was also analysed. 
5.2.1 Outcomes according to Initial Shoulder Shrug Test 
In those with moderate/severe shoulder weakness at baseline (Shoulder Shrug Test (71) score 
0 or 1), arm function as measured by the total ARAT(e 7) score at 3 months was statistically 
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significantly better in the control group than the intervention group. With respect to the other 
measures of upper limb impairment and disability at 3 months, differences were also seen in 
favour of the control group and these reached statistical significance in the grasp, grip and 
gross subsections of the ARAT(6,7), the FAT(8) and the Arm Motricity Index(g) (Table 25). 
Table 25: 3-month u 
, 
pper limb outcomes (affected side), according to Initial 
Shoulder Shrug Test' , 
Intervention Control P Intervention Control P value 
value 
Shoulder Shoulder Shoulder Shoulder 
Shrug=0-1 Shrug=O-1 Shrug=2 Shrug=2 
N=58 n=54 n=21 n=20 
ARAT"** 33 [0-57] 54 [30-57) 0.046 57 [47.5-57] 58 [51-57] 0.859 
median [IQR] 
Grasp 6 [0-18] 18 [4.5-18] 0.022 18 [13.5-18] 18 [18-18] 0.234 
Grip 12 [0-12] 12 [2.3-12) 0.077 12 [12-12] 12 [12-12] 0.582 
Pinch 6 [0-18] 16 [0-18] 0.104 18 [15-18] 18 [13-18] 0.975 
Gross 9 [0-91 9 F6.8-91 0.023 9 [9-91 9 [9-91 0.299 
FAV") median [IQRI 3 [0-51 4 [2-51 0.014 5 [4-51 5 [4.3-51 0.455 
Motricitýý') Index- 
median [IQR] 
Arm 77 [43.8-94.8] 89 [77-100] 0.018 100 [88.5-100] 100 [93-100] 0.683 
Leg 84 [64-100] 84 [61.5-100] 0.993 100 (92-100] 100 [86-100] 0.899 
Total 76.5 [48.9-971 84.5 [69.3-1001 , 0.210 100 [90.5-1001 100 [90.4-1001 , 0.793 J 
In those with no shoulder weakness at baseline (Shoulder Shrug Test (71) score 2), no 
statistically significant differences were seen between groups at 3 months in terms of arm 
function, disability and impairment as measured by the ARAT (6,7) , FAV) and Motricity 
Index(9) (Table 25). However, the numbers in these groups were small, and there may have 
been a ceiling effect as all of the scores were at the top end of the ranges. 
5.2.2 Outcomes according to NIHSS 
In those with less severe strokes (NIHSS(197) 0_9), the control group achieved statistically 
significantly higher scores in the grasp and gross subsections of the ARAT(e 7) , and the FAT 
at 3 months than the intervention group (Table 26). 
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Table 26: 3-month upper limb outcomes (affected side), according to NIHSS(19 
1 
Intervention Control P Intervention Control P 
value value 
Initial NIH Initial NIH Initial NIH score Initial NIH score 
score 0-9 score 0-9 >/=10 >/=10 
n=49 n=47 n=30 n=27 
ARAVO, 57 [30-57] 57 [51-57] 0.181 0 [0-40.5] 33 [0-54) 0.167 
median [IOR] 
Grasp 18 [6-18] 18 [18-18] 0.006 0 [0-12.81 10 [0-18] 0.244 
Grip 12 [12-121 12 [12-12] 0.171 0 [0-121 9 [0-121 0.137 
Pinch 18 [6-181 18115-181 0.293 0 [0-12] 0 [0-17] 0.405 
Gross 919-91 9 [9-9] 0.048 0 [0-9] 9 [0-9] 0.099 
FAVO) n=50 n=47 n=30 n=28 
median [IQR] 5 [3-51 5 [4-51 0.011 0 [0-41 3 [0-41 0.107 
Motricitytý')'Index n=49 n=47 n=30 n=27 
median [IQR] 
Arm 93 [77-100] 100 [86-100] 0.056 53 [7.8-81.5] 77 [30-100] 0.125 
Leg 100 [76-1001 100 [77.5-100] 0.719 76 [38-100] 76 [34-86] 0.728 
Total 96 [76.5-1001 96.3 [84.4-1001 0.383 67.5 1`36.4-88.11 76.5 [39-891 0.391 
In those with more severe strokes (NIHSS('97) >/=10), absolute differences were seen in 
favour of the control group at 3 months in terms of arm function, disability and impairment as 
measured by the total ARAT(S. 7), grasp, grip and gross subsections of the ARAT(5 . 
7) 
, FAT(") 
and Arm Motricity Index(') (Table 26). None of these differences reached statistical 
significance but the numbers in both of these groups were small. 
5.2.3 Outcomes according to stroke subtype 
Table 27. - 3-month upper limb outcomes (affected side), according to stroke 
subtype(198) 
Intervention Control P Intervention Control P 
value value 
TACS/PACS TACS/PACS LACS/POCS LACS/POCS 
n=46 n=37 n=33 n=37 
ARAVu"F----- 34 [0-57] 43 [10.5-57] 0.573 54 [17.5-57] 57 [52.5-57] 0.043 
median [IQR] 
Grasp 6 [0-181 18 [0-181 0.226 18 [5.5-181 18 [16.5-18] 0.024 
Grip 12 [0-12] 12 [0-12 0.693 12 [2.5-121 12 [0-121 0.019 
Pinch 6 [0-18] 12 [0-18] 0.686 18 [6-181 18 [13.5-181 0.139 
Gross 910-91 9 [2-91 0.221 19 [4-91 9 [9-91- 0.035 
ýAýT T- n=46 n=38 n=34 n=37 
median [IORI 3.5 [0-51 4 [1.5-51 0.474 4 [2-51 5 [4-51 0.003 
Motricitytý') Index 
median [1QR] 
Arm 77 [46.5-1001 92 [76-100] 0.417 85 [70-1001 100 [84.5-100] 0.016 
Leg 92 [57.5-100] 84170-1001 0.977 92 [76-1001 92 [76-100] 0.936 
Total 86 [46.8-1001 88 [71.5-1001 , 0.671 88 [70.8-1001 92 [80.6-1001 , 0.223 
In those with lacunar strokes (LACS) or posterior circulation strokes (POCS) i. e. no 
disturbance of higher cortical dysfunction, the control group achieved statistically significantly 
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, 7) higher scores at 3 months in the total ARAT(e , grasp, grip and gross subsections of 
the 
ARAT(6 . 7), FAT and Arm Motricity Index(9) than the intervention group (Table 27). 
In those with total or partial anterior circulation strokes (TACS or PACS), differences were 
, 
7) 
seen in favour of the control group at 3 months in the total ARAT(6 , grasp and pinch 
subsections of the ARAT(6- 7) and Arm Motricity Index(9) (Table 27). None of these 
differences reached statistical significance. 
5.2.4 Outcomes according to side of upper limb impairment 
There were statistically significant differences in favour of the control group in the grasp and 
gross subsections of the ARAT(6,7) in those participants with left sided impairment. In these 
subjects, arm function as measured by the total ARAT(6 J) score at 3 months, was also better 
in the control group but the difference did not reach statistical significance (Table 28). 
In terms of the other measures of upper limb impairment and disability (the FAT(8) and the 
Arm Motricity Index(9)), there were differences in favour of the control group in those with left 
sided impairment but these differences did not reach statistical significance (Table 28). 
Table 28: 3-month upper limb outcomes (affected side), according to side of 
upper limb impairment 
Intervention Control P value Intervention Control P value 
Side of Impairment Left Left Riqht Riaht 
ARAT", " n=53 n=45 n=26 n=29 
median [IQR] 
Total 33 [0-571 54 [27-57] 0.124 55.5 [31.3-57] 57 [43-57] 0.480 
Grasp 6 [0-181 18 [3-18] 0.044 18 [6-18] 18 [13.5-18] 0.263 
GOp 12 [0-121 12 [3-121 0.129 12 [8.8-12] 12 (12-12] 0.511 
Pinch 6 [0-181 17 [0-181 0.240 18 [5.3-18] 18 [12-181 0.618 
Gross 9 [0-91 9 [8-9] 0.047 9 f6.8-91 9 [9-91 0.310 
FAT" n=54 n=45 n=26 n=30 
median FIQRJ 3.510-51 4 [2.5-51 0.065 4.5 f2-51 5 [4-51 0.176 
Motricity"I Index n=53 n=44 n=26 n=30 
median [IQR] 
Arm 78 [46.5-100] 92.5 [77- 0.142 85 [70-1001 96.5 [84- 0.093 
100] 100] 
Leg 92 [64-1001 85 [70-100] 0.961 92 [76-1001 100 [76-100] 0.900 
Total 86 [48.3-100] 88.5 [84- 0.440 88 V3.1-100] 93 [76.5- 0.488 
1001 1001 
The median total ARAT(6 . 7) score at 3 months in those with right sided impairment was also 
greater in the control group but, again, this difference did not reach statistical significance. 
In these subjects, there were also differences in favour of the control group in terms of other 
measures of upper limb impairment and disability (the FAT(') and the Arm Motricity Index(9)), 
but these were not statistically significant (Table 28). 
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5.2.5 Outcomes according to whether or not dominant hand affected 
In those with the non-dominant hand affected, the control group achieved statistically 
significantly higher scores at 3 months in the total ARAT(6,7), grasp and gross subsections of 
the ARAT(S. 7), FAT and Arm Motricity Index(g) than the intervention group (Table 29). 
In those with the dominant hand affected, small absolute differences were seen in favour of 
the control group at 3 months in the total ARAT (6,7) and Arm Motricity Index(") but these did 
not reach statistical significance (Table 29). The numbers in these groups were small and 
the subjects may have had less severe strokes as many individuals were excluded because 
of dysphasia. There may have been a ceiling effect as all of the scores were at the top end 
of the ranges. 
Table 29: 3-month upper limb outcomes (affected side), according to whether 
or not dominant hand affected 
Intervention Control P Intervention Control P 
value value 
Dominant hand Dominant hand Non-dominant Non-dominant 
affected affected hand affected hand affected 
n=25 n=26 n=53 n=47 
ARAT"') 57 [40-571 57 [43-571 0.925 30 [0-57] 54 [24-571 0.043 
median [IQR] 
Grasp 18 [9-18] 18 [14.3-18] 0.787 6 [0-181 18 [1.5-181 0.014 
Grip 12 [12-12] 12 [12-12] 0.913 12 [0-12] 12 [3.8-12] 0.056 
Pinch 18 113.5-18] 18 [12-18] 0.830 6 [0-18] 16.5 [0-18] 0.110 
Gross 9 [9-9] 9 [9-9] 0.610 9 (0-9] 9 V. 5-9] 0.020 
FAr") n=26 - n=27 n=54 n=48 
median [IQRI 5 [3-51 5 [4-51 0.677 3 [0-51 4.512.3-51 0.013 
Motricity"I Index n=26 n=27 n=53 n=47 
median [IQR] 
Arm 92 [77-100] 100 [84-1001 0.338 77 [46.5-100] 92 [77-100] 0.049 
Leg 100 [76-1001 100 [76-100] 0.704 92 [64-100] 84 [70-1001 0.786 
Total 96 [75.5-1001 94.5 [76.5-1001 0.977 84 [48.3-1001 88.5 [76.5-1001 0.225 
5.2.6 Outcomes according to presence/absence of visuospatial deficit at 
baseline 
In those with no visuospatial deficit at baseline, the control group achieved statistically 
significantly higher scores than the intervention group at 3 months in the following measures 
of arm function, disability and impairment: total ARAT(O . 7) , grasp, grip and gross subsections 
of the ARAT (1.7) , FAT and Arm Motricity Index(") (Table 30). 
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Table 30: 3-month upper limb outcomes (affected side), according to 
presencelabsence of visuospatial deficit at baseline 
Intervention Control P Intervention Control P 
value value 
Visuospatial Visuospatial No visuospatial No visuospatial 
deficit at deficit at deficit at baseline deficit at baseline 
baseline baseline n=39 n=51 
n=40 n=23 
ARATIO, 'J 24.5 [0-571 33 [0-54] 0.682 54 [26-571 57 [51-571 0.067 
median [IQR] 
Grasp 6 [0-181 1210-181 0.988 18 [6-18] 18 [18-181 0.010 
Grip 8.5 [0-12] 7 [0-12] 0.752 12 [5-121 12 [12-12] 0.045 
Pinch 3 [0-18] 0 [0-17] 0.403 18 [6-18] 18 [15-18] 0.126 
Gross 7.5 [0-9] 9 [0-9] 0.866 9 [7-9] 9 [9-9] 0.019 
FATIOJ n=40 n=23 n=40 n=52 
me an IQRJ 3 [0-51 310-41 0.720 4 [2.3-51 5 [4-51 0.004 
Motricity"" Index n=39 n=22 n=40 n=52 
median [IQR] 
Arm 77 [40-100] 77 [29.8-100] 0.866 92 [77-100] 100 [84.3-100] 0.039 
Leg 92 [48-100] 76 [33.8-100] 0.451 92 [76-1001 100 [76-100] 0.835 
Total 76 [44-1001 77 [29.5-1001 0.903 90.5 [73.6-1001 92 [81-1001 0.309 
In those with v1suospatial deficit at baseline, absolute differences were seen in favour of the 
control group at 3 months in the total ARAT(6 . 7) and grasp and gross subsections of the 
ARAT (11.7) but these did not reach statistical significance (Table 30). The numbers in these 
groups were small. 
5.2.7 Outcomes according to presence/absence of sensory loss at baseline 
In those with no sensory loss at baseline, the control group achieved statistically significantly 
higher scores at 3 months in the total ARAT(6.7), grasp, grip and gross subsections of the 
ARAT(6.7) 
, FAT and Arm Motricity Index(') than the intervention group (Table 31). 
For those with sensory loss at baseline, absolute differences were seen in favour of the 
control group at 3 months in the total ARAT (6,7) , grasp and pinch subsections of the ARAT(6- 
7) 
, and Arm Motricity Index(g) but these did not reach statistical significance (Table 31). The 
numbers in these groups were small. 
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Table 31: 3-month upper limb outcomes (affected side), according to 
presencelabsence of sensory loss at baseline 
Intervention Control P Intervention Control P value 
value 
Sensory loss Sensory loss No sensory loss No sensory loss 
at baseline at baseline at baseline at baseline 
n=36 n=32 n=43 n=42 
ARAT(b, " 36.5 [0-57] 48.5 (5.3-571 0.689 51 [8-57] 57 [42.8-57] 0.027 
median [IQR] 
Grasp 9.5 [0-18] 18 [0-181 0.338 15 [4-18] 18 [14.3-18] 0.013 
Grip 12 [0-12] 12 [0-12] 0.573 12 [0-12] 12 [12-121 0.045 
Pinch 6 [0-18] 13.5 [0-18] 0.821 17 [0-18] 18 [12-18] 0.071 
Gross 9 [0-9] 9 11-9] 0.267 9 [2-91 9 [9-9] 0.022 
FAT"' n=36 n=33 n=44 n=42 
median [IQRj 3.5 [0-51 4 [1-5] 0.224 4 [2-51 5 [4-51 0.024 
Motricityý" Index n=36 n=33 n=43 n=41 
median [IQR] 
Arm 77 [45.8-100] 86 [77-1001 0.355 85 [71-100] 100 [84-100] 0.024 
Leg 92 [54.3-100] 80 [71.5-100] 0.667 92 [70-100] 100 [76-1001 0.722 
Total 84 [47.6-100] 83.3 [65.5- 0.771 88.5 [68.5-100] 92 [77-100] 0.178 
96.51 
5.2.8 Change from initial assessment 
5.2.8.1 Change from initial to 4-week assessment 
There were no statistically significant differences between the groups in any of the upper 
limb outcome measures when assessing the change from the initial to the 4-week 
assessment (i. e. upper limb impairment and disability (ARAT(6.7), FAT(8), Motricity Index(g), 
Star Cancellation Test(79), and Shoulder Shrug Test(71)), and upper arm girth (133)) (Table 32). 
p In terms of upper limb function, the median A 'AT(6,7) gain was 3.5 and 1 in the intervention 
and control groups respectively. Clinically, this reflects an improvement from not being able 
to do a subtest and then to partially complete it, or being able to partially do a subtest and 
then complete it fully. Median FAT(8) gains were 0 and 1 in the intervention and control 
groups respectively. The FAT(8) consists of 5 tasks and is scored from 0 to 5. Clinically, a 
gain of 1 indicates the ability to complete a task that could not be done previously. 
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Table 32: 4-week upper limb outcome measures (affected side) - change from 
initial to 4-week assessment 
Intervention (n=83) Control (n=82) P value 
ARAT" " change median [IQR] n=80 n=79 
Total 3.5 [0-24.3] 1 [0-301 0.602 
Grasp 0 [0-7] 0 [0-9] 0.865 
Grip 0 [0-7] 0 [0-6] 0.698 
Pinch 0 [0-6] 0 [0-91 0.725 
Gross 0 [0-41 0 [0-41 0.482 
FAVOJ change n=83 n=82 
median [IOR] 0 [0-21 110-21 0.920 
MobiciW"J Index change n=83 n=81 
median [IQR] 
Arm 14 [0-29] 21 (5-35.5] 0.137 
Leg 9 [0-221 8 [0-221 0.986 
Total 12.5 [0-24.51 14.5 [4.3-27.31 0.258 
Star cancellation tesF', ""J n=83 n=82 
change n (%) 
Baseline Fail - 4-week Fail 23(28%) 21(26%) 0.607* 
Baseline Fail - 4-wk Pass 11(13%) 7(9%) 
Baseline Pass - 4-wk Fail 4(5%) 7(9%) 
Baseline Pass - 4-wk Pass 45(54%) 47(57%) 
Shoulder Shrug Tesf "r-change n=83 n=81 
median [IQRI 0 [0-11 0 [0-11 0.162 
Upper arm girthl""'J (cm) change n=75 n=74 
median [IQRI 1 [-1-2.51 0 [-1.5-2.01 0.366 
'A chi square test on a 42 table was used (to show whether the distribution of the values in the cells is 
significantly different or not) therefore only one p value for the whole table. 
Change in affected upper limb pain from the initial assessment to 4 weeks was also similar 
between groups in terms of presence of pain, severity of pain 
(127.128), 
and pain-free range of 
humeral lateral rotation 
(130,131) (Table 33). 
Table 33: 4-week upper limb pain (affected side) 
(127,128 , 130,131). change from 
initial to 4-week assessment 
Intervention (n=83) Control (n=82) P value 
Pain change n (%) 
Baseline no pain - 4-wk no pain 52(63%) 47(57%) 0.748* 
Baseline no pain - 4-wk pain 11(13%) 16(20%) 
Baseline pain - 4-wk no pain 9(11%) 9(11%) 
Baseline pain - 4-wk pain 11(13%) 10(12%) 
Severity scale change - median 0 [0-0] 0 [0-0.3] 0.900 [lQR] 
Numerical rating scale change - 
median [IQRI 0 [0-0] 0 (0-0] 0.636 
Humeral lateral rotation change - 
median [IQR] 
Passive n=80 n=79 
14.5 [-5-27.3] 10 [-15-34] 0.960 
Active n=81 n=77 
-5 F60-01 -10 f-42.5-21 0.822 
-A cm square test on a 4XZ table was used (to Show whether the distribution of the values in the cells is 
significantly different or not) therefore only one p value for the whole table. 
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5.2.8.2 Change from initial to 3-month assessment 
The change in arm function (measured by the total ARAT(6 7) and FAT(8)) from the initial to 
the 3-month assessment was greater in the control group than the intervention group but this 
difference did not reach statistical significance. There were, however, significant differences 
in favour of the control group in the grasp and gross subsections of the ARAT(e , 7) when 
analysing change from the initial to the 3-month assessment (Table 34). The gains in 
ARAT(6,7) and FAT(8) scores in the intervention group were similar to those at 4 weeks, 
whereas those in the control group were greater, indicating further improvements in the 
controls between 4 weeks and 3 months. 
In terms of change from the initial to the 3-month assessment for the other measures of 
upper limb impairment and disability (i. e. the Motricity Index("), the Star Cancellation Test(79' 
80) 
, and Shoulder Shrug Test(7')), and upper arm girth(133) , there were no statistically 
significant differences between the randomisation groups (Table 34). 
Table 34: 3-month upper limb outcome measures (affected side) - change from 
initial to 3-month assessment 
Intervention (n=80) Control (n=75) P value 
ARATI*-') change n=79 n=71 
median [IQR] 
Total 6.0 [0-301 12 [0-43] 0.100 
Grasp 0 [0-6] 3 [0-15] 0.027 
Grip 0 [0-11] 3 [0-12] 0.197 
Pinch 3 [0-9] 6 [0-13] 0.278 
Gross 0 [0-31 1 (0-7] 0.025 
FAT"" change n=80 n=75 
median [IQRI 1 [0-2.81 1 [0-41 0.053 
Motricitylý" Index change n=79 n=74 
median [IOR) 
Arm 23 [1-371 24 [9.8-47.3] 0.209 
Leg 16 [8-27] 16 [0-29] 0.782 
Total 19 [8.5-30.51 17.5 [10-34.31 0.483 
Star cancellationý"', u") change n n=80 n=75 
N 
Baseline Fail - 3-month Fail 19(24%) 13(17%) 0.624 
Baseline Fail - 3-month Pass 12(15%) 9(12%) 
Baseline Pass - 3-month Fail 6(8%) 5(7%) 
Baseline Pass - 3-month Pass - 
43(54%) 48(64%) 
Shoulder Shrug Tesf "T change n=79 n=74 
median [IQR] 010-11 1 [0-11 0.226 
Upper arm girth' ... ) (cm) change n=73 n=70 
_median 
[IQR] .1 [-3.0-0.51 0 [-2.0-2.01 0.181 
Change in affected upper limb pain from the initial to the 3-month assessment was similar 
between groups for presence of pain, severity of pain, and pain-free range of hurneral lateral 
rotation 
(127,128.130,131) (Table 35). 
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Table 35: 3-month upper limb pain (affected side) 
(127,128,130 , 131) _ change from 
initial to 3-month assessment 
Intervention (n=80) Control (n=75) P value 
Pain change n (%) 
Baseline no pain - 3-month no pain 34(43%) 31(41%) 0.906 Baseline no pain - 3-month pain 27(34%) 27(36%) Baseline pain - 3-month no pain 9(11%) 10(13%) Baseline pain - 3-month pain 10(13%) 7(9%) 
Severity scale - median [1QR] 0 [-2.0-2.0] 0 [-2.0-0.0] 0.727 Numerical rating scale - median 0.0 [0.0-4.0] 0.0 [0.0-5.0] 0.952 [IQR] 
Humeral lateral rotation - median [IQRI 
Passive -10 [-35-101 -16 [-30-10] 0.788 Active 17.5 [0-58.81 12 [-6-551 0.476 
5.2.9 Change from initial assessment, according to initial arm function 
5. Z9.1 Change from initial to 4-week assessment 
Table 36: 4-week upper limb outcome measures (affected side) - change from 
initial to 4-week assessment, according to initial arm function. 
Intervention Control P value Intervention Control P value 
(n=39) (n=37) (n=43) (n=42) 
ARAT=O ARAT=O ARAT>O ARAT>O 
ARAV', 1) change n=37 n=37 n=43 n=42 
median [10R] 
Total 0 [0-20.5] 0 [0-43] 0.917 7 [1-26] 3 [0-26.3] 0.405 
Grasp 0 [0-7] 0 [0-12] 0.702 0 [0-8] 1 [0-9] 0.881 
Grip 0 [0-4.5] 0 [0-12] 0.555 1 [0-7] 2 [0-6] 0.996 
Pinch 0 [0-1.5] 0 [0-8.5] 0.520 3 [0-91 0 [0-10] 0.409 
Gross 0 ro-91 0 [0-91 0.844 0 [0-31 0 [0-41 0.447 
FAT"I change n=39 n=37 n=43 n=42 
med an lQRj 0 [0-21 010-11 0.702 1 [0-21 1 [0-31 0.900 
Motricity lndexý"' n=39 n=36 n=43 n=42 
change 
median [IQR] 
Arm 14 [0-341 31.5 [9.5-46.3] 0.042 13 [0-27] 13 [4-24] 0.772 
Leg 14 [-2-23] 8 [-5.8-31.3] 0.941 8 [0-16] 9.5 [0-22] 0.901 
Total 14.5 [-2-30.5] 21 [8.9-34] 0.110 12.5 [4-21.5] 11.5 [-0.3- 0.775 
23.51 
Star cancellation"', n=39 n=37 n=43 n=42 so) change n (%) 
Fail - Fail 17(44%) 18(49%) 0.507 5(12%) 3(7%) 0.771 Fail - Pass 6(15%) 4(11%) 5(12%) 3(7%) Pass - Fail 2(5%) 5(14%) 2(5%) 2(5%) Pass- Pass 14(36%) 10(27%) 31(72%) 34(81%) 
Shoulder Shrug n=39 n=36 n=43 n=42 TeSf7l) change 
median jlQRj 0 0-11 0 [0-11 0.641 0 [0-11 0 [0-11 0.127 
Upper arm girth""") n=34 n=32 n=41 n=39 (cm) change 
_median 
[lQRl 1.5 [0-3.01 0 [-1.8-2.0 0.120 1 F-1.8-2.01 0 -1.5-2.0 0.954 
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The change from the initial to the 4-week assessment was also analysed according to initial 
arm function (i. e. ARAT=O vs. ARAT>O). In the ARAT=O group, the increase in Arm Motricity 
Index score from baseline to 4 weeks was statistically significantly greater in the control 
group than the intervention group. No other statistically significant differences were seen 
between groups on any of the upper limb outcome measures i. e. upper limb impairment and 
disability (ARATO . 7) , FAT("), Motricity Index(9), Star Cancellation Test(79' 
80), and Shoulder 
Shrug Test(71)), and upper arm girth(133) (Table 36). 
There were no statistically significant differences between groups for the affected upper limb 
pain assessment("- 128,130,131) when analysing change from the initial to the 4-week 
assessment, according to initial arm function (Table 37). 
Table 37. - 4-week upper limb pain (affected side) 
(127,128,130 , 131) - change from 
initial to 4-week assessment, according to initial arm function 
Intervention Control P value Intervention Control P value 
ARAT=O ARAT=O ARAT>O ARAT>O 
Pain change n n=39 n=37 n=43 n=42 
No pain - No pain 19(49%) 18(49%) 0.244 32(74%) 27(64%) 0.350 No pain - Pain 8(21%) 13(35%) 3(7%) 3(7%) Pain - No pain 3(8%) 3(8%) 6(14%) 5(12%) Pain - Pain 9(23%) 3(8%) 2(5%) 7(17%) 
Severity scale n=39 n=37 n=43 n=42 
change- median 0 [0-1] 0 [0-1.5] 0.516 0 [0-0] 0 [0-01 0.793 
[IQR] 
Numerical rating n=38 n=36 n=43 n=42 
scale change- 




Passive n=37 n=34 n=43 n=42 
20 [12.5-35.5] 28 [-2.5-4.7] 0.913 01-35-151 0 [-16.3-20] 0.579 
Active n=37 n=32 n=43 n=42 
-10 [-60-01 -40 [-65.8-01 . 0.401 -5 [45-101 -3.5 [-20-26.31 . 0.309 1 
5. Z9.2 Change from initial to 3-month assessment 
The change from the initial to the 3-month assessment was analysed according to initial arm 
function (ARAT=O vs. ARAT>O). 
Differences were seen in favour of the control group when analysing participants who scored 
0 on the ARAT(6.7) initially (Table 38). The control group achieved greater improvements in 
arm function as measured by the FAT(8) and Arm Motricity Index(O), and this difference in the 
Arm Motricity Index scores reached statistical significance. For the ARAT=O group, no 
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significant differences were seen in the other measures of upper limb impairment and 
disability (i. e. the Star Cancellation Test(7- ") and Shoulder Shrug Test(71)), and 
measurement of upper arm girth(133) (Table 38). 
For those participants scoring more than 0 on the ARAT(6, ") at the initial assessment, no 
statistically significant differences were seen between randomisation groups on any of the 
upper limb outcome measures when analysing change from the initial assessment (Table 
38). 
Table 38: 3-month upper limb outcome measures (affected side) - change from 
initial to 3-month assessment, according to initial ARA7ý6,7) score 
Intervention Control P value Intervention Control P value 
ARAT=O ARAT=O ARAT>O ARAT>O 
ARAr",? Tchange - n=37 n=30 n=42 n=41 
median [IQR] 
Total 0 [0-33.5] 34.510-54] 0.057 9 [2-26.51 10 [1.5-33.5] 0.788 
Grasp 0 [0-6] 11 [0-18] 0.049 0.5 [0-81 2 [0-121 0.246 
Grip 0 [0-12] 9.5 [0-12] 0.124 1 [0-10] 2 [0-7) 0.743 
Pinch 0 [0-6] 3 [0-17.3] 0.179 5.5 [0-9) 6 [0-12] 0.876 
Gross 0 ro-91 9 ro-91 0.034 010-21 0 [0-3.51 0.129 
FAT"' change n=37 n=30 n=43 n=42 
median [IQRI 0.0 [0-31 2.510-4.31 0.065 1.0 [0-21 1.0 [0-41 0.268 
Motricitylý' Index n=36 n=29 n=43 n=42 
change 
median [IQR] 
Arm 28.5 [0-42.81 47 [15.5- 0.027 23 [7-27] 16 [8-27.31 0.771 
72.5] 
Leg 23.5 [0-27) 17 [0-34] 0.921 16 [8-24] 16 [8-27] 0.860 
Total 20 f 10.8-30.91 31 [9-45.51 0.122 15 [8-291 13 [10-26.81 0.. 932 
Star n=37 n=30 n=43 n=32 V9,80) 
cancellation 
test change n(%) 
Fail - Fail 13(35%) 12(40%) 0.831 6(14%) 1(2%) 0.188 Fail - Pass 8(22%) 5(17%) 4(9%) 4(10%) Pass - Fail 2(5%) 3(10%) 4(9%) 2(5%) Pass- Pass 14(38%) 10(33%) 29(67%) 35(83%) 
Shoulder Shrug n=36 n=29 n=43 n=42 TeSefl) change 
median JIQRJ 
-0 
[0-11 1 [0-11 0.155 010-11 0.5 [0-11 0.637 
Arm girthl'ý' n=32 n=28 n=41 n=39 
(cm) change 
median [IQRI -0.8 [-3.0-0.01 0.0 [-3.0-2.01 1 0.282 -1.0 [-2.0-0.51 0.0 [-2.0-2.01 , 0.492 
There were also no statistically significant differences between groups for the affected upper 
limb pain assessment(127,128,130,131 ) at 3 months when analysing change from baseline, 
according to initial arm function (Table 39). 
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Table 39: 3-month upper limb pain (affected side) 
(127,121,130,131). 
change from 
initial to 3-month assessment, according to initial arm function 
Intervention Control P 
value 
Intervention Control P 
value 
ARAT=O ARAT=O ARAT>O ARAT>O 
Pain change n n=37 n=30 n=43 n=42 
No pain - No pain 9(24%) 10(33%) 0.384 25(58%) 20(48%) 0.598 
No pain - Pain 17(46%) 16(53%) 10(23%) 10(24%) 
Pain - No pain 5(14%) 1(3%) 4(9%) 8(19%) 
Pain - Pain 6(16% 3(10%) 4(9%) 4(10%) 
Changein 
Severity scale - 
median [IQR] -1 [-2-0] .1 [-2-0] 0.943 0 [-1-0] 0 [-1-0] 0.515 Numerical rating 
scale - median 2 [0-5] 2 (0-7] 0.476 0 [0-1.01 0 [-0.3-2] 0.520 
[IQR] 
Humeral lateral 
rotation - median 
[lQR] 
Passive -30 [-40- -4] -25 [-38.5- -3.8] 0.622 0 [-15-201 . 10 [-21.3-14.3] 0.205 Active 40 [0-601 40 [0-80.5] 0.755 5 [-20-451 0 [-30-20.51 0.221 
ill 
5.3 Summary of secondary analysis 
There were more dropouts between 4 weeks and 3 months in the control group than the 
intervention group. These dropouts were less impaired than the dropouts in the 
intervention group at 4 weeks, achieving higher scores on the ARAT(6- 7) , FAT(8) and 
Arm 
Motricity Index(9). 
In the analysis of absolute outcomes at 3 months according to initial ARAT(6,7) score, 
those in the control group with an initial ARAT(O . 7) of 0 achieved statistically significantly 
higher scores on the grasp and gross subsections of the ARAT and the Arm Motricity 
Index than those in the intervention group. These significant differences were not seen 
in those scoring more than 0 in the ARAT(e, ') at baseline. 
9 Other measures of stroke severity: 
In those with moderate to severe shoulder weakness at baseline (Shoulder Shrug 
Test =0 or 1), the control group achieved statistically significantly higher scores than 
7) the intervention group in the following outcome measures: total ARAT(G, , grasp, grip 
and gross subsections of the ARAT (6,7), FATO) and Motricity Index(9). These 
differences between groups were not seen in those with no initial shoulder weakness. 
In those with less severe strokes (NIHSS(197) 0-9), the control group achieved 
statistically significantly higher scores than the intervention group in the grasp and 
gross subsections of the ARAT(S. 7), and the FAT(8) at 3 months. Similar differences 
were seen in favour of the controls in those with more severe strokes (NIHSS(197) 
>/=10) but these did not reach statistical significance. 
In those with LACS or POCS, the control group achieved statistically significantly 
(6 - 7) higher scores than the intervention group at 3 months in the total ARAT , the 
grasp, grip and gross subsections of the ARAT(6,7), FAT(8) and Arm Motricity Index(9). 
Again, differences were seen in favour of the control group in those with TACS or 
PACS but none reached statistical significance. 
In the analysis of results according to side of upper limb impairment, those participants in 
the control group with left sided impairment scoring 0 on the ARAT(e , 7) at baseline, 
achieved statistically significantly higher scores than the intervention group on the grasp 
and gross subsections of the ARAVO . 7) at 3 months. 
In those with the non-dominant hand affected, the control group achieved statistically 
(- 7) significantly higher scores than the intervention group at 3 months in the total ARATO , 
the grasp and gross subsections of the ARAT(6- 7), FAT(8) and Arm Motricity Index(9). 
Differences in favour of the control group in those with the dominant hand affected did 
not reach statistical significance. 
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" In those with no visuospatial deficit at baseline, the controls achieved statistically 
significantly higher scores than the intervention group at 3 months in the total ARAT (6,7) 
the grasp, grip and gross subsections of the ARAT(e, 7), FAT(8) and Arm Motricity Index(g). 
" In those with no sensory loss at baseline, the control group achieved statistically 
significantly higher scores than the intervention group at 3 months in the total ARAT(e, 7), 
the grasp, grip and pinch subsections of the ARAT(6 . 7) , FAT(8) and Arm Motricity Index("). 
" Differences were seen between groups in favour of the control group in those with 
visuospatial deficit and in those with sensory loss at baseline, but none of these 
differences reached statistical significance. 
In the ARAT=O group, the increase in Arm Motricity Index(9) score from baseline to 4 
weeks was statistically significantly greater in the control group than the intervention 
group. 
In the analysis of change from baseline to 3 months, the control group achieved 
statistically significantly higher scores on the grasp and gross subsections of the ARAT(, 
7) 
When analysing change from baseline to 3 months according to initial ARAT(6- 7) score, 
significantly higher scores in the control group were seen for those participants scoring 0 
on the ARAT (6,7) at baseline. In this subgroup, the change in Arm Motricity Index was 
also statistically significantly greater in the control group than those in the intervention 
group. However, no statistically significant results were seen when analysing the change 
from baseline to 3 months in those scoring greater than 0 in the ARAT(G. 7) at baseline. 
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Chapter 6 Compliance with Treatment 
6.1 Compliance with treatment 
Previous studies of electrical stimulation have described the participants' intended amount of 
stimulation. However, only two studies (152.167) reported the amount of stimulation actually 
received 
Peurala et al(161) looked at the use of ES to both the upper and lower limbs to enhance 
sensorimotor recovery in chronic stroke. It was intended that participants receive 20-minute 
sessions twice daily (i. e. 14 sessions per week) for a 3-week period (i. e. a total of 42 
sessions). Sham treatment was given to the control group. The authors reported that 
participants received a mean of 21.6 +/- 6 sessions in total but do not state whether there 
were any differences between the intervention and control groups. it is also unclear how 
many of the sessions received lasted for the full 20 minutes. No reasons were given for non- 
receipt of treatment. 
Powell et al('52) looked at electrical stimulation to wrist extensors and intended that 
participants received 30 minutes of stimulation 3 times daily for 8 weeks. They monitored 
compliance using a diary and report that 19 participants (out of the 27 receiving ES) 
complied well, 3 missed occasional treatment sessions, and 5 complied poorly. Good 
compliance was not defined. Poor compliance was defined as receiving less than 50% of 
intended sessions. 
In the current study, the treatment sessions were recorded in the participants' diaries by 
documenting the start and finish times. The diaries were also used to record reasons for 
non-receipt of treatment. They were completed by nursing staff or by the participants and 
carers. It was intended that all participants receive the full four-week course of treatment as 
prescribed i. e. 82 sessions (total of 76 hours). Participants received less than the intended 
stimulation either because the treatment was stopped early, or because individual sessions 
were missed, or both. When analysing the diaries, the number of hours given was looked 
at, rather than the number of sessions. Sessions where only one of the start or stop times 
was documented, and sessions left blank in the diary, were recorded as 'missed' sessions. 
Three of the diaries were lost (i. e. not returned at the 3-month assessment), therefore 173 
were analysed. 
114 
The actual time (hours) that the sNMES was given as documented in the diaries is shown in 
Table 40. The maximum actually received in both groups was greater than the maximum 
prescribed time of 76 hours. This was because the stimulator was occasionally left on for 
longer than the prescribed session. For all the planned 60 minute sessions with times 
recorded, the actual time given varied from 5 minutes to 320 minutes. Further analysis of 
this shows that out of the 8051 recorded 60-minute sessions, 7531 (94%) were given for 60 
minutes, 326 (4%) were for less than 60 minutes, and 194 (2%) were for more than 60 
minutes. As shown in Table 40, the amount of sNMES actually received was similar 
between randomisation groups. 
Table 40: Surface NMES received (actual time in hours) 
Intervention (n=87) Control (n=86) All (n=173) 
Mean 51.6 51.0 51.3 
Standard deviation 20.1 21.7 20.9 
Minimum 1.0 0.5 0.5 
Maximum 76.2 78.1 78.1 
Median [QR] 1 55.6 [43.3-68.31 1 55.0 [3 55.5 [39.8-69.11 
The overall diary data was then analysed in two ways: 'treatment as per protocol' and 
'treatment as prescribed'. In the 'treatment as per protocol' analysis, all participants should 
have received the full 28 day treatment (i. e. 76 hours) unless they died during the treatment 
period. In the 'treatment received as prescribed' analysis, the amount of sNMES given was 
analysed as a percentage of sNMES prescribed. 
In the 'treatment as per protocol', the participants received, on average, 67.8% of the 
intended 76 hours of stimulation, and this was similar between randomisation groups (Table 
41 and Figure 8). 
Table 41: Percentage of total sNMES given (treatment as per protocol) 
Intervention (n=87) Control (n=86) All (n=173) 
Mean 67.91 67.7 67.81 
Standard deviation 26.48 28.06 27.20 
Minimum 1.32 0.66 0.66 
Maximum 100.22 102.79 102.79 
LMLqýiaLnjLQEj 1 72.4 [52.8-92.38] 73 [53.95-90.82] 777 
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In the 'treatment received as prescribed' analysis, we analysed compliance with treatment 
prescribed. The course of sNIVIES was discontinued early in some cases as discussed 
below and, in these cases, the sNIVIES was not prescribed for the total 76 hours. 
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Compliance with treatment prescribed was 76% overall, and similar between randomisation 
groups (Figure 9 and Table 42). 
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Table 42: Percentage of total sNMES received as prescribed 
Intervention (n=87) Control (n=86) All (n=173) 
Mean 74.03 75.53 74.78 
Standard deviation 19.72 19.48 19.56 
Minimum 23.08 10.00 10.00 
Maximum 100.22 102.79 102.79 
Median [IQR] 78 f6l. 84-93.321 1 77.7 [60.65-92.1 
It is of note that both the above analyses may be underestimates of the actual amount of 
stimulation received in view of the fact that we had to record sessions as 'missed' where only 
one of the start or stop times was documented. 
(a) Treatment stopped early 
The sNMES treatment was discontinued early in thirty eight participants for a variety of 
reasons (Table 43). 
Table 43: Reasons for early discontinuation of sNMES course 
Reasons for early discontinuation of sNMES course Number of participants 
All Intervention Control 
_Earticipant 
died 2 0 2 
Participant withdrawn from study 2 1 1 
Discharged home - passed ARAT* 7 4 3 
Discharged home - participant unable/unwilling to 
continue sNMES at home 
7 3 4 
Discharged home - no reason given by nursing staff for discontinuing the sNMES on discharge 
4 0 4 
Stimulation stopped by study staff due to subject non- 
Mp Liance e. g. ot toleratiqg reatneq, suU ject unwell 
6 4 2 
Stimula!! 2ýýparticlpant's request 5 3 2 
Other (2 due to inter-hospital transfer, I due to side 
effects, I due to broken stimulator, 2 no reason given). 
6 3 3 
- varEicipants pianned for discharge during the SNMF-. 5 course performed the ARXP" 'I and were discharged 
without the sNMES if they achieved the maximum score. This was only undertaken for the first 6 months of the 
study as it was found to be impractical. 
Treatment sessions missed 
The maximum potential number of sessions given to each participant was 82. For the 173 
diaries available, this is a total of 14186 sessions. As described above, some of the 
treatment courses were stopped early, accounting for 1644 missed sessions. Out of the 
remaining 12542 sessions, 2930 (23%) were not given. The reasons for these 2930 missed 
treatment sessions are shown in Table 44. 
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Table 44: Reasons for missed sNMES sessions 
Reason sNMES session not given Intervention Control All 
Not stated (e. g. no start/stop time, box left blank, 'not 1152(75%) 1127(81%) 2279(78%) 
given' box ticked but no reason given 
Technical (e. g. no stickers, battery problems etc. ) %) 56(4%) 148(5%) 
Unavailable for treatment (e. g. off ward/out of house) 86 (60Y. ) _! 
ý? 
_(i%) 
148 (§ýOý. L_ 
__ Participant reasons __ 120(8%) 55(4%) 175(6%) 
n (% of n (% of n (% of 
participant participant participant 
reasons) reasons) reasons) 
Painful 10(8%) 0 10(6%) 
Anxious 3(3%) 0 3(2%) 
Unwell 8(7%) 2(4%) 10(6%) 
Tired I (1%) 0 1 (1 %) 
Asleep 4(3%) 9(16%) 13(7%) 
No reason 58(48%) 39(71%) 97(55%) 
Non-compliant 30(25%) 4(7%) 34(19%) 
Other ý6)_ 2%)_ IiNl_ 
Staff reasons -forgot, subject unwell, busy, other 55(4%) 620% 117(4%) 
Other e. g. blisters, rash 21(1%) 00) 11! 0ý - 
30(1%) 
Discharged home - without stimulator, or passed ARAT 17(1%) 16(1%) 33(1%) 
Total 1543(100%) 1387(100%) 2930 
1 (100%) 
6.2 Summary 
The amount of sNMES actually received by participants was similar between 
randomisation groups. 
Participants received 67.8% of intended stimulation and this was similar between groups. 
The sNMES course was discontinued early in 38 participants. Four of the participants in 
the control group (compared with none in the intervention group) were discharged 
without their stimulator with no reason given. Other reasons for early discontinuation of 
the sNMES course occurred with similar frequency between groups. 
During the treatment courses, 23% of sessions were missed. No reason was given for 
the majority of these missed sessions. Participant reasons of pain, anxiety, and 
tiredness were only seen in the intervention group. 
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Chapter 7 Inter-observer study 
7.1 Background 
In this study, outcome measures chosen were valid, reliable, relevant and feasible to use. 
The initial assessments were all undertaken by the research fellow (CC), and the outcome 
assessments by 2 research nurses. This inter-observer study was undertaken to look at the 
inter-observer reliability of our outcome measures. We wanted to ensure that there was 
good reliability, i. e. minimal inter-observer variability, between the 2 nurses, and between the 
nurses and the research fellow (CC). 
7.2 Methods 
The most appropriate statistical approach to analyse the level of agreement between the two 
observers for continuous data is to use the methods described for assessing agreement 
between two methods or observers. The methods used involve graphical techniques and 
simple calculations to determine the relation between differences to the mean, and to 
estimate limits of agreement. It should be noted that the correlation, a measure of linear 
association, is often erroneously interpreted as a measure of agreement. 
For the categorical measures (i. e. the Shoulder Shrug Test (71 ) and FAT(8)) the level of 
agreement can be determined by the kappa statistic (202). The kappa statistic is becoming an 
increasingly common tool for determining agreement between two observers. It is also more 
appropriate than other methods such as calculating the correlation coefficient which is a 
measure of association rather than agreement. Kappa has a maximum value of 1.00 when 
agreement is perfect, and a value of 0 indicates no agreement better than chance. A 
weakness of the kappa statistic is that it takes no account of the degree of disagreement, 
therefore the weighted kappa can be calculated which gives different weights to the 
disagreements according to the magnitude of the discrepancy. 
Inter-observer agreement was measured for both the primary outcome measure (the ARAT(6, 
7) ) and the objective secondary outcome measures (the Motricity Index(g), FAT("), Shoulder 
Shrug Test("), passive and active range of pain free movement(' 30,131 ) and upper arm girth). 
As these measures are included in both the 4 week and 3 month assessments, the inter- 
observer assessment was completed for either assessment. A short questionnaire 
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(Appendix 2.18) for the inter-observer comparisons was compiled from the relevant sections 
of the main assessment proformas. 
The inter-observer agreement was measured on two separate occasions, the first set (A) of 
comparisons were between the two research nurses and the second (B) between one of the 
research nurses and the research fellow (CC). Patients due their 3-month or 4 week 
assessment were contacted by one of the research nurses, either in person if they were still 
in hospital, or by telephone if they had been discharged. 
On both occasions that the inter-observer agreement was measured, half of the patients 
received their study assessment first and half received the inter-observer agreement 
assessment first to remove any potential bias for the second series of assessments. 
7.3 Results 
A total of 16 patients were recruited, eight on each of the two occasions that the inter- 
observer variability comparisons were made. 
The scatterplot (Figure 10) shows the difference in the ARAT(6) scores vs. the mean ARAT(6- 
7) score for inter-observer test B. From the scatterplot the relationship between the 
measurement and true value can be seen. As we do not actually know the true value, the 
mean of the two measurements is the best estimate that we have. We can see visually that 
the differences do not appear to be related to the magnitude of the ARAT measurement. 
Figure 10 
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The scatterplots for the other continuous variables for inter-observer test B are shown in 
Figures 11 to 14. The relationships between the measurement and true value can be seen 
and, as with the ARAT, the differences do not appear to be related to the magnitude of the 
measurement. 
Figure 11 
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Figure 12 
Scatterplot of difference vs mean for Total Motricity 
Figure 13 
Scatterplot of difference vs mean for Active range of 
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The ARAT (6) scores for both Observer 1 and Observer 2, the mean of the two scores and the 
difference for inter-observer test B are seen in Table 45. 
Table 45 
ARAT Observed ARAT Observer2 Mean Score Difference between the scores 
57 57 57 0 
57 51 54 6 
0 3 1.5 -3 
0 0 0 0 
16 16 0 
57 57 57 0 
51 45 48 6 
57 57 57 0 
Table 46 shows the 95% limits of agreement for the continuous measures. All measures lie 
within the 95% limits of agreement, except the difference for the Total Motricity Index score(9) 
in test A. 
Table 46 
outcome measure 
(for affected side) 
Inter-observer test -A 
(research nurse vs. research 
nurse) 
95% limits of aareement 
2- Inter-observer test -B 
(research nurse vs. research 
fellow) 
95% limits of aareement 
Arm Motricity Index 
score(9) 
Total Motricity Index 
score(9) 
AGtive range of pain free 
movement' "', "') 
Upper affn airth 
Max difference 20.5 oub 
-12 to 13 
-20 to 36 
-13 to 19-t- 
-17 to 84 
-9 to 5 
the 95% limits of agreement 
-5 to 7 
-6 to 19 
-3 to 15 
-26 to 23 
-4 to 6 
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Table 47 shows the weighted kappa statistics for the categorical measures. 
Table 47 
Outcome measure Inter-observer test -A 2110 Inter-observer test -B 
(for affected side) (Research nurse vs. Research (Research nurse vs. Research 
nurse) doctor) 
Weighted Kappa Weighted Ka pa 
Shoulder Ic 0.69* 0.69* 
Frenchay Arm TesfuJ 0.83** 0.90** 
U. 41-U. bU Moderate agreement 
0.61-0.8 Good agreement 
** 0.81-1 Very good agreement 
7.4 Summary 
These analyses of inter-observer agreement include only a very small number of participants 
due to both practical and time constraints. The results must therefore be interpreted with 
caution. The 95% limits of agreement are fairly wide, reflecting the very small sample sizes. 
The mean difference, shown in the scatterplot (Figure 10) is an estimate of the average bias 
of one observer against the other. So the closer the points are to zero, the better the 
agreement. One also needs to consider how well the observers agree for an individual 
patient, which can be done by using the standard deviation to construct the 95% limits of 
agreement. 
There are difficulties with the use and interpretation of the kappa statistic, particularly as it 
depends on the proportion of subjects in each category, because the expected frequencies, 
by chance, can be very different, depending on the specific data distribution. The weighted 
kappa values for the first test of agreement (A) showed good agreement for the Shoulder 
Shrug Test(71) and very good agreement for the FAT(") between the two research nurses. 
The second test (B) showed good agreement for the Shoulder Shrug Test(71) and very good 
agreement for the FAT(8) between the research nurse and research fellow (CC). 
Good agreement between the observers is only likely if the methods used are both accurate 
and repeatable. Whilst we did not have the resources to make any assessment of 
repeatability of any of the assessments for the same observer with the same patients, these 
measures have been widely validated in other studies. 
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Chapter 8 Discussion 
This randomised controlled trial was undertaken to evaluate a 4-week programme of surface 
neuromuscular electrical stimulation (sNMES) for patients with upper limb impairment 
following acute stroke. The results showed no statistically significant difference in arm 
function between groups in terms of the primary outcome measure, the total ARATM . 7) score 
at 3 months after stroke. 
There were significant differences in favour of the control group when using other measures 
of arm function (subsections of the ARAT(" . 7) ; FAT(8)), and upper limb impairment (the Arm 
subsection of the Motricity Index(g)) at 3 months. Despite these differences in secondary 
outcomes, this did not influence disability (ADLs) at 3 months. No significant differences in 
upper limb pain, visuospatial impairment or global health status were seen between groups 
at 3 months. There were no statistically significant differences between groups in any of the 
outcome measures at 4 weeks. 
The primary results of the study were neutral i. e. a4 week programme of sNMES to the 
shoulder did not improve upper limb function when initiated within 10 days of stroke onset. 
However, a number of secondary outcomes (upper limb impairment, other measures of arm 
function) were better in the control group 3 months after stroke. This was an unexpected 
result. These differences were not seen at 4 weeks i. e. immediately after the intervention 
period. None of the previous studies of sNMES to the upper limb after stroke have reported 
unfavourable outcomes in the intervention group. 
The following need to be considered in order to try to understand and explain these results: 
m study design: strengths and weaknesses 
sNMES regime and delivery 
mechanism by which sNMES can affect upper limb recovery 
8.1 Study design: strengths and weaknesses 




Study participants were typical stroke patients who were treated by two specialist stroke 
services within the same NHS Trust. The majority of previous studies did not state the 
setting where the research took place. A specialist service is the ideal setting for 
randomised controlled trials of stroke rehabilitation as this is currently the 'gold standard' for 
stroke care. 
8.1.2 Eligibility 
Subjects with a wide range of upper limb impairment were recruited. All participants were 
required to have evidence of upper limb weakness/drift and/or finger-nose in-coordination 
and/or visual inattention. However, nearly all had some degree of weakness and none had 
visual inattention alone. There is a wide variation in beliefs as to who this intervention is 
appropriate for and, in clinical practice, it is given to patients with both mild and severe 
deficits. We believe that our patients are similar to those in previous studies of ES to the 
upper limb following stroke. Subjects recruited for studies of EMG-stim and PFST were 
required to have some movement of the upper limb at baseline (143,158), but most other 
previous studies did not recruit patients based on their initial level of upper limb weakness or 
impairment (Table 3) 
Although eligibility criteria were broad and clearly defined, only 12% of stroke admissions 
were recruited (Figure 4). The inclusion criteria were appropriate as most subjects for whom 
the intervention was clinically indicated were included; 28% were excluded because they 
had no upper limb deficit, 10% received palliative care and 12% had previous significant co- 
morbidity which would have affected treatment or assessments (Table 5). By widening the 
time window and geographical area for recruitment, it would have been possible to have 
increased participation. However, the study was designed to look at the effect of early 
treatment, and it was not logistically possible to cover the whole of Northumberland. 
Some of the previous studies of ES have not reported exclusion criteria or the population 
screened(155- 167) . Other studies have detailed exclusions but with some important omissions. 
For example, Faghri et al(82) excluded subjects if they had a permanent pacemaker in situ, 
but did not report excluding any other subjects e. g. those with previous shoulder problems. 
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8.1.3 Initial assessment 
This was undertaken by a single observer (CC) using a standardised protocol. Where 
possible, validated instruments were used, and when these were not available data items 
were clearly defined. The initial assessment was comprehensive, covering demography, pre 
stroke characteristics and neurological deficit. Intervention and control groups were well 
matched at baseline. It is unlikely that an important baseline variable was omitted which 
could have produced an initial difference between intervention and control groups, 
accounting for the differences in secondary outcomes at 3 months. 
Some previous studies have reported little or no demographic data or clinical features of 
study subjects (143,173) . Others have reported 
baseline demographics but do not appear to 
have made other important initial assessments e. g. pain (82) . 
8.1.4 Randomisation 
This was by a central independent computerised randomisation service. Less than 50% 
(8/17) of previous studies had a secure randomisation process. 
8.1.5 Treatment received by intervention and control groups 
Within a RCT, the treatment received by randomisation groups should differ only in receipt of 
the intervention. The amount of sNMES or sham given was recorded, and randomisation 
groups did not differ in terms of this. Compliance with treatment was similar for both groups. 
Very few sessions were missed because of reported side effects (10/1543 sessions, all of 
which were in the intervention group) (Table 44). There was no formal reporting system for 
adverse events so this may be an underestimate. The study relied upon participants and 
staff to complete diaries and there were a number of occasions when the reason for missed 
sessions was not recorded. The sNMES course was well tolerated and was discontinued 
early in only 5 cases (3 intervention, 2 control) at the participants' request. 
The amount of upper limb rehabilitation received during the intervention period was not 
measured, but similar numbers in each randomisation group were still receiving 
physiotherapy at 3 months (Table 12). It is possible but unlikely that randomisation groups 
received different amounts of therapy during the ES treatment period. Differences in the 
intensity of general and upper limb physiotherapy and occupational therapy could account 
for the results. A recent systematic review has shown that early intensive stroke 
(45) rehabilitation may be associated with enhanced recovery after stroke . If the intervention 
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group did receive less therapy this could have been because they were less inclined to 
participate because of tiredness, pain or other adverse effects which were not reported or 
recorded. Fourteen participants (18%) in the intervention group attributed shoulder pain to 
the stimulator. 
Another explanation for possible differences between the amount of therapy received may 
have been that therapists were less likely to interrupt ES sessions for those with an active 
stimulator. Therapists and nurses were not informed of the subjects' randomisation groups 
but may have been aware of the treatment by their own observations. There may have been 
other differences between groups in the treatment provided by stroke unit staff or ways in 
which patients and carers spent their day which were not measured or considered. 
Only two previous studies of ES have looked at compliance with treatment(152,167). Both 
reported very high compliance levels. None have reported the amount of physiotherapy and 
occupational therapy received. 
8.1.6 Blinding 
Subjects 
Participants were not informed of randomisation group allocation, and a sham stimulator was 
given to control subjects. The active stimulator did produce a regular visible movement of 
the shoulder so complete blinding was not possible. However, not all subjects could identify 
whether or not they had received active treatment. At 3 months, 71 % of the intervention 
group thought that they had had active treatment compared with 20% of subjects in the 
control group (Table 16). In previous studies of ES to the upper limb, very few (5117) have 
used sham treatments. 
Stroke unit staff 
The treatment regime and placement of electrodes was undertaken by a single researcher 
(CC) who prescribed treatment, specifying the stimulator settings. Other than connecting the 
stimulators, nurses were not involved in adjusting the ES. Physiotherapists were not 
involved in delivery of the ES. Staff were not informed of the subjects' randomisation groups 
but may have been aware of the treatment by their own observations. The opinions of staff 
as to whether subjects were receiving active or sham treatment were not sought. Neither 
were their views about the efficacy of ES. Previous studies have not discussed the blinding 
of clinical staff. 
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Outcome assessors 
Outcome assessments were undertaken by two research nurses who were blinded to the 
participants' randomisation groups. We believe that this blinding was secure. However, the 
nurses were not asked to guess the group allocation at any stage or to indicate whether or 
not the participant had given an opinion regarding their randomisation group prior to the final 
question of the 3 month assessment. We did not ask the outcome assessors to give their 
views regarding group allocation as we felt that this would have introduced bias. The 
assessors questioned the participants regarding their views at the end of the 3-month 
assessment so that they weren't unblinded during outcome assessments. Outcomes were 
undertaken by blinded assessors in 11/17 previous studies. 
8.1.7 Drop outs and data completeness 
Losses to follow up and missing data were not a problem in this study (Figure 4). Eighteen 
participants died (9 in each group). Only one participant was lost to follow up and two 
refused. The level of follow-up in previous studies was similar. 
8.1.8 Analysis 
Analysis was on an intention to treat basis. This method was also used in the majority of 
previous studies. 
8.1.9 Outcome Assessments 
Stroke patients wish to regain useful upper limb movement, so the primary outcome 
measure chosen for this study was upper limb function. Previous studies have looked at the 
effect of ES on subluxation, motor recovery and pain, and although there is evidence of the 
beneficial effect of ES on these, it is not clear whether this translates into improved 
functional recovery. 
A range of scales of upper limb disability, pain and impairment were used. These were 
relevant to the intervention and have previously been widely used in trials of upper limb 
rehabilitation after stroke. Although there is evidence that ES is beneficial in improving joint 
alignment (i. e. reducing or preventing subluxation) and reducing spasticity (5.62) , these 
outcomes were not measured in this study. There is often confusion when trying to define 
subluxation (33) , and its measurement is unreliable and often of no new clinical 
significance(181). There is no validated measure of upper limb spasticity other than at the 
elbow(156). 
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The timings of outcome assessments were chosen to coincide with the end of the treatment 
period and to look at longer term effects. These time points have also been used in previous 
studies. A longer period of follow up would have been desirable to see if the differences at 3 
months were sustained. As analysis of outcomes was not undertaken until the final outcome 
measure was completed, it was not possible to undertake a6 or 12 month assessment once 
the results of the study became available. 
The primary outcome was arm function measured by the Action Research Arm Test 
(ARAT) (6.7) . This is a robust test which measures 
4 domains of upper limb function: grasp, 
grip, pinch and gross. Its limitation is that subjects have to be able to sit to perform the test. 
It also has a ceiling effect i. e. subjects achieving a maximal score may still have a degree of 
upper limb impairment. Although there were no significant differences in total ARAT (6 , 7) 
score between intervention and control groups, differences were seen in the grasp and gross 
subsections at 3 months. These subsections involve predominantly proximal rather than 
distal movement (i. e. shoulder movement), and are those most likely to have been 
influenced by the intervention. 
Upper limb outcomes were also worse in the control group at 3 months for the Arm Motricity 
Index(") and Frenchay Arm Test (FAT)(8). The fact that four of our secondary measures of 
upper limb outcome show significant differences between intervention and control groups 
makes it unlikely that this is a chance finding. 
Electrical stimulation has been used to treat and prevent shoulder pain (5) . There was no 
difference between groups in the prevalence of shoulder pain. Pain was assessed using 
both a 5-point severity scale and a 0-10 numerical rating scale (127,128) . The severity scale 
alone can be insensitive to small changes, but its sensitivity can be increased by using it 
together with a numerical rating scale. Pain was also assessed by measuring pain-free 
range of humeral lateral rotation (130,131) which has been used successfully in a previous study 
of electrical stimulation (132) .A Visual Analogue Scale was not used to measure pain as 
previous work has shown that many stroke subjects are not able to complete these scales 
129) successfulY . 
At the 3-month assessment, participants were asked whether or not they had experienced 
symptoms from the ES, and to give their views on which stimulator they thought they had 
received. Ideally, more information should have been sought regarding their views, including 
the acceptability of ES and how the treatment affected their daily activity. 
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8.1.10 Study Size 
This is the largest study to date of electrical stimulation to the upper limb following acute 
stroke. The study had adequate statistical power. Surprisingly, a 'clinically significant 
difference' in ARAT('3 . 7) scores has not previously been defined and a pragmatic decision to 
define it as a difference of 8 points was made. No similar definition has been made in 
(1,52,59.152) previous studies 
8.1.11 Conflict of interest 
There was no conflict of interest for any member of the study team. 
8.2 sNMES regime and delivery 
In this study, ES to the shoulder did not improve outcome following acute stroke and may 
have had a detrimental effect on upper limb recovery. This could have related to the sNMES 
regime and/or delivery. 
8.2.1 Site 
The ES was applied to the shoulder as there is evidence that proximal upper limb recovery 
precedes distal recovery (66). Electrical stimulation to the shoulder is widely used in clinical 
practice and is thought to be a safe method of improving upper limb outcome following 
stroke (5.62). The ES may have had a detrimental effect on proximal recovery i. e. at the 
shoulder (suggested by the differences in the grasp and gross subsections of the ARAT(6- 7) 
at 3 months). Studies of ES to the distal upper limb have reported motor improvements with 
the treatment(88- 154,158) . Whilst it 
is unclear whether these improvements translate into 
functional benefit, there has been no suggestion that ES to the distal upper limb has a 
(88,154,158) detrimental effect on either motor or functional recovery 
8.2.2 Duration, frequency and intensity 
The ES regime chosen was one that has been used in previous studies and is widely 
accepted in clinical practice. No evidence exists regarding the optimal regime in terms of 
duration and frequency. 
The intensity of ES given to subjects in the intervention group was at a level required to 
produce a comfortable gross movement of the shoulder. Again, this is accepted practice 
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and this method has been used in previous studies of ES to the shoulder. The optimal 
intensity of ES is not known. 
It is conceivable that subjects in the intervention group were given suboptimal ES in terms of 
duration, frequency and/or intensity. This might explain why no beneficial effects were seen 
in the intervention group, but does not account for the fact that those in the control group 
achieved higher scores in some of the secondary outcome measures at 3 months. 
8.2.3 Supervision of ES treatment 
No therapists were involved in the delivery of the ES, and it is possible that the intervention 
stimulators were applied wrongly and thus had a detrimental effect on upper limb recovery. 
However, the ES machines were checked regularly by the research fellow (CC), and 
electrode sites marked to ensure correct positioning. Also, if the ES was applied incorrectly, 
those in the intervention group may have reported more pain at 4 weeks than those in the 
control group, and this was not the case (Table 11). 
8.2.4 Effect on other treatment 
As already discussed in Section 8.15, those in the intervention group may have received 
less therapy. 
8.2.5 Study participants 
Participants in the study were typical stroke patients. There is no reason to suggest that the 
ES would have affected these patients any differently from stroke subjects in previous ES 
studies, or stroke patients in clinical practice. 
8.2.6 Timing of the ES 
Most functional recovery occurs within the first 6 months after stroke and is most rapid within 
the first few weeks (64). It is thought that early intervention offers the greatest opportunity to 
improve recovery(45,46). A review of ES by Ada et al in 2002(184) concluded that early, rather 
than late, ES may enhance upper limb motor recovery following stroke. Subjects were, 
therefore, recruited early after stroke in this study, although the ideal time is not known. It 
was a pragmatic decision to recruit within the first 10 days following acute stroke. Many 
previous studies of electrical stimulation have recruited patients several months or years 
after stroke. 
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8.3 Mechanisms by which sNMES can affect upper limb recovery 
Surface neuromuscular electrical stimulation has been proposed as a safe method of 
improving upper limb outcome following stroke by a variety of mechanisms. It is thought to 
promote motor re-learning through afferent stimulation to the somatosensory cortex, and 
through effects such as muscle strengthening, enhanced joint alignment and reduction in 
spasticity and pain 
In this study, however, the sNMES may have had a detrimental effect on upper limb 
recovery. No differences were seen between groups at 4 weeks, so the effect was seen 
after the sNMES had been discontinued. The sNMES may have interfered with motor re- 
learning processes, influencing and impeding recovery after the treatment period. 
Previous experimental models have suggested that very early constraint therapy and early 
overuse after cerebral ischaernia in rodents may be harmful(203,204) . The relevance of 
this is 
not known in humans but these are possible explanations for the differences seen between 
groups at 3 months in this study. As the intervention stimulator produced movement of the 
shoulder, it is possible that whilst it was being given participants used their affected arm less 
i. e. the stimulator promoted learned non-use of this arm. Alternatively, the movement 
produced at the shoulder may have resulted in early over-use and thus adversely affected 
upper limb recovery. 
Previous studies of ES in patients with cerebral palsy, head injury and spinal injury have not 
(170,205,206) 
reported a detrimental effect on recovery 
8.4 Subgroup and secondary analyses 
There was one pre-planned subgroup analysis in this study. This was to look at the 
outcomes of participants with mild/moderate upper limb function (ARAT>O) and those with 
severe functional impairment (ARAT=O) at the initial assessment. We chose to look at initial 
ARAT (6,7) score as there is evidence that the severity of initial upper limb motor impairment 
is a predictor of upper limb recovery(3,65). There is also some evidence that ES is more 
beneficial in stroke patients with a milder degree of upper limb impairment("'). 
There was no difference in any of the outcome measures at 4 weeks or 3 months between 
intervention and control groups for those with mild/moderate upper limb impairment. Those 
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with severe functional impairment in the control group had significantly better outcomes - 
grasp and gross subsections of the ARAT (6.7) and Arm Motricity Index(g). No difference was 
seen at 4 weeks. 
The negative effect of sNMES to the upper limb following acute stroke was seen only in 
those with initial severe impairment. The potential reasons for this observation are 
discussed in Section 8.3 and include an adverse effect of sNMES upon natural recovery, 
over-stimulation of the affected arm, and learned non-use. Hypotheses to explain why the 
negative effect was only seen in those with severe impairment include: 
" Surface NMES impedes recovery by producing abnormal afferent stimulation and 
inhibiting plasticity in a group who are not receiving any other afferent stimulation to 
the upper limb. 
" Those with severe impairment may have been less aware of the stimulation and 
therefore less likely to report adverse events or be aware if the stimulator was 
wrongly delivered. 
" Over-stimulation may have produced tiredness and shoulder subluxation in this 
group. Neither of these effects was measured. 
" Those with severe initial impairment may also be more likely to develop learned non- 
use. 
Further analysis was undertaken once these results were available. However, the results 
from further subgroup and secondary analyses should be regarded as hypothesis-generating 
as they were not pre-specified. 
As the results of our single pre-planned subgroup analysis showed that the negative effect of 
sNMES was only seen in those with initially severe upper limb impairment, we chose other 
subgroups which were measures of stroke severity: the presence or absence of shoulder 
weakness at baseline (measured by the Shoulder Shrug Test(71)), the NIHSS(197) , and the 
stroke subtype (TACS/PACS vs. LACS/POCS)(19"). 
The ES had a detrimental effect on recovery in those with moderate to severe shoulder 
weakness at baseline, which is consistent with our findings in the ARAT=O group. However, 
it also appeared to have had a negative effect on recovery in those with less severe strokes 
and in those with LACS or POCS. These negative effects in the less severe and non-cortical 
strokes could have been due to overuse or learned non-use but it seems unlikely that they 
relate to a direct influence on cortical plasticity. The results must, however, be interpreted 
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with caution. It is noteworthy that differences were also seen in favour of the control group in 
those with more severe strokes and in those with TACS/PACS, but they did not reach 
statistical significance, possibly due to the small numbers in these groups. There may also 
have been a ceiling effect in less severely impaired subjects. 
In the subgroup analysis according to side of impairment, the detrimental effects of ES on 
recovery were seen in those with left sided impairment. We hypothesised that this might 
have been because these were right hemisphere strokes and so more likely to have 
visuospatial and sensory deficits. The absence of afferent input in these cases may have 
meant that these subjects were more susceptible to the negative effects of ES on natural 
recovery, and the possible effects of over-stimulation and learned non-use. However, the 
subgroup analyses showed that those without visuospatial and sensory deficits experienced 
negative effects from the ES. Again, these results must be viewed cautiously as differences 
were also seen between groups in those with visuospatial deficit and sensory loss but may 
not have reached statistical significance due to the small numbers in each group. 
We also hypothesised that the differences seen between groups in subjects with left sided 
impairment may in fact be due to hand dominance. Our subgroup analysis showed that the 
negative effects of ES were seen in those with the non-dominant hand affected. These 
subjects may have been more susceptible to learned non-use from the ES. They may have 
been less likely to use their affected arm, if it was their non-dominant side, when the ES was 
in situ or in between sessions if the arm was tired. This may have been especially the case 
if their initial arm weakness was severe. 
8.5 Implications for practice and future research 
8.5.1 Implications for practice 
It has been proposed that sNMES to the upper limb is a safe method of improving outcome 
after stroke but our results suggest that this assumption should be challenged. Surface 
NMES may, in fact, be harmful to certain stroke subjects and its use in routine practice 
cannot be recommended. 
Those involved in the application of ES should be aware of its potential negative 
consequences, and of the lack of evidence to support its use in routine clinical practice. 
There is the potential for ES to be wrongly applied, and it should therefore only be given 
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under the supervision of specialists in the field. The costs of the ES equipment, therapist 
and nursing time, influence on other therapy input, and the inconvenience and possible 
discomfort to the patient must be weighed up against any benefits of ES treatment. 
8.5.2 Future Research 
We have scrutinised our results and the potential reasons for them, particularly since the ES 
may have had a detrimental effect on recovery in certain subjects. The Medical Research 
Council (MRC) framework (207) was available when we designed our study and at that time we 
felt that there was sufficient evidence to justify undertaking a definitive RCT. We have 
returned to this framework to address issues regarding further research in this area (Figure 
15). 
Figure 15: A framework for development and evaluation of RCTs for complex 
interventions to improve health (MRC) 
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8.5.2.1 Theoretical phase 
In evaluating a complex intervention, the first step is to establish the theoretical basis that 
suggests that the intervention should have the effect(s) that it is expected to. Basic science 
and clinical studies have been undertaken to look at possible mechanisms of action of ES in 
upper limb recovery. A number of theories have been suggested: muscle strengthening, 
improved joint alignment; analgesic effects; improvement of visuospatial awareness. 
Studies have not addressed the mechanisms of action of ES with respect to theories of 
neurological recovery, particularly neuroplasticity and motor relearning. Electrical stimulation 
is widely used in clinical practice and we therefore felt comfortable proceeding with an RCT 
even though the mechanism of action was not clearly understood. 
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In retrospect, a clearer understanding about the effect of ES upon recovery following stroke 
is vital, and further research in this area should address this e. g. by the use of fMR1 and 
PET. 
8.5. Z2 Modelling phase 
The next step is to develop an understanding of the intervention and its possible effects. It is 
vital to know the specific effects of an intervention on specific outcomes and measure these 
appropriately. ES is thought to improve the following upper limb outcomes: shoulder 
subluxation; upper limb pain; arm function; motor impairment. We felt that arm function was 
the most important clinical outcome. We did not measure subluxation as this is difficult to do 
reliably and is of doubtful clinical relevance. We recruited patients with a wide range of 
deficits because this was a pragmatic study, relevant to current clinical practice. Previous 
studies had suggested that certain subjects might gain more benefit from ES treatment e. g. 
those with less severe upper limb impairment at baseline(155), but none had suggested that 
ES could be detrimental to any subject groups. Reviews of the literature of ES to the upper 
limb following stroke have not re-analysed primary data, and a further meta-analysis of 
individual patient data may be warranted. 
Future studies should recruit specific groups of patients, with clearly defined neurological 
deficits, who are most likely to benefit from ES treatment. Outcomes chosen must be 
relevant to the intervention effects studied, and also valid, reliable, sensitive and important to 
patientS(208). Patients' views should also be sought regarding their perceptions of ES and its 
acceptability. 
8.5. Z3 Exploratory trial phase 
Any intervention must be definable and reproducible and given by trained individuals. 
During this phase, testing of alternative forms ('doses') of an intervention can be undertaken. 
In drug studies, optimal dosages are developed but this is not done for interventions in 
rehabilitation studies. The optimal sNIVIES regime, in terms of duration and intensity, is not 
known. We reviewed the literature about regimes used in previous studies, and 
pragmatically chose one that had been used both in research and in clinical practice 
The intervention must also be compared to an appropriate alternative and we used a 
placebo stimulator. We feel that further studies of ES must use a sham treatment for those 
in the control group. Ideally, a record of all other upper limb therapy should be kept(209.210). 
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Although this can be difficult and time-consuming, it has previously been undertaken 
successfully by our research teaM(55). We did not record routine therapy for this study 
because of the resources required to ensure that data collection was complete and accurate. 
In our previous single centre study, two research therapists were responsible for this task. 
There should also be a formal mechanism in place for adverse event reporting in future 
trials. 
The exploratory trial phase is also used to identify appropriate outcome measures and to 
make estimates of recruitment for a main trial. We based our methodology and power 
calculations on previous ES studies and on our previous studies of upper limb rehabilitation 
(55.129) following stroke 
&5. Z4 Main trial phase 
Our study was adequately powered and had robust methodology. Future studies should be 
similarly robust with adequate statistical power, be based in stroke units, and ideally be 
multi-centred to enable results to be generalisable. Outcome measures chosen in future 
studies should be relevant to the intervention studied, simple to use, and with proven validity 
and reliability in stroke patients. 
8.5.2.5 Long-term surveillance phase 
The final step in the evaluation of a complex intervention is a separate study to establish the 
long-term and real-life effectiveness of the intervention. Given that we have not 
demonstrated effectiveness a Phase IV study is not justified at present. 
8.6 Conclusions 
The primary results of the study were neutral i. e. a4 week programme of sNMES to the 
shoulder did not improve upper limb function when initiated within 10 days of stroke onset. 
However, a number of secondary outcomes (upper limb impairment, other measures of arm 
function) were unexpectedly better in the control group 3 months after stroke, although this 
did not translate into differences in ADI-s. 
It is unlikely that the differences seen between the control and intervention group at 3 
months were due to study design or conduct. Differences in upper limb therapy between 
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groups may explain these differences, as the amount of therapy received was not formally 
recorded. Potential pathophysiological mechanisms to explain these differences include an 
adverse effect of sNMES upon natural recovery, overstimulation of the affected arm, and 
learned non-use. 
The use of ES to the upper limb following stroke cannot be recommended in routine practice. 
Further research in this area should address the effects of ES upon recovery following 
stroke. Studies should be adequately powered and have robust methodology. They should 
be undertaken in a stroke unit setting, and should study a specific intervention in a defined 
population using valid, reliable and relevant outcome measures. 
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Appendix 1 
1.1 Motricity Index 
Arm (in sitting position) 
A. Pinch grip; 2.5cm cube between thumb and forefinger 
B. Elbow flexion; from 90 degrees, voluntary contraction/movement 
C. Shoulder abduction; from against chest 
A. Pinch grip 
0 No movement 
11 Beginnings of prehension (any movement of finger or thumb) 
19 Grips cube, but unable to hold against gravity 
22 Grips cube, held against gravity, but not against weak pull 
26 Grips cube against pull, but weaker than other side 
33 Normal pinch grip 
Score R arm F-I 0 Score L arm F-I 1-1 
B. Elbow flexion 
0 No movement 
9 Palpable contraction in muscle, but no movement 
14 Movement seen, but not full range/not against gravity 
19 Movement; full range against gravity, not against resistance 
25 Movement against resistance, but weaker than other side 
33 Normal power 
Score R arm Score L arm F710 
C. Shoulder abduction 
0 No movement 
9 Palpable contraction in muscle, but no movement 
14 Movement seen, but not full range/not against gravity 
19 Movement; full range against gravity, not against resistance 
25 Movement against resistance, but weaker than other side 
33 Normal power 
Score R arm F-I Ll Score L arm F-10 
Leg (in sitting position) 
D. Ankle dorsiflexion; from plantar flexed position 
E. Knee extension; from 90 degrees, voluntary contraction/movement 
F. Hip flexion; usually from 90 degrees 
D. Ankle Dorsiflexion 
0 No movement 
9 Palpable contraction in muscle, but no movement 
14 Movement seen, but not full range/not against gravity 
19 Movement; full range against gravity, not against resistance 
25 Movement against resistance, but weaker than other side 
33 Normal power 
Score R leg F-I 0 Score L leg F-10 
E. Knee Extension 
0 No movement 
9 Palpable contraction in muscle, but no movement 
14 Movement seen, but not full range/not against gravity 
19 Movement; full range against gravity, not against resistance 
25 Movement against resistance, but weaker than other side 
33 Normal power 
Score R leg F-I 0 Score L leg F-I F-I 
F. Hip Flexion 
0 No movement 
9 Palpable contraction in muscle, but no movement 
14 Movement seen, but not full range/not against gravity 
19 Movement; full range against gravity, not against resistance 
25 Movement against resistance, but weaker than other side 
33 Normal power 
Score R leg FI ID Score L leg 0 ID 
Arm score = scores (1) + (2) + (3) +I (to make 100) Leg scores (4) + (5) + (6) +1 (to make 100) 
TOTAL RIGHT LEG 
TOTAL RIGHT ARM 
LJOLI 
F-I F-I 0 
TOTAL LEFT LEG 
TOTAL LEFT ARM 
r-i r-i LI 
r-i r-i EI 
Side score = (ARM + LEG)12 
RIGHT SIDE 
000 
LEFT SIDE F-1 00 
2 
1.2 Shoulder Shrug Test 
" Subject should be sitting up straight. 
" Ask subject to shrug both shoulders together. 
" Observer watches for symmetry and then attempts to push down the shoulders. 
" Normally it is not possible to force someone's shoulders down with moderate 
effort. 
0 Score each side in turn : 
Scoring 
0= no shoulder elevation at all 
1= elevation of the shoulder, but less marked or weaker than the other side 





1.3 Brunnstrom Fugl-Meyer Assessment 
For arm movement 




1. Biceps/triceps/finger- 0- no reflex activity 4 
flexor reflexes 2- reflex activity 
IL a. Flexor synergy 0- cannot be performed 10 
Shoulder 1- partial motion 
Elbow 2 -full motion 
Forearm 
b. Extensor synergy 0- no motion 8 
Shoulder 1- weak motion 
Elbow 2- almost full strength 
Forearm compared to normal 
Ill. Volitional motion 0- unable 2 
a. Hand to lumbar spine I- hand passes anterior 
superior iliac spine 
2- hand reaches lumbar 
spine 
b. Shoulder flexion 0-90 0- unable 2 
degrees 1 -partial 
2- able to perform 90 
degrees shoulder flexion 
c. Forearm pronation- 0- unable 2 
supination 1- partial 
2- able 
IV. Volitional motion 0- unable 2 
a. Shoulder abduction I- partial 
2- able 
b. Shoulder flexion 90- 0- unable 2 
180 degrees 1- partial 
2- able 
c. Elbow pronation- 0- unable 2 
supination 1- partial 
2- able 
V. Normal reflexes 0- two or three are 2 
Biceps markedly hyperactive 
Triceps 1- one reflex is hyperactive, 
Finger-flexors or two reflexes are lively 
2- no more than 1 reflex is 
lively 
Wrist B. 0- unable 10 
Elbow 90 degrees, wrist 1- partial 
stability 2- able 
Elbow 90 degrees, wrist 
flexion/extension 
Elbow 0 degrees, wrist 
stability 
Elbow 0 degrees, wrist 
flexion/extension 
I Circumduction 
For arm movement 
Area Test Scoring Criteria Maximum 
Possible 
Score 
Hand C. 0- unable 14 
Fingers mass flexion I -weak 






D. 0- marked tremor 2 
Coordination/speed 1- slight tremor 
Finger-nose test 2- no tremor 
a. Tremor 
b. Dysmetria 0- pronounced or 2 
unsystematic 
I- slight or systematic 
2- no dysmetria 
c. Speed 0- six seconds slower than 2 
affected side 
1- two to five seconds 
slower 




Total upper extremity 66 
score for p tient 
For leg movement, sensation and balance 
Area Test Scoring Criteria Maximum 
Possible 
Score 
Lower extremity E. 
(supine) 1. Reflex activity - tested in 0- no reflex activity 4 
supine position 2- reflex activity 
11. a. Flexor synergy 0- cannot be performed 6 
Hip flexion I- partial motion 
Knee flexion 2 -full motion 
Ankle dorsiflexion 
b. Extensor synergy 0- no motion 8 
(motion is resisted) 1 -weak motion 
Hip extension 2- almost full strength 
Hip adduction compared to normal 
Knee extension 
Ankle plantar flexion 
Sitting (knees free of 111. Movement combining 0- no active motion 2 
chair) synergies I -from slightly 
a. Knee flexion beyond extended position 
90 degrees knee can be 
flexed but not 
beyond 90 degrees 
2- knee flexion beyond 
1 1 90 degrees 
For leg movement, sensation and balance 
Area _ Test Scoring Criteria Maximum 
Possible 
Score 
b. Ankle dorsiflexion 0- no active flexion 2 
1- incomplete active 
flexion 
2- normal dorsiflexion 
Standing IV. Moving out of synergy 0- knee cannot flex 2 
(hip at 0 degrees) without hip flexion 
a. Knee flexion 1- knee begins flexion 
without hip flexion 
but does not reach 90 
degrees, or hip flexes 
during motion 
b. Ankle dorsiflexion 0- no active motion 2 
1- partial motion 
2 -full motion 
Sitting V. Normal reflexes 0- two or three are 2 
Knee flexors markedly hyperactive 
Patellar 1- one reflex is hyperactive, 
Achilles or two reflexes are lively 
2- no more than 1 reflex is 
lively 
Supine F. 0- marked tremor 2 
Coordination/speed - I- slight tremor 
heel to opposite knee 2- no tremor 
(5 repetitions in rapid 
succession) 
a. Tremor 
b. Dysmetria 0- pronounced or 2 
unsystematic 
I- slight or systematic 
2- no dysmetria 
c. Speed 0- six seconds slower than 2 
affected side 
1- two to five seconds 
slower 
2- less than 2 seconds 
difference 
Total lower extremity 34 
score for patient 
Balance G. 0- unable 14 
Sit without support 1- partial 




Stand with support 
Stand without support 
Stand on non-affected leg 
Stand on affected leg 
For leg movement, sensation and balance 
Area Test Scoring Criteria Maximum 
Possible 
Score 
Sensation - upper and H. 0- anaesthesia 8 
lower extremities I. Light touch 1- hyperaethesia/ 
a. Upper arm dysaethesia 
b. Palm of hand 2- normal 
c. Thigh 
d. Sole of foot 
ii. Proprioception 0- no sensation 16 
a. Shoulder 1- three quarters of answers 
b. Elbow are correct, but 
c. Wrist considerable difference 
D. Thumb in sensation compared 
E. Hip to unaffected side 
F. Knee 2- all answers are correct, 
G. Ankle little or no difference 
H. Toe 
Passive joint Shoulder 0- only a few degrees range 44 
motion/joint pain Flexion of motion 
Abduction to 90 degrees I- decreased passive range 
Outward rotation of motion 
Inward rotation 2- normal passive range of 
Elbow motion 
Flexion 
Extension 0- pronounced pain during 44 
Forearm all the movement 
Pronation 1- some pain 





















1.4 Grip Strength 
Measured using dynamometer 
Instructions for use 
The electronic dynamometer consists of two flat padded bars mounted parallel to each other 2cm 
apart. When these are squeezed together they maximum force is indicated on a digital display. A 
standardised position of grip is used. The patient sits with hand resting comfortably in lap. The 
dynamometer is placed with a marker point on one bar against the cleft between thumb and index 
finger. 
The digital display is set to zero (the patient is not able to see the display). The patient is then asked 
to squeeze as hard as possible and then release. No encouragement or feedback is given. The 




1.5 Rivermead Motor Assessment 
General Instructions 
Go through the items in order of difficulty. Score 1 if patient can perform activity, 0 if he cannot. 
Three tries are allowed. After three consecutive failures, stop that section and proceed to the next. 
Give no feedback of whether correct or incorrect, just give general encouragement. Repeat 
instructions and demonstrate them to the patient if necessary. All exercises to be carried out 




1. Sit unsupported 
Without holding on, on edge of bed, feet unsupported F-I 
2. Lying to sitting on side of bed 
Using any method 
ID 
3. Sitting to standing 
- May use hands to push up. Must stand up in 15 sec and stand for 15 sec, F I With an aid if necessary. 
4. Transfer from wheelchair to chair towards unaffected side F May use hands 
5. Transfer from wheelchair to chair towards affected side 
May use hands 
6. Walk 10m indoors with an aid 
Any walking aid. No stand-by help. 
7. Climb stairs independently 
Any methods. May use banister and aid - must be a full flight of stairs. 
8. Walk 1 Orn indoors without an aid F No stand-by help. No caliper, splint or walking aid. 
9. Walk 10m, pickup beanbag from floor, turn and carry back F-I Bend down any way, may use aid to walk if necessary. No stand-by help. May use either hand to pick up bean bag. 
10. Walk outside 40m 
May use walking aid, caliper or splint. No stand-by help. 
11. Walk up and down four steps. 
Patient may use an aid if he would normally use one, but may not hold 
on to a rail. This is included to test ability to negotiate curb or stairs 
without a rail. 
12. Run 10m 
Must be symmetrical. 
13. Hop on affected leg five times on the spot 
Must hop on ball of foot without stopping to regain balance. 
No help with arms. 
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Leg and Trunk 
1. Roll to affected side 
Starting position should be lying, not crook lying 
2. Roll to unaffected side 
Starting position should be lying, not crook lying 
LI 
3. Half-bridging 
Starting position - half-crook lying. Patient must put some weight through 
affected leg to lift hip on affected side. Therapist may position leg, but 
patient must maintain position even after movement is completed. 
4. Sifting to standing -I 
May not use arms - feet must be flat on floor - must put weight through 
both feet. 
5. Half-crook lying: lift affected leg over side of bed and return it to same position 
Affected leg in half-crook position. Lift leg off bed on to support; for example, 
ED 
box, stool, floor, so that hip is in neutral and knee at 90 degrees while 
resting on support. Must keep affected knee flexed throughout movement. 
Do not allow external rotation at hip. This tests control of knee and hip. 
6. Standing, step unaffected leg on and off block 
Without retraction of pelvis or hyperextension of knee. This tests knee 
and hip control while weight bearing through the unaffected leg. 
7. Standing, tap ground lightly five times with unaffected foot 
Without retraction of pelvis or hyperextension of knee. Weight must 
stay on affected leg. This again tests knee and hip control while weight 
bearing through the affected leg but is more difficult than in 6. 
8. Lying, dorsiflex affected ankle with leg flexed 
Physiotherapist may hold affected leg in position, knee at 90 degrees. 
Do not allow any inversion. Must have half range of movement of 
unaffected foot. 
9. Lying, dorsiflex affected ankle with leg extended 
Same conditions as in 8, with leg extended. Do not allow any inversion 
or knee flexion. Foot must reach plantigrade (90 degrees). 
10. Stand with affected hip in neutral position, flex affected knee 
Therapist may not position leg. This is extremely difficult for most 




1. Lying, protract shoulder girdle with arm in elevation F-I Arm may be supported 
2. Lying, hold extended arm in elevation (some external rotation) for 
at least 2 seconds 
Therapist should place arm in position and patient must maintain position 
with some external rotation. Do not allow pronation. Elbow must be held 
within 30 degrees of full extension. 
3. Flexion and extension of elbow, with arm as in 2 above 
Elbow must extend to at least 20 degrees full extension. Palm should 
not face outward during any part of movement. 
4. Sifting, elbow into side, pronation and supination 
Three-quarters range is acceptable, with elbow unsupported and at 
right angles. 
5. Reach forward, pick up large ball with both hands and place down again 
Ball should be on table so far in front of patient that he has to extend 
Arms fully to reach it. Shoulders must be protracted, elbows extended, 
wrists neutral or extended, and fingers extended throughout movement. 
Palms should be kept in contact with the ball. 
6. Stretch arm forward, pick up tennis ball from table, release on mid-thigh on 
affected side, return to table, then release again on table. Repeat five times. 
Shoulder must be protracted, elbow extended and wrist neutral or extended 
during each phase. 
7. Same exercise as in 6 above with pencil 
Patient must use thumb and fingers to grip. 
8. Pick up a piece of paper from table in front and release five times 
Patient must use thumb and fingers to pick up paper and not pull it 
to edge of table. Arm position as in 6 above. 
9. Cut putty with a knife and fork on plate with non-slip mat and put pieces 
into container at side of plate F-I Bite-size pieces 
10. Stand on spot, maintain upright position, pat large ball on floor with palm of 
hand for 5 continuous bounces 
ID 
11. Continuous opposition of thumb and each finger more than 14 times in 10 sec 
Must do movements in consistent sequence. Do not allow thumb to 
slide from one finger to the other. 
12. Supination and pronation on to palm of affected hand 20 times in 10 sec 
Arm must be away from body, the palm and dorsum of hand must touch 
palm of good hand. Each tap counts as one. This is similar to 4 above, 
but introduces speed 
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Score 
Standing, with affected arm abducted to 90 degrees with palm flat against I 
wall. Maintain arm in position. Turn body towards wall and as far as possible F-I 
towards arm i. e. rotate body beyond 90 degrees 
Do not allow flexion at elbow, and wrist must be extended with palm of 
hand fully in contact with wall. 
14. Place string around head and tie bow at back 
Do not allow neck to flex. Affected hand must be used for more than F-I 
just supporting string. This tests function of hand without help of sight. 
15. 'Pat-a-cake' seven times in 15 sec 
Mark crosses on wall at shoulder level. Clap both hands together 
(both hands touch crosses - clap - one hand touches opposite cross). 
Must be in correct order. Palms must touch. Each sentence counts 
as one. Give patient three tries. This is a complex pattern which involves 
co-ordination, speed, and memory, as well as good arm function. 
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1.6 Star Cancellation Test 
Place the star chart flat in front of the subject so that the central arrow of the page is in the 
subject's midline. 
Explain that this is a page full of small stars, big stars and letters. 
" You are going to ask them to cross out all the small stars that they can see on the page. 
" Demonstrate by crossing out the two small stars immediately above the arrow. 
" Give the pen to the subject, or if they are unable to hold the pen ask them to point to the small 
stars so that you can then cross them out. 
Continue to cross out stars until the subject confirms that they cannot see any more. 
There is no time limit, but do not prompt subject or move the page once it has been put in the 
midline. 
Score : number of stars subject crossed out = 
PASS (52 - 54) 
11 FAIL (0 - 51) 
(max = 54) 
n UNABLE TO ASSESS n 
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1.7 Bobath Assessment Chart 
Tests for Arm and Shoulder Girdle (to be tested separately in supine, sitting and standing, as the 
result will be different in these positions). 
All to be answered 'Yes' or 'No' 
Grade I 
a. Can he hold extended arm in elevation having placed it there? 
With internal rotation? 
With external rotation? 
Can he lower the extended arm from the position of elevation to the horizontal plane and back 
again to elevation? 
Forward-downwards? 
Sideways-downwards? 
With internal rotation? 
With external rotation? 
C. Can he move the extended abducted arm from the horizontal plane to the side of his body 
and back again to the horizontal plane? 
With internal rotation? 
With external rotation? 
Grade 2 
a. Can he lift his arm to touch the opposite shoulder? 
With palm of hand? 
With back of hand? 
b. Can he bend his elbow with his arm in elevation to touch the top of his head? 
With pronation? 
With supination? 
C. Can he fold his hands behind his head with both elbows in horizontal abduction? 
With wrist flexed? 
With wrist extended? 
Grade 3 
a. Can he supinate his forearm and wrist? 
Without side-flexion of trunk on the affected side? 
With flexed elbow and flexed fingers? 
With extended elbow and extended fingers? 
Can he pronate his forearm without adduction of arm at shoulder? 
C. Can he externally rotate his extended arm? 
In horizontal abduction? 
By the side of the body? 
In elevation? 
d. Can he bend and extend his elbow in supination to touch the shoulder of the same side? 
Starting with: 
Arm by sid6 of body? 
Horizontal abduction of the arm? 
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Tests for Wrist and Fingers 
Grade I 
Can he place his flat hand forward down on table in front? 
Can he do this sideways when sitting on plinth? 
With fingers and thumb adducted? 
With fingers and thumb abducted? 
Grade 2 
a. Can he open his hand to grasp? 
With flexed wrist? 
With extended wrist? 
With pronation? 
With supination? 
With adducted fingers and thumb? 
With abducted fingers and thumb? 
Grade 3 
a. Can he grasp and open his fingers again? 
With flexed elbow? 
With extended elbow? 
With pronation? 
With supination? 




2 nd and 3 rd finger? 
C. Can he oppose fingers and thumb? 
Thumb and index finger? 
Thumb and 2 nd finger? 
Thumb and little finger? 
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1.8 Nine-hole Peg Test 
Equipment 
9 wooden dowels, 9mm diameter, 32mm long. 
Wood base with 9 holes (1 Omm diameter, 15mm deep) spaced 15mm apart in three rows of 
three holes. 
Lid to base, with tray 1 00mm square and 1 00mm deep to hold pegs. 
Instructions 
Patient to sit at table, and asked to place pegs in holes. Observer times from start to end, but can 
stop at 50 sec and record number of pegs placed. 
Results 
Best presented as number of seconds taken to place each peg. 
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1.9 Box and Block Test 
A box with a partition directly in the centre, creating two equal sides, is used for this test. A number of 
small wooden blocks are placed in one side of the box. 
The subject is required to use their dominant had to grasp one block at a time and transport it over the 
partition and release it into the opposite side. The subject is given 60 seconds in which to complete 
the test, and the number of blocks transported to the other side is counted. The test is then repeated 
with the non-dominant hand. 
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1.10 Frenchay Arm Test 
Instructions 
The patient sits at a table with his/her hands on his/her lap. Each task starts from this position. The 
patient scores one for each task completed successfully (and nought if he/she fails), and is asked to 
use each hand to: 
R L 
1. Stabilise a ruler while drawing a line with a pencil held in the 
other hand. To pass, the ruler must be held firmly. 
2. Grasp a cylinder (1 2mm diameter, 5cm long) set on its end 
approximately 15cm from the table edge, lift it about 30cm 
and replace it without dropping. 
3. Pick up a glass half-full of water positioned 15-30cm from 
the table edge, drink some water and replace the glass without 
spilling any water. 
4. Remove and replace a sprung clothes peg from a 10mm 
diameter dowel, 15cm long, set in a1 Ocm square base, placed 
15-30cm from the table edge. He/she is not to drop the peg 
or knock the dowel over. 
5. Comb his/her hair (or imitate); he/she must comb across the top, 
down the back and down each side of the head. 




1.11 Action Research Arm Test 
Instructions - There are four subtests: grasp, grip, pinch and gross movement. 
If a subject passes the first the first task in each subtest then they score top marks and move onto the 
next subtest. If a subject fails the first and the second task in a subtest, then they score zero overall 
for that subtest and move onto the next. The patient must be able to sit unaided in order to attempt 
the test. If not, the patient scores 0. 
Score 0= can perform no part of the test ARAT done 
1= performs test partially unable to sit (score 0) 
2= completes test, but takes abnormally long time ARAT not done (score missing value) 
3= performs test normally (Give reason 
Start with the least impaired arm first 
RL 
a) Grasp 
10cm cube (if score =3 then total = 18 & go to Grip 
1.2.5cm cube (if Grasp score =0 so far then Grasp total =0& go to Grip 
2.5cm cube 
3.7.5cm cube 




1. Pour water glass to glass (if score =3 then total = 12 & go to Pinch) 
2.2.25cm tube (if Grip score =0 so far then Grip total =0& go to Pinch) 
3.1cm tube 
4. washer over bolt 
c) Pinch 
Grip total: 
1.6mm bearing 3rd finger & thumb (if score =3 then total = 18 & go to Gross) 
2. marble index & thumb (if Pinch score =0 so far then Pinch total =0& go to Gross) 
3.6mm bearing 2nd finger & thumb 
4.6mm bearing 1 st finger& thumb 
5. marble 2nd finger & thumb 
6. marble 3rd finger & thumb 
Pinch total: 
d) Gross 
1. Place hand behind head (if score =3 then total =9& finish) 
2. Place hand on top of head 




1.12 Barthel Activities of Daily Living Index 
Function Description Score 
Bowels Incontinent (or needs to be given enema) 0 
Occasional accidence (once a week) 1 
Continent 2 
Bladder Incontinent, or catheterised and unable to manage 
Occasional accident (max. once per 24 hours) 
0 
1 
Continent (for more than 7 days) 2 
Grooming Needs help with personal care: face, hair, teeth, shaving 0 
Independent (implements provided) 1 
Toilet Use Dependent 0 
Needs some help but can do some things alone 1 
Independent (one and off, wiping, dressing) 2 
Feeding Unable 0 
Needs help in cutting, spreading butter etc. I 
Independent (food provided within reach) 2 
Transfer Unable - no sitting balance 0 
Major help (physical, 1 or 2 people), can sit 1 
Minor help (verbal or physical) 2 
Independent 3 
Mobility Immobile 0 
Wheelchair independent, including corners etc. I 
Walks with help of one person (verbal or physical) 2 
Independent 3 
Dressing Dependent 0 
Needs help but can do about half unaided 1 
Independent (including buttons, zips, laces etc. ) 2 
Stairs Unable 0 
Needs help (verbal, physical, carrying aid) 1 
Independent up and down 2 
Bathing Dependent 0 
Independent (Bath: must get in and out unsupervised 1 
and wash self. Shower: unsupervised/unaided). 
Total (0-20) II -I 
20 
1.13 Rivermead Activities of Daily Living Scale 
Instructions 
1. Decide where to start. If the patient can do that item, go back three to make sure that the patient 
can do these as well, and forward until three consecutive failures - then stop. This applies to 
each section. 
2. All aids supplied or recommended to be stated on form. 
3. Guidelines are given on next page. 
Scoring 
3= Independent with/without aid 
2= Verbal assistance only 
1= Dependent (i. e. if unfit, un-assessable, unsafe or time taken is beyond practical bounds) 














Wash in bath 
In/out bath 
Overall wash 
Floor to chair 
Household 1 
Preparation of hot drink 
Preparation of snack 
Cope with money 














1.14 Nottingham Extended Activities of Daily Living Index 
Before your recent stroke, were you living alone? No Yes Don't know 
U 
Not at With Alone Alone 
all help with easily 
a) Mobility difficulty 
In the month before your stroke, did you: 
i ? " walk around outs de 
" climb stairs? 
" get in and out of the car? 
" walk over uneven ground? 
" cross roads? 
" travel on public transport? F-1 F1 
b) In the kitchen 
In the month before your stroke, did you: 
" manage to feed yourself? 
" manage to make yourself a hot drink? 
" take hot drinks from one room to another? F1 F-1 
" do the washing up? 
" make yourself a hot snack? 
c) Domestic tasks 
In the month before your stroke, did you: 
manage your own money when you were 
out? 
wash small items of clothing? 
do your own shopping? FA 
do your own housework? 
Ij 
do a full clothes wash? Ij 
d) Leisure Activities 
In the month before your stroke, did you: 
" read newspapers or books? 
" use the telephone? 
" write letters? 
" go out socially? 
" manage your own garden? 
" drive a car? 
Scoring 0= Not at all 1= With help 2= On my own with difficulty 3= Alone easily 
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1.15 Functional Independence Measure and Functional 
Assessment Measure 
Scale: 
7 Complete Independence (timely, safely) 
6 Modified Independence (extra time, devices) 
5 Supervision (cuing, coaxing, prompting) 
4 Minimal Assist (performs 75% or more of task) 
3 Moderate Assist (performs 50-74% of task) 
2 Maximal Assist (performs 25-49% of task) 
I Total Assist (performs less than 25% of task) 




4. Dressing upper body 




8. Bladder management 
9. Bowel management 
Mobility items (Type of transfer) 
10. Bed, chair, wheelchair 
11. Toilet 
12. Bath or shower 
13. Car transfer* 
Locomotion 
14. Walking/wheelchair (circle) 
15. Stairs 
16. Community access* 
Communication items 
17. Comprehension - audio/visual (circle) 
18. Expression - verbal, non-verbal (circle) 
19. Reading* 
20. Writing* 
21. Speech intelligibility* 
Psychosocial adjustment 
22. Social interaction 
23. Emotional status* 
24. Adjustment to limitations* 
25. Employability* 
Cognitive function 




30. Safety judgement* 
* FAM items 
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1.16 Frenchay Activities Index 
Score Activity Code (score) 
In the last three months 
Preparing main meals 0= Never 
Washing up 1= Under once weekly 
2= 1-2 times/week 
3= Most days 
Washing clothes 0= Never 
Light housework 1= 1-2 times in three months 
Heavy housework 2= 3= 12 times in three months 
Local shopping 3= At least weekly 
Social occasions 
Walking outside >1 5 mins 
Actively pursuing hobby 
Driving car/going on bus 
In last six months 
Travel outings/car rides 0= never 
1= 1-2 times in 6 months 
2= 3-12 times in 6 months 
3= At least twice weekly 
Gardening 0= Never 
Household/car maintenance 1= Light 
2= Moderate 
3= All necessary 
Reading books 0= None 
I= One in 6 months 
2= Less than one in a fortnight 
3= Over one each fortnight 
Gainful work 0 None 
1 Up to 10 hours/week 
2 10-30 hours/week 
3 Over 30 hours/week 
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1.17 Motor Assessment Scale 
General instructions 
1. The test should preferably be carried out in a quiet private room or curtained-off area. 
2. The test should be carried out when the patient is maximally alert and not when under the 
influence of hypnotic or sedative drugs. Record if the patient is under the influence of sedative 
drugs. 
3. Patient should be dressed in suitable street clothes with sleeves rolled up and without shoes and 
socks. Items 1 to 3 inclusive may be scored if necessary with the patient in his right clothes. 
4. Each item is recorded on a scale of 0 to 6. 
5. AJI items are to be performed independently by the patient unless otherwise stated. 'Stand-by 
help' means that the physical therapist stands by and may steady patient but must not actively 
assist. 
6. Items 1 to 8 are recorded according to the patient's responses to specific instructions. General 
Tonus (item 9) is scored from continuous observations and handling throughout the assessment. 
7. Patient should be scored on best performance. Repeat three times unless other specific 
instructions are given. 
8. Because the scale is designed to score the patient's best performance, the physical therapist 
should give general encouragement but should not give specific feedback on whether response is 
correct or incorrect. Sensitivity to the patient is necessary to enable him to produce his best 
performance. 
9. Instructions should be repeated and demonstrations given to the patient if necessary. 
10. The order of administration of the items can be varied according to convenience. 
11. If the patient becomes emotionally labile at any stage during scoring, the physical therapist should 
wait 15 sec before attempting the following procedures: 
" ask patient to close his mouth and take a deep breath; and 
" hold the patienCs jaw closed and ask the patient to stop crying. 
If patient is unable to control behaviour, the examiner should cease testing him and re-score this 
item and any other items unscored at a more suitable time. 
12. If performance is scored differently on left and right side, the physical therapist may indicate this 
with an V in one box and an W in another box. 
13. The patient should be informed when being times. 
14. You will need: a low, wide plinth, a stopwatch, a polystyrene cup, eight jelly-beans, two teacups, a 
rubber ball 14cm (5 in) in diameter, a stool, a comb, a top of a pen, a table, a dessert spoon and 
water, a pen, a prepared sheet for drawing lines, and a cylindrical object such as a jar. 
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A. Supine to side lying on to Intact side 
1. Pulls himself into side lying 
Starting position must be supine lying, not knees flexed. Patient pulls himself into side lying 
with intact arm, moves affected leg with intact leg. 
2. Moves leg across actively and lower half of body follows 
Starting position as above. Arm is left behind. 
3. Arm is lifted across body with other arm. Leg is moved actively and body follows in a block. 
Starting position as above. 
4. Moves arm across body actively and rest of body follows in a block. 
Starting position as above. 
5. Moves arm and leg and rolls to side but overbalances 
Starting position as above. Shoulder protracts and arm flexes forward. 
6. Rolls to side in 3 sec 
Starting position as above. Must not use hands. 
B. Supine to sitting over side of bed 
1. Side lying, lifts head sideways but cannot sit up 
Patient assisted to side lying. 
2. Side lying to sitting over side of bed 
Therapist assists patient with movement. Patient controls head position throughout. 
3. Side lying to sitting over side of bed. 
Therapist gives stand-by help by assisting legs over side of bed. 
4. Side lying to sitting over side of bed 
With no stand-by help. 
5. Supine to sifting over side of bed 
With no stand-by help. 
6. Supine to sitting over side of bed within 10 sec 
With no stand-by help. 
C. Balanced sitting 
1. Sits only with support 
Therapist should assist patient into sitting. 
2. Sits unsupported for 10sec 
Without holding on, knees and feet together, feet can be supported on floor 
3. Sits unsupported with weight well forward and evenly distributed 
Weight should be well forward at the hips, head and thoracic spine extended, weight evenly 
distributed on both sides. 
4. Sits unsupported, turns head and trunk to look behind 
Feet supported and together on floor. Do not allow legs to abduct or foot to move. Have 
hands resting on thighs, do not allow hands to move on to plinth. 
5. Sits unsupported, reaches forward to touch floor, and returns to starting position. 
Feet supported on floor. Do not allow patient to hold on. Do not allow legs and feet to move, 
support affected arm if necessary. Hand must touch floor at least 1 Ocrn (4 in) in front of feet. 
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6. Sits on stool unsupported. reaches sideways to touch floor, and returns to starting position. 
Feet supported on floor. Do not allow patient to hold on. Do not allow legs and feet to move. 
support affected arm if necessary. Patient must reach sideways, not forward. 
D. Sitting to standing 
1. Gets to standing position with help from therapist. 
Any method. 
2. Gets to standing position with stand-by help. 
Weight unevenly distributed, uses hands for support. 
3. Gets to standing position 
Do not allow uneven weight distribution or help from hands. 
4. Gets to standing position and stands for 5 sec with hips and knees extended. 
Do not allow uneven weight distribution. 
5. Sitting to standing with no stand-by help. 
Do not allow uneven weight distribution. Full extension of hips and knees. 
6. Sitting to standing with no stand-by help three times in 10 sec. 
Do not allow uneven weight distribution. 
E. Walking 
1. Stands on affected leg and steps forward with other leg. 
Weight-bearing hip must be extended. Therapist may give stand-by help. 
2. Walks with stand-by help from one person. 
3. Walks 3m (10 ft) along or uses any aid but no stand-by help. 
4. Walks 5m (16 ft) with no aid in 15 sec. 
5. Walks 10m (33 ft) with no aid, turns around, picks up a small sandbag from floor, and walks back 
in 25 sec. 
May use either hand. 
6. Walks up and down four steps with or without an aid but without holding on to the rail three times 
in 35 sec. 
F. Upper-arm function 
I. Lying, protract shoulder girdle with arm in elevation. 
Therapist places arm In position and supports it with elbow in extension. 
2. Lying, hold extended arm In elevation for 2 sec. 
Therapist should place arm in position and patient must maintain position with some external 
rotation. Elbow must be within 20 degrees of full extension. 
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3. Flexion and extension of elbow to take palm to forehead with arm as in 2 above. 
Therapist may assist supination of forearm. 
4. Sitting, hold extended arm in forward flexion at 90 degrees to body for 2 sec. 
Therapist should place arm in position and patient must maintain position with some external 
rotation and elbow extension. Do not allow excess shoulder elevation. 
5. Sitting, patient lifts arm to above position, holds it therefor 10 seconds, and then lowers it. 
Patient must maintain position with some external rotation. Do not allow pronation. 
6. Standing, hand against wall. Maintain arm position while turning body towards wall. 
Have arm abducted to 90 degrees with palm flat against the wall. 
G. Hand movements 
1. Sifting, extension of the wrist. 
Therapist should have patient sitting at table with forearm resting on the table. Therapist 
places cylindrical object in palm of patient's hand. Patient is asked to lift object off the table by 
extending the wrist. Do not allow elbow flexion. 
2. Sitting, radial deviation of wrist. 
Therapist should place forearm in mid-pronation-supination (i. e. resting on u1nar side, thumb in 
line with forearm and wrist in extension, fingers around a cylindrical object). Patient asked to 
lift hand off table. Do not allow elbow flexion or pronation. 
3. Sitting, elbow into side, pronation and supination. 
Elbow unsupported and at a right angle. Three-quarter range is acceptable. 
4. Reach forward, pick up large ball of 14 cm (5-1n) diameter with both hands and put it down. 
Ball should be on table so far in front of patient who has to extend arms fully to reach it. 
Shoulders must be protracted, elbows extended, wrist neutral or extended. Palms should be 
kept in contact with the ball. 
5. Pick up a polystyrene cup from table and put it on table across other side of body. 
Do not allow alteration in shape of cup. 
6. Continuous opposition of thumb and each finger more than 14 times in 10 sec. 
Each finger in turn taps the thumb, starting with index finger. Do not allow thumb to slide from 
one finger to the other, or to go backwards. 
H. Advanced hand activities 
1. Picking up the top of a pen and putting it down again. 
Patient stretches arm forward, picks up pen top, releases it on table close to body. 
2. Picking up one jellybean from a cup and placing it in another cup. 
Teacup contains eight jellybeans. Both cups must be at arms length. Left hand takes 
jellybean from cup on right and releases it in cup on left. 
3. Drawing horizontal lines to stop at a vertical line 10 times in 20 sec 
At least five lines must touch and stop at the vertical line. 
4. Holding a pencil, making rapid consecutive dots on a sheet of paper. 
Patient must do at least two dots a second for 5 sec. Patient picks pencil up and positions it 
without assistance. Patient must hold pen as for writing. Patient must make a dot and not a 
stroke. 
28 
5. Taking a dessert spoon of liquid to the mouth. 
Do not allow head to lower towards spoon. Do not allow liquid to spill. 
6. Holding a comb and combing hair at back of head. 
1. General tonus 
I. Flaccid, limp, no resistance when body parts are handled. 
2. Some response felt as body parts are moved. 
3. Variable, sometimes flaccid, sometimes good tone, sometimes hypertonic. 
4. Consistently normal response. 
5. Hypertonic 50 per cent of the time. 
6. Hypertonic at all times. 
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1.18 Health Assessment Questionnaire 
We are interested in learning how your illness affects your ability to function in daily life. Please feel 
free to add any comments at the end of this form. Please choose from the answers given. 
Answers 
0= without any difficulty 1= with some difficulty 2= with much difficulty 3= unable to do 
Item Answer 
score) 
1- Dressing and grooming 
Are you able to: 
dress yourself, including tying shoelaces and doing-up buttons? 
shampoo your hair? 
2. Rising 
Are you able to: 
stand up from an armless straight chair? 
get in and out of bed? 
3. Eating 
Are you able to: 
cut your meat? 
lift a full cup or glass to your mouth? 
open a new carton of milk (or soap powder)? 
4. Walking 
Are you able to: 
walk outdoors on flat ground? 
climb up five steps? 
5. Hygiene 
Are you able to: 
wash and dry your entire body? 
take a bath? 
get on and off the toilet? 
6. Reach 
Are you able to: 
reach and get down a5 lb (2 kg) object from above your head 
(for example, a bag of potatoes)? 
bend down and pick up clothing from the floor? 
7. Grip 
Are you able to: 
open car doors? 
open jars which have been previously opened? 
turn taps (faucets) on and off? 
8. ActiWies 
Are you able to: 
run errands and go shopping? 
get in and out of the car? 
do chores such as vacuuming, housework, or light gardening? 
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1.19 The Modified Rankin Scale 
0N 
0 
o symptoms at all 
Li 
1 No significant disability despite symptoms 
able to carry out all usual duties and activities 
Li 
2 Slight disability, unable to carry out all previous activities, 
but still able to look after own affairs without assistance 
ID 
3 Moderate disability, requiring some help 
4 Moderately severe disabilitT, 
LI 
needing help but not so bad as to need attention day and night 
5 Severe disability-, requiring constant attention 
L) 
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1.20 Nottingham Health Profile 
Listed below are some problems that people might have in their daily lives. Please read the list 
carefully and put a tick in the box 3 under Yes for any problem that applies to you at the moment. 
Tick the box under No for any problem that does not apply to you. PLEASE TRY TO ANSWER 
EVERY QUESTION. If you are not sure whether to answer Yes or No, tick whichever answer you 
think is MOST true at the moment. 
No Yes 
0) I'm tired all the time F] D 
1) I have pain at night 
L) Ll 
2) Things are getting me down 
L) L) 
3) 1 have unbearable pain 
Ll D 
4) 1 take tablets to help me sleep 
F1 D 
5) I've forgotten what it's like to enjoy myself Ll F] 
6) I'm feeling on edge 
0 
7) 1 find it painful to change position 
8) 1 feel lonely 
9) 1 can only walk about indoors 
L) 
10) 1 find it hard to bend 
L) 
11) Everything is an effort 
12) I'm waking up in the early hours of the morning 
13) I'm unable to walk at all 
14) I'm finding It hard to make contact with people 
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No Yes 
15) The days seem to drag 
0 0 
16) 1 have trouble getting up and down stairs 
or steps 
D 
17) 1 find it hard to reach for things 
D D 
18) I'm in pain when I walk 
0 L) 
19) 1 lose my temper easily these days 
L) 
20) 1 feel there is nobody I am close to 
21) 1 lie awake for most of the night 
L) 
22) 1 feel as if I'm losing control F] F] 
23) I'm in pain when I'm standing 
0 0 
24) 1 find it hard to dress myself 
25) 1 soon run out of energy 
26) 1 find it hard to stand for long (e. g. at 
the kitchen sink or waiting for a bus) 
L] 
27) I'm in constant pain 
28) It takes me a long time to get to sleep 
29) 1 feel I am a burden to people 
0 
30) Worry is keeping me awake at night 
31) 1 feel that life is not worth living 
32) 1 sleep badly at night 







I need help to walk about outside (e. g. 
a walking aid or someone to support me) 
I'm in pain when going up and down stairs 
DD 
or steps 
I wake up feeling depressed F1 Ll 
I'm in pain when I'm sitting n F1 
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1.21 Health Status Questionnaire (SF-36) 
The following questions ask for your views about your health, how you feel and how well you are 
able to do your usual activities. 
If you are unsure about how to answer a question, please give the best answer you can and make 
any comments in the space available at the end of the questionnaire. 
1. In general, would you say your health is: 
(Circle one) 
Excellent 1 




2. Compared to three months a-qo. how would you rate your health in general now? 
(Circle one) 
Much better than 3 months ago I 
Somewhat better than 3 months ago 2 
About the same 3 
Somewhat worse now than 3 months ago 4 
Much worse now than 3 months ago 5 
HEALTH AND DAILY ACTIVITIES 
3. The following questions are about activities that you might do during a typical day. Does your 
health limit you in these activities? If so, how much? (Circle one number on each line) 
ACTIVITIES Yes, limited a 
lot 
Yes, limited a 
little 
No, not limited 
at all 
a Vigorous activities, such as running, 
lifting heavy objects, participating in 
strenuous sports 
1 2 3 
b Moderate activities, such as moving a 
table, pushing a vacuum cleaner, bowling 
or playing golf 
1 2 3 
c Lifting or carrying groceries 1 2 3 
d Climbing several flights of stairs 1 2 3 
e Climbing one flight of stairs 1 2 3 
f Bending, kneeling or stooping 1 2 3 
g Walking more than a mile 1 2 3 
h Walking half a mile 1 2 3 
1 Walking 100 yards 1 2 3 
j Bathing or dressing yourself 1 2 3 
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4. During the past 4 weeks, have you had any of the following problems with your work or other 
regular daily activities as a result of your physical health? 
(Circle one number on each line) 
Yes No 
a Cut down on the amount of time you spent on work or 2 
other activities 
b Accomplished less than you would like 2 
c Were limited in the kind of work or other activities 2 
d Had difficulty in performing the work or other activities 2 
(e. g. it took extra effort) 
5. During the 12ast 4 weeks, have you had any of the following problems with your work or other 
regular daily activities as a result of anv emotional problems (such as feeling depressed or 
anxious)? 
(Circle one number on each line) 
Yes No 
a Cut down on the amount of time you spent on work or 2 
other activities 
b Accomplished less than you would like 2 
C Didn't do work or other activities as carefully as usual 2 
6. During the past 4 weeks, to what extent has your physical health or emotional problems interfered 
with your normal social activities with family, friends, neighbours or groups? 
(Circle one) 
Not at all 1 
Slightly 2 
Moderately 3 
Quite a bit 4 
Extremely 5 
7. How much tb9odi pain have you had during the gast 4 weeks? y 
(Circle one) 
None 1 




Very severe 6 
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8. During the past 4 weeks, how much did pain interfere with your normal work (including work 
both outside the home and housework)? 
(Circle one) 
Not at all I 
A little bit 2 
Moderately 3 
Quite a bit 4 
Extremely 5 
YOUR FEELINGS 
9. These questions are about how you feel and how things have been with you during the past 4 
weeks. (For each question, please indicate the one answer that comes closest to the way you 
have been feeling). 
(Circle one number on each line) 
How much of the time AJ1 of Most of A good Some of A little of None of 
during the past 4 weeks: the time the time bit of the the time the time the time 
time 
a Did you feel full of life? 123456 
b Have you been a very 123456 
nervous person? 
C Have you felt so down in 1 2 3 4 5 6 
the dumps that nothing 
could cheer you up? 
d Have you felt calm and 1 2 3 4 5 6 
peaceful? 
e Did you have a lot of 1 2 3 4 5 6 
energy? 
f Have you felt down- 1 2 3 4 5 6 
hearted and low? 
g Did you feel worn-out? 1 2 3 4 5 6 
h Have you been a happy 1 2 3 4 5 6 
person? 
Did you feel tired? 123456 
Has your health limited 123456 
your social activities (like 
visiting friends or close 
relatives) 
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10. Please choose the answer that best describes how true or false each of the following 
statements is for you? 
(Circle one number on each line) 
Definitely Mostly true Not sure Mostly Definitely 
true false false 
aI seem to get ill more easily than 12345 
other people 
bI am as healthy as anybody 112345 
know 
cI expect my health to get worse 12345 
d My health is excellent 12345 
Comments 
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1.22 Stroke Specific Quality of Life Scale 
Response Set Key 
1 Total A lot of Some A little No help 
help help help help needed 
12345 
2. Couldn't A lot of Some A little No 
do it at trouble trouble trouble trouble 
all at all 
12345 
3. Strongly Moderately Neither Moderately Strongly 







1. I spent a lot of time in bed 3 
2. 1 felt tired most of the time 3 
3. 1 had to stop and rest often during the day 3 
4. 1 was too tired to do what I wanted to do 3 
Fam ily Roles 
1. Did you need help to do regular daily work around the house? 1 
2. Did you have to stop and rest when you were working around the house? 2 
3. Did you need help to do the shopping? 1 
4. Did you need help taking care of personal jobs, for example, paying bills, 1 
going to the bank, making appointments? 
5. 1 didn't join in activities just for fun with my family 3 
6. Did someone else have to drive you around? 2 
7. 1 felt I was a burden to my family 3 
8. My physical condition interfered with my family life 3 
Language 
I Did you have trouble communicating, for example, need to use gestures or 2 
pointing? 
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1.23 Stroke Impact Scale 
The purpose of this questionnaire is to evaluate how stroke has impacted your health and life. We 
want to know from YOUR POINT OF VIEW how stroke has affected you. We will ask you questions 
about impairments and disabilities caused by your stroke, as well as how stroke has affected your 
quality of life. Finally, we will ask you to rate how much you think you have recovered from your 
stroke. 
These auestions are about the DhVSiCaI Droblems that mav have occurred as a result of your stroke. 
1. In the past week, how would you rate A lot of Quite a bit Some A little No strength 
the strength of your ..... stren th of strength stren th strength at all 
a. Arm that was most affected by your 5 4 3 2 1 
stroke? 
b. Grip of your hand that was most 5 4 3 2 1 
affected by your stroke? 
c. Leg that was most affected by your 5 4 3 2 1 
stroke? 
d. Foot/ankle that was most affected by 5 4 3 2 1 
your stroke? 
These questions are about your memory and thinking. 












a. Remember things that people just told 
you? 
5 4 3 2 1 
b. Remember things that happened 
yesterday? 
5 4 3 2 1 
c. Remember to do things (e. g. keep 
scheduled appointments or take 
medication? ) 
5 4 3 2 1 
d. Remember the day of the week? 5 4 3 2 1 
e. Add and subtract numbers? 5 4 3 2 
f. Concentrate? 5 4 3 2 
g. Think quickly? 5 4 3 2 
h. Solve problems? 5 4 3 2 1 
These questions are about how you feel, about changes in your mood and your ability to control your 
emotions since your stroke. 
3. In the past week, how often did you ..... None of the time 




Most of the 
time 
All of the 
time 
a. Feel sad? 5 4 3 2 1 
b. Feel that there is nobody you are close 
to? 
5 4 3 2 1 
c. Feel that you are a burden to others? 5 4 3 2 1 
d. Feel that you have nothing to look 
forward to? 
5 4 3 2 1 
e. Blame yourself for mistakes? 5 4 3 2 1 
f. Enjoy things as much as you ever have 5 14 3 2 1 
g. Feel quite nervous? 5 4 3 2 1 
h. Feel that life is worth living? 5 4 3 2 1 
I. Smile and laugh at least once a day? 5 4 3 2 1 
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The following Items are about your ability to communicate with other people, as well as your ability to 
i indPrczfnnri whnf vni i rpnri nnd whnt vnu hear in a conversation. 












a. Say the name of someone whose face 
was in front of you? 
5 4 3 2 1 
b. Understand what was being said to you 
in a conversation? 
5 4 3 2 1 
c. Reply to questions? 5 4 3 2 1 
d. Correctly name objects? 5 4 3 2 1 
e. Participate in a conversation with a 
group of people? 
5 4 3 2 1 
f. Have a conversation on the telephone? 5 4 3 2 1 
g. Call another person on the telephone 
(select correct phone number and dial)? 
5 4 3 2 1 
Thp fnflnwinn itpmq nqk Phni it nrtivitipi; vou minht do durina a tvDical dav 












a. Cut your food with a knife and fork? 5 4 3 2 1 
b. Dress the top part (waist up) of your 
body? 
5 4 3 2 1 
c. Bathe yourself? 5 4 3 2 
d. Clip your toenails? 5 4 3 2 
e. Get to the toilet on time? 5 4 3 2 
f. Control your bladder (not have an 
accident)? 
5 4 3 2 
g. Control your bowels (not have an 
accident)? 
5 4 3 2 
h. Do light household tasks/chores (e. g. 
dust, make a bed, take out rubbish, do the 
dishes)? 
5 4 3 2 1 
1. Go shopping? 5 4 3 2 1 
J. Handle money (e. g. make change)? 5 4 3 2 1 
k. Manage finances (e. g. pay monthly 
bills, manage current account)? 
5 4 3 2 1 
1. Do heavy household chores (e. g. 
vacuum, laundry or garden work)? 
5 4 3 2 1 
1 -1 
The followino ouestinns arp shnut vour abilitv to be mobile. at home and in the community. 












a. Sit without losing your balance? 5 4 3 2 1 
b. Stand without losing your balance? 5 4 3 2 1 
c. Walk without losing your balance? 5 4 3 2 1 
d. Move from a bed to a chair? 5 4 3 2 1 
e. Get out of a chair without using your 
hands for support? 
5 4 3 2 1 
f. Walk down one street? 5 4 3 2 1 
g. Walk fast? 5 4 3 2 1 
h. Climb one flight of stairs? 5 4 3 2 1 
I. Climb several flights of stairs? 5 4 3 2 1 
. 
ýGeFin and out of a car? 5 4 3 2 1 
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The following questions are about your ability to use your hand that was MOST AFFECTED by your 
stroke. 
7. In the past 2 weeks, how difficult was it 
to use your hand that was most affected 











a. Carry heavy objects (e. g. bag of 
groceries)? 
5 4 3 2 1 
b. Turn a doorknob? 5 4 3 2 1 
C. Open a can or jar? 5 4 3 2 1 
d. Tie a shoelace? 5 4 3 -2 1 
e. Pick up a coin? 5 4 3 2 1 
The following questions are about how stroke has affected your ability to participate in the activities 
that you usually do, things that are meaningful to you and help you to find purpose in life. 
8. During the past 4 weeks, how much of 
the time have you been limited in.... 
None of the 
time 




Most of the 
time 
All of the 
time 
a. Your work, volunteer or other activities? 5 4 3 2 1 
b. Your social activities? 5 4 3 2 1 
c. Quiet recreation (crafts, reading)? 5 4 3 2 1 
d. Active recreation (sports, outings, 
travel)? 
5 4 3 2 1 
e. Your role as a family member and/or 
friend? 
5 4 3 2 1 
f. Your participation in spiritual or religious 
activities? 
5 4 3 2 1 
g. Your ability to feel emotionally 
connected to another person? 
5 4 3 2 1 
h. Your ability to control your life as you 
wish? 
5 4 3 2 1 
L Your ability to help others in need? 5 4 3 2 
9. Stroke Recovery 
On a scale of 0 to 100, with 100 representing full recovery and 0 representing no recovery, how much 
have you recovered from your stroke? 










0 Experienced no recovery 
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1.24 EuroQol EQ-5D Questionnaire 
By placing a tick in one box in each group below, please indicate which 
statement best describes your own health state today. 
Do not tick more than one box in each group. 
Mobility 
I have no problems walking about El 
I have some problems walking about 11 
I am confined to bed F1 
Self-care EJ I have no problems with self-care 
I have some problems washing or dressing myself EJ 
I am unable to wash or dress myself M 
Usual activities (e. g. work, study, housework, family or leisure activities) 
I have no problems with performing my usual activities R 
I have some problems with performing my usual activities F] 
I am unable to perform my usual activities FJ 
Pain/Discomfort 
I have no pain or discomfort 
I have moderate pain or discomfort 
I have extreme pain or discomfort 
Anxiety/Depression 
I am not anxious or depressed 
I am moderately anxious or depressed 
I am extremely anxious or depressed 
To help people say how good or bad a health state is, we have drawn a scale (rather like a thermometer) on which 
the best state you can imagine is marked 100 and the worst state you can imagine is marked by 0. We would like 
you to indicate on this scale how good or bad your own health is today, in your opinion. Please do this by drawing 
a line from the box below to whichever point on the scale indicates how good or bad your health state is. 
Worst imaginable 0 
health state 
100 Best imaginable 
health state 
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1.25 5-point Severity Scale and 0-10 Numerical Rating Scale 
Do you have pain 
In your arms most days? 
If yes, which arm(s) has been painful? 
How would you describe this pain (mark one only)? 
NoD YesO 
RE] L0 BothO 





If 0 (zero) is no pain at all, and the number 10 (ten) means as painful as it could be, then how painful was it? 
(please give a number between one and ten) 
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1.26 Visual Analogue Scale 
Horizontal visual analogue scale 
If the right hand end of the line is as painful as could be, and the left hand end is no pain, please mark on the line 
where your shoulder pain would be. 
poin i 
J) o/1 
Not hurting Hurting a whole lot 
W discomfort Very uncomfortable 
No pain Seyere pain 
Vertical visual analogue scale 
If the top of the line is as painful as could be, and the bottom end is no pain, please mark on the line where your 
Shoulder pain would be. 
Wn 
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1.27 Upper Extremity Functioning Test 
This tests the subjects' ability to perform typical daily activities. 
1. Combing hair 
2. Using a fork 
3. Picking up a VHS (Video Home System) format videotape 
4. Picking up a full juice can (volume 0.33 litres) 
5. Picking up a full bottle (volume 0.33 litres) 
6. Writing with a pen 
7. Using the telephone receiver 
8. Brushing teeth 
9. Pouring from aI litre juice box 
10. Drinking from a mug (volume 0.25 litres) 
11. Handling finger food 
The activities include palmar grasp (tasks 4,5,7, and 9), lateral grasp (tasks 1,2,3 8, and 10), and precision grip 
(tasks 6 and 11). The test evaluates the ability to handle small objects (tasks 1,2,5,6,8,10, and 11), large 
objects (tasks 3,4,7, and 9), light objects (tasks 1,2,3,6,8, and 11), and heavy objects (tasks 4,5,7,9, and 10). 
The UEFT score is the number of successful repetitions of a task that a subject can perform during a2 minute 
period. A successful operation is one in which the subject grasped, manipulated, and used the object with his or 
her paretic arm. 
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1.28 Drawing Test 
This measures the subject's ability to coordinate shoulder and elbow movements when the hand is moving in the 
horizontal plane within the typical workspace. 
Subjects are asked to track a square (20cm x 20cm) with their paretic; hand. They are instructed not to move their 
trunk and shoulder during the drawing. 
The outcome measure is the ratio between the surface area surrounded by the drawn line and the surface of the 
square expressed as a percent. The time needed to draw the square is also calculated. 
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1.29 Modified Ashworth Scale 
Positioning: 
The patient is examined sitting in a relaxed position 
The patient's shoulder joint is in 90* abduction or less, depending on patient comfort 
The patient's elbow joint is flexed 
The patient's forearm is supported distally 
The patient's upper arm is stabilised proximal to the elbow 
The patient's forearm is in neutral position in terms of pronation/supination 
Ashworth Scale Scoring 
No increase in muscle tone 
Slight increase in muscle tone, manifested by a catch and release or by minimal 
resistance at the end of the range of motion when the affected part(s) is moved in 
flexion or extension 
1+ Slight increase in muscle tone, manifested by a catch, followed by minimal resistance 
throughout the remainder (less than half) of the range of movement (ROM) 
2 More marked increase in muscle tone through most of the ROM, but affected part(s) 
easilv moved 
13 Considerable increase in muscle tone, passive movement difficult 
[4 Affected part(s) rigid in flexion or extension 
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1.30 Reduced Upper Extremity Motor Activity Log Questionnaire 
This is a structured interview that examines how much and how well subjects use their paretic arm. Subjects are 
instructed to rate what they were actually able to do, not what they thought they could do. Subjects are rated on 
the amount they use their paretic arm ("Amount Scale") and the quality of their movement during the functional 
activities ("How Well" Scale). The maximum score in each scale is 60, and the minimum 0. 
The questionnaire includes the following 12 activities: 
I. Pick up phone 
2. Open a door 
3. Eat finger foods 
4. Control the bathroom tap 
5. Pick up a glass, bottle or can 
6. Brush teeth 
7. Use a key to unlock the door 
8. Write on a paper 
9. Use the removable computer storage media (CID or floppy disk) 
10. Use utensils for eating 
11. Pick up a cup by the handle 
12. Carry an object in the hand 
49 
Appendix 2 
2.1 Ethics approval letters 
Newcostle and North Tyneside 
Health Authority 
JOINT ETHICS COMMITTEE 
Newcastle & North Tyneside Health Authority 
University of Newcastle upon Tyne 
University of Northumbria at Newcastle 





19 December 2DOI 
Dr H Rodgers 
Centre for Health Services Research 
21 Claremont Place 
NEWCASTLE UPON TYNE 
NE2 4AA 
Dear Dr Rodgers 
Does Surface Neurornuscull# Sflmulation (NMES) To The Upper Limb Following 
Stroke Improve Outcome? 
(Min Ref 2001/320) 
Your application In respect ýf thIs study was considered at the December meeting of 
the Joint Ethics Committee. 
Before reaching a final deci4ion In respect of your application the Committee wished: 
to know whether the NMES, treatment will be offered to the placebo group if it Is 
found to be effective: 
to seek clarification as to why a placebo group will be Included If it Is likely that they 
will know they am not receýfng the active. treatment. The Committee suggested that 
it might be valuable to ask the patients whether they were aware which group they 
were in; 
(Iii) to seek further details regarding the method used to assess ellgibMity criteria such as 
cognitiveAanguage impairmýnt; and 
(IV) to seek confirmation that NOrthumbria Healthcare NHS Trust will indemnify against 
any injury that results from the treatment being undertaken as well as as a result of 
negligence. 
rodgers 
Please noie revised cotitoc 
tal: (0191)256.3295 
fat (Oigi)258.3099 
leonard. keyCnant-ha. northy. nhs. uk 
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I note the information proviýed in your response to the Committee dated 14 December 
and confirm thaL In the right of this Inforniation, ethical approval is granted In respect of your 
research study application, 
ýours--s)ilnc rely 
Dr PA Heasman 
Ch2in, nan 




24 December 2001 
Dr H Rodgers 
Reader In Stroke Medicine 
Centre for Health Services Research 
21 Claremont Place 
NEWCASTLE UPON TYNE 
NE24AA 






Tel: 01 670 394400 
Fax: 01670 394501 
NLREC 3812001 Does surface neuromuscular electrical stimulation (NMES) to the 
upper limb following acute stroke Improve outcome? 
Dr Church's letter confirming the remaining outstanding issue has been considered 
by the Chair of the LREC and I am pleased to inform you that ethical approval has 
now been given to your study. 
Northumberland Local Research Ethics Committee 'is always Interested in the outcome of 
research and would welcome a copy of any final report which may be produced. This should 
be sent to Dr Sue Gordon, Consultant in Public Health Medicine at the above address. 
Can I also point out that in the event of any major modification in any study, the researcher is 
asked to resubmit the application for approval by the LREC. The Chairman of the LREC 




cc Dr R Barton, R&D Dept, Northumbria Healthcare NHS Trust 
Northumberland 
HEALTH ACTION ZONEE) 
Chairman: Dr Michael O'Brien 
Acting Chief Executive: Dr Stephen Singleton 
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2.2 Screening Questionnaire (WGH) 
Does surface NMES to the upper limb following acute stroke improve outcome? 
SCREENING QUESTIONNAIRE 
Date of screening: Patient's name: 
Ward: Patient's DOB: 
1) Is the patient's usual residence in the catchment area for MCH/BCH? NO YES 
2) Has the patient sustained a stroke within the last 10 days? NO YES 
If you have answered NO to question 1 andlor question Z the patient is inekg/ble, therefore do Lot continue with 
this screening questionnaire. 
3) Does the patient have any other condition likely to significantly 
interfere with rehabilitation? NO YES 
4) Is the pre-stroke OHS score 4 or 5? NO YES 
5) Does the patient have significant UL impairment from a previous 
stroke affecting the same side as the current stroke? NO YES 
Is there an upper limb amputation or atresia (stroke-affected side)? NO YES 
Is there a diagnosis of frozen shoulder, dislocation or fracture 
of the UL (stroke-affected side) within 1 month? NO YES 
Is the patient taking regular analgesia specifically for the UL 
(stroke-affected side)? NO YES 
Does the patient have My_of the following: 
a) permanent pacemaker 
b) implantable defibrillator 
C) metallic shoulder implant (stroke-affected side) 
d) history of life threatening cardiac arrhythmias (e. g. VF/VT)? NO 
ýj YES 1: 1 
If you have answered YES to any of questions 3 to 9, the patient is ineAgible therefore please do not continue with 
this questionnaire. 
Is the patient medically stable? NO YES 
1: 1 
6) Is the patient currently eye opening spontaneously or to speech? NO YES 
Ll 
7) Can the patient obey the following second order commands? 
a) 'Point to the ceiling and then to the curtain. ' 
b) 'Before pointing to the ceiling, touch the chair. ' NO 
El YES 
8) Does the patient have evidence of any of the following: 
a) UL weakness/drift? 
b) Finger nose incoordination? 
C) Star cancellation fail (see over - only perform if 12a&b are 'no') NO YES 
if you have answered NO to any of questions 10-13, the patient is ineAgible. However please review questions 9 and 10 within 
the I 0-day period following stroke as this may alter the patient's eligibility. 
Please keep ALL completed screening questionnaires In the designated file on the ward for collection by Cath Church 
who will visit on Tuesdays and Fridays. If the patient Is eligible for the study (i. e. all the ticked boxes are in bold and 
capital print), please provide the patient with an Information leaflet. Thank you. 
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2.3 Screening Questionnaire (NTGH) 
Does surface NMES to the upper limb following acute stroke Improve outcome? 
SCREENING QUESTIONNAIRE 
Date of screening: Patient's name: 
Ward: Patient's DOB: 
9) Is the patient's usual residence in the catchment area for MCH/BCH? NO YES 
10) Has the patient sustained a stroke within the last 10 days? NO YES 
If you have answered NO to question I andlor question Z the patient is inelýqible therefore do not continue with 
this screening questionnaire. 
11) Does the patient have any other condition likely to significantly 
interfere with rehabilitation? NO YES 
12) Is the pre-stroke OHS score 4 or 5? NO YES 
13) Does the patient have significant UL impairment from a previous 
stroke affecting the same side as the current stroke? NO YES 
Is there an upper limb amputation or atresia (stroke-affected side)? NO YES 
Is there a diagnosis of frozen shoulder, dislocation or fracture 
of the UL (stroke-affected side) within 1 month? NO YES 
Is the patient taking regular analgesia specifically for the UL 
(stroke-affected side)? NO YES 
Does the patient have poLof the following: 
a) permanent pacemaker 
b) implantable defibrillator 
C) metallic shoulder implant (stroke-affected side) 
d) history of life threatening cardiac arrhythmias (e. g. VF/VT)? NO YES 
If you have answered YES to any of questions 3 to 9, the patient is ineAgible therefore please do -not continue with this questionnaire. 
Is the patient medically stable? NO YES 
14) Is the patient currently eye opening spontaneously or to speech? NO 
ýj YES El 
15) Can the patient obey the following second order commands? 
a) 'Point to the ceiling and then to the curtain. ' 
b) 'Before pointing to the ceiling, touch the chair. ' NO 
U YES Ij 
16) Does the patient have evidence of any of the following: 
a) UL weakness/drift? 
b) Finger nose incoordination? 
C) Star cancellation fail (see over - only perform if 12a&b are 'no') NO YES 
if you have answered NO to any of questions 10-13, the patient is Inelligible. However please review questions 9 and 10 within 
the I 0-day period following stroke as this may alter the patient's eligibility. 
Please keep ALL completed screening questionnaires In the designated file on the ward for collection by Cath Church 
who will visit on Mondays and Thursdays. If the patient Is eligible for the study (i. e. all the ticked boxes are In bold and 
capital print), please provide the patient with an Information leaflet. Thank you. 
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2.4 Patient Information Sheet 
Does surface neuromuscular electrical stimulation (NMES) to the upper limb following 
acute stroke improve outcome? 
INFORMATION FOR PATIENTS 
We would like to invite you to participate in a study about arm recovery following stroke. 
Why are we doing this study? 
We are constantly trying to improve the services that are available to people who have had a stroke. Arm 
weakness, numbness and poor co-ordination are common problems following a stroke and there is some evidence 
that electrical stimulation to the arm can help to improve outcome. We are conducting a study to confirm whether 
or not this is the case. 
Do I have to agree to take part? 
We hope that you will want to help us with this important study but if you choose not to take part it will not affect 
your care. Your participation is voluntary and you are free to withdraw at any time without giving a reason. 
What is involved? 
If you agree to participate in the study, we will first ask you a few questions about your stroke and examine your 
arm. This will take up to 20 minutes and once this assessment is completed you will be'randomised' into one of 
two groups. One group will receive the electrical stimulation and the other group will receive placebo ('dummy') 
treatment. Evervone in the studv will stillqet the theraov that thev would normallv receive following a stroke no 
matter which woup thev are in. 
All patients in the study will need to wear the electrical stimulation equipment. The equipment is shown in the 
picture and is similar to a TENS machine which is used to treat pain. The electrodes that deliver the electrical 
current are placed on the surface of the skin around the shoulder. There are no needles involved. The basic 
stimulation is low (30 Hz). We are not sure whether simply wearing the electrodes is effective in improving arm 
recovery following a stroke or whether the electrodes need to deliver electrical current in order to be effective. It is 
therefore important that the 2 groups are the same in every way apart 
from the fact that one group receives the electrical current and the other 
one doesn't. This will enable us to make comparisons and to find out 
IL 
whether the electrical stimulation makes any difference to the function of 
the arm. 
We are recruiting patients into the study within 10 days of their stroke. 
Trained staff will put the equipment on you for 30 minutes initially. Over 
the first week, the time you wear the equipment will gradually increase to 
3 sessions (1 hour each) daily. During these sessions, you wear the 
equipment under your clothes and must avoid getting it wet. 
The full course of electrical stimulation is four weeks but if you are to be discharged from hospital during this 
Period, we can teach a relative, friend or carer to use the equipment so that the treatment can continue at home. 
We will keep a diary to record the sessions of electrical stimulation that you receive and also to record any other 
treatment or therapy that you receive for your stroke. 
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We would like to assess your recovery at the end of the four-week treatment period and again at 3 months 
following your stroke. This will involve a visit to the hospital to see a member of our team who will ask you 
questions about your recovery and measure your arm function. If you prefer, this could be done in your own home. 
Are there any side effects? 
Whilst wearing the equipment, you may notice some tingling of the arm or see some mild jerking of the shoulder 
muscles. We have experience of using this equipment and do not expect it to cause you pain or any significant 
side effects. 
How will this study benefit future stroke patients? 
This study will involve almost 200 people who have suffered a stroke and asks an important question as to whether 
electrical stimulation improves the function of the arm after a stroke. As a result of this work, we shall be able to 
answer this question and improve care and treatment to future stroke patients. 
Will Information obtained from the study be confidential? 
All information obtained will be entirely confidential. The data from this study may be published and will be 
submitted as part of a research thesis. The information however is anonymous and no individuals can be identified 
from the data. 
Will anybody else be told about my participation In the study? 
If you agree to participate, we will contact your GP to let him/her know about the study. 
What if I am harmed as a result of the study? 
If you are harmed by taking part in this research project, there are no special compensation arrangements. If you 
are harmed due to someone's negligence, then you may have grounds for a legal action but you may have to pay 
for it. Regardless of this, if you wish to complain, or have any concerns about any aspect of the way you have 
been approached or treated during the course of this study, the normal National Health Service complaints 
mechanism is available to you. 
What if I have further questions? 
If you would like further information about this study please contact Dr. Catherine Church, The Education Centre, 
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2.6 Consent Form 
Does surface neuromuscular electrical stimulation (NMES) to the 
upper limb following acute stroke improve outcome? 
CONSENTFORM 
No Yes 
Have you read the patient information sheet? 
Have you had an opportunity to ask questions and discuss the study? 
Have all of your questions been answered satisfactorily? 
Have you received enough information about the study? 
Who have you spoken to? 
Dr/Mr/Ms ........................................................................ 
Do you understand that you are free to withdraw from the study at any time? 
Without having to give reason? 
Without affecting your future medical care? 
Do you agree to participate in the study? 
0 
0 
If you are harmed by taking part in this research project, there are no special compensation 
arrangements. If you are harmed due to someone's negligence, then you may have grounds 
for a legal action but you may have to pay for it. Regardless of this, if you wish to complain, 
or have any concerns about any aspect of the way you have been approached or treated 
during the course of this study, the normal National Health Service complaints mechanism is 
available to you. 
Name (Block Capitals) ...................................................................................... 
Signature 
..................................................................................................... 





2.7 Initial Assessment Form 
Does surface neuromuscular electrical stimulation (NIVIES) to the upper limb following 








Date of Birth: 





Next of kin details 













Sex: MaleEl Female 0 
Date of stroke: 
Age: 
F-I ED 
Date of admission: 
Date of randomisation _/_/ 
Patient history 
Is the patient right or left handed? 
Right El Left El Ambidextrous El Uncertain 11 
Has the patient had previous strokes? No Yes 
If no, qo to Qu. 31 
Side of body affected by previous strokes RE] L El Both 
0 Uncertain 0 
Did the patient have residual neurological deficit? No EJ Yes El 
(Describe deficit 
Give the date of the last stroke 
Other co-morbidity 
Known diabetes 
Other relevant co-morbidity 
No 11 Yes El 
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New neurological impairment (from the history, medical notes and clinical examination)" 





Unilateral weakness affecting arm/hand NoFý Yes 
11 YesEJ 
Unilateral weakness affecting leg/ foot No 
11 Yes 11 Yes El 
Sensory deficit affecting face NoD Yes 
11 Yes 7 
Sensory deficit affecting arm/hand No 
11 Yes 11 YesEl 
Sensory deficit affecting leg/foot No[ 
I Yes 11 Yes 11 
Homonymous hemianopia No 11 YesEl YesEl 
Visuospatial disorder e. g. sensory inattention No Yes 
11 YesF-1 
Brainstem/cerebellar signs No Yes 
11 Yes 7 
Other deficit NoEl Yes 7 Yes 7 
Dysphasia NoD Yes D 
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Oxford Handicap Scale 
Please tick one box oniv 
Before your recent stroke, which one of the following best describes you: 
0 1 had no symptoms at all and coped well with life .............................. F-A 
1 1 had a few symptoms but these did not interfere with my 
everyday life ...................................................................................... 71 
2 1 had symptoms which had caused some changes in my 
life but I was still able to look after myself ....................................... 
L-D 
3 1 had symptoms which had significantly changed my life 
and prevented me from coping fully, and I needed some help in 
looking after myself ......................................................................... F-I 
4 1 had quite severe symptoms which meant that I needed to have 
help from other people but I was not so bad as to need 
attention day and night ................................................................... 
ILI 
5 1 had major symptoms which severely handicapped me and 
I needed constant attention day and night ..................................... F-I 
Score F-I 
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Pre-stroke Pain Scale 
In the month prior to your recent stroke, did you have pain 
in your arms for most days? NoEl YesEl 
If yes, which arm(s) has been painful? RE] L0 BothO 
How would you describe this pain (mark one only)? 





If 0 (zero) is no pain at all, and the number 10 (ten) means as painful as it could be, then how 
painful was it? (please give a number between one and ten) 
Post-stroke Pain Scale 
Since your recent stroke, have you had any pain in your arms? NoEl YesD 
If yes, which arm(s) has been painful? R 
11 LEI BothO 
How would you describe this pain (mark one only)? 





If 0 (zero) is no pain at all, and the number 10 (ten) means as painful as it could be, then how 
painful was it? (please give a number between one and ten) 
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Nottingham Extended-ADL Index 
Before your recent stroke, were you living alone? NoEl Yes 
F] Don'tknowEl 
a) Mobility 
In the month before your stroke, did you: 
walk around outside? 
climb stairs? 
get in and out of the car? 
walk over uneven ground? 
cross roads? 
travel on public transport? 
b) In the kitchen 
In the month before your stroke, did you: 
manage to feed yourself? 
manage to make yourself a hot drink? 
take hot drinks from one room to another? 
do the washing up? 
make yourself a hot snack? 
c) Domestic tasks 
In the month before your stroke, did you: 
" manage your own money when you were 
out? 
" wash small items of clothing? 
" do your own shopping? 
" do your own housework? 
" do a full clothes wash? 
d) Leisure Activities 
In the month before your stroke, did you: 
" read newspapers or books? 
" use the telephone? 
" write letters? 
go out socially? 
manage your own garden? 
drive a car? 
Not at With Alone Alone 
all help with easily 
difficulty 
F-I 1: 1 11 
El Fý F-I El 
El Fý F-I F-I 
11 F-1 El 11 
El F-I El F71 
Fý 7 E-1 F-1 
El El 0 11 
El 1: 1 11 El 
El F-1 7 7 
7 7 F-1 El 




El El F-I 
El El El El 
F-I Fý F71 
Fý m Fý 
El F-I Fý El 
El El El Fý 
F-1 F-I El Fl 
El El F-1 El 
Scoring 
0= Not at all 1 =With help 2= On my own with difficulty 3= Alone easily 
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Abbreviated Mental Health Test Scores 
Age 
Time (to nearest hour) 
Address: 42 West Street 




Date of Birth 
Month 
Years of First World War 
Name of monarch 








Sheffield Aphasia Screening Test for Acquired Language 
Disorders 
RECEPTIVE SKILLS Score 1 for correct answer 
Score 0 for incorrect answer 
a. Verbal comprehension of single words 
I'm going to ask you to point to some of the things in the room Score 
door Fý light El chair F-1 
ceiling EJ corner Iý 
b. Comprehension of sequential command 
i) point to the ceiling and then to the curtain 
ii) before pointing to the ceiling, touch the chair 
c. Comprehension of a complex command 
Tap the chair twice with a clenched fist, while looking at the ceiling 
d. Recognition of differences In meaning between words 
I'm going to read you a list of words and I want you to tell me which is the odd one out: 
i) chicken, duck, apple, turkey 
ii) run, drink, walk, sprint 
iii) small, large, massive, huge 
e. Comprehension of a narrative 
I) I'm going to read you a short paragraph and then ask you a question about it. 
John went to the shop to buy a pen. When he got there he found that he had forgotten his wallet, 
so he came home and made himself a cup of tea. 
What should he have taken with him? II 
ii) I'm going to read you another paragraph. 
Mrs Smith visited several shops. She bought a newspaper, a cauliflower, a stamp and some 
sausages. 
What was the second shop she visited ? 
Receptive skills total score 
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EXPRESSIVE SKILLS Score I for correct answer 
Score 0 for incorrect answer 
f. Word finding 
Tell me the names of three well-known places in client's home town. 
Score one mark if three names are given correctly 
g. Abstract word finding 





Describe how you would make a cup of tea. 
A correct answer contains two or more appropriate stages in the right order. 
1. Definitions 





I'd like you to tell me: 
i) why you would use an umbrella; 
ii) why people go on holiday; 
iii) what would you do if you were locked out of the house. 
Expressive skills total score 
Receptive and expressive skills total score 
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Motricity Index 
Arm (in sitting position) 
A. Pinch grip; 2.5cm cube between thumb and forefinger 
B. Elbow flexion; from 90 degrees, voluntary contraction/movement 
C. Shoulder abduction; from against chest 
A. Pinch grip 
0 No movement 
11 Beginnings of prehension (any movement of finger or thumb) 
19 Grips cube, but unable to hold against gravity 
22 Grips cube, held against gravity, but not against weak pull 
26 Grips cube against pull, but weaker than other side 
33 Normal pinch grip 
Score R arm LIFA Score L arm Fn 
B. Elbow flexion 
0 No movement 
9 Palpable contraction in muscle, but no movement 
14 Movement seen, but not full range/not against gravity 
19 Movement; full range against gravity, not against resistance 
25 Movement against resistance, but weaker than other side 
33 Normal power 
Score R arm F-171 Score L arm FILI 
C. Shoulder abduction 
0 No movement 
9 Palpable contraction in muscle, but no movement 
14 Movement seen, but not full range/not against gravity 
19 Movement; full range against gravity, not against resistance 
25 Movement against resistance, but weaker than other side 
33 Normal power 
Score R arm FILI Score L arm F-I Ll 
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Leg (in sitting position) 
D. Ankle dorsiflexion; from plantar flexed position 
E. Knee extension; from 90 degrees, voluntary contraction/movement 
F. Hip flexion; usually from 90 degrees 
D. Ankle Dorsiflexion 
0 No movement 
9 Palpable contraction in muscle, but no movement 
14 Movement seen, but not full range/not against gravity 
19 Movement; full range against gravity, not against resistance 
25 Movement against resistance, but weaker than other side 
33 Normal power 
Score R leg 
DFI 
Score L leg FALI 
E. Knee Extension 
0 No movement 
9 Palpable contraction in muscle, but no movement 
14 Movement seen, but not full range/not against gravity 
19 Movement; full range against gravity, not against resistance 
25 Movement against resistance, but weaker than other side 
33 Normal power 
Score R leg 
LI LI 
Score L leg 
ID LI 
F. Hip Flexion 
0 No movement 
9 Palpable contraction in muscle, but no movement 
14 Movement seen, but not full range/not against gravity 
19 Movement; full range against gravity, not against resistance 
25 Movement against resistance, but weaker than other side 
33 Normal power 
Score R leg F-IF-I Score L leg 1-11-1 
Arm score = scores (1) + (2) + (3) +1 (to make 100) Leg scores (4) + (5) + (6) +1 (to 
make 100) 
TOTAL RIGHT LEG F-1 TOTAL LEFT LEG Ll 
TOTAL RIGHT ARM F- IF -ID TOTAL LEFT ARM FIDE] 
Side score = (ARM + LEG)12 
RIGHT SIDE LILIF-1 LEFT SIDE ID F-I Ll 
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Frenchay Arm Test 
Instructions 
The patient sits at a table with his/her hands on his/her lap. Each task starts 
from this position. The patient scores one for each task completed 
successfully (and nought if he/she fails), and is asked to use each 
hand to: 
RL 
1. Stabilise a ruler while drawing a line with a pencil held in the 
other hand. To pass, the ruler must be held firmly. 
2. Grasp a cylinder (12mm diameter, 5cm long) set on its end 
approximately 15cm from the table edge, lift it about 30cm 
and replace it without dropping. 
3. Pick up a glass half-full of water positioned 15-30cm from 
the table edge, drink some water and replace the glass without 
spilling any water. 
4. Remove and replace a sprung clothes peg from a 10mm 
diameter dowel, 15cm long, set in a1 Ocrn square base, placed 
15-30cm from the table edge. He/she is not to drop the peg 
or knock the dowel over. 
5. Comb his/her hair (or imitate); he/she must comb 









Action Research Arm Test 
Instructions - There are four subtests : Grasp, Grip, Pinch and Gross movement. 
If a subject passes the first the first task in each subtest then they score top marks and move onto the next 
subtest. If a subject fails the first and the second task in a subtest, then they score zero overall for that subtest and 
move onto the next. The patient must be able to sit unaided in order to attempt the test. If not, the patient scores 0. 
Score 0= can perform no part of the test ARAT done 
I= performs test partially Unable to sit (score 0) 
2= completes test, but takes abnormally long time ARAT not done 
3= performs test normally. (Give reason 
Start with the least impaired arm first. 
R L 
a) Grasp 
1. 1 Ocm cube (if score =3 then total = 18 & go to Grip 
2. 2.5cm cube (if Grasp score =0 so far then Grasp total =0& go to Grip 
3. 5cm cube 
4. 7.5cm cube 




1. Pour water glass to glass (if score =3 then total = 12 & go to Pinch) 
2. 2.25cm tube (if Grip score =0 so far then Grip total =0& go to Pinch) 
3. 1cm tube 
4. washer over bolt 
Grip total 
c) Pinch 
1.6mm bearing 3rd finger & thumb (if score =3 then total = 18 & go to Gross) 
2. marble index & thumb (if Pinch score =0 so far then Pinch total =0& go to Gross) 
3.6mm bearing 2nd finger & thumb 
4.6mm bearing 1 st finger & thumb 
5. marble 2nd finger & thumb 
6. marble 3rd finger & thumb 
Pinch total 
d) Gross 
1. Place hand behind head (if score =3 then total =9& finish) 
2. Place hand on top of head 
3. Hand to mouth 
4. 
Gross total : 
ARAT Total F---Il 
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Shoulder Shrug Test 
Subject should be sitting up straight. 
Ask subject to shrug both shoulders together. 
Observer watches for symmetry and then attempts to push down the shoulders. 
Normally it is not possible to force someone's shoulders down with moderate 
effort. 
Score each side in turn 
Scoring 
0= no shoulder elevation at all 
1= elevation of the shoulder, but less marked or weaker than the other side 






National Institute of Health Stroke Scale 
a) Level of consciousness 
0= Alert, keenly responsive 
I= Drowsy, but rousable by minor stimulation to obey, answer, or respond 
2= Stuporous, requires repeated stimulation to attend, or lethargic or obtunded, 
requiring strong or painful stimulation to make movements. 
3= Coma, responds only with reflex motor or autonomic effects, or unresponsive. 
b) Level of consciousness - questions 
Ask patient the month and his/her age. Score first answer. 
0= Answers both correctly 
1= Answers one correctly 
2= Incorrect 
c) Level of consciousness - commands 
Ask patient to open/close hand and eyes. Score if he/she makes unequivocal attempt. 
0= Obeys both correctly 
1= Obeys one correctly 
2= Incorrect 
d) Pupillary response 
0= Both reactive 
I= One reactive 
2= Neither reactive 
e) Best gaze 
0= Normal 
1= Partial gaze palsy; abnormal but not forced deviation 










0 Best visual 
Confrontation testing using finger movements, including double simultaneous stimulation. Use visual threat if 
consciousness or comprehension limit testing, scoring Tfor any asymmetry demonstrated. 
0= No visual loss 
I= Partial hemianopia 
2= Complete hemianopia, to within 5 degrees of fixation 









h) Best motor - arm 
Arms held for 10 seconds at 90 degrees if sitting, 45 degrees if lying. Grade weaker arm. Place arms in position if 
comprehension reduced. 
0= No drift in 10 seconds 
I= Drift, after brief hold 
2= Cannot resist gravity, falling immediately but some effort made 






1) Best motor - leg While lying, patient to hold weaker leg raised 30 degrees for 5 sec. Place leg if comprehension reduced. 
0= No drift in 5 seconds 
1= Drift, lowering within 5 sec 
2= Cannot resist gravity, falling to bed but some effort made 
3= No effort against gravity 
RIGHT SIDE LEFT SIDE 
LD 
j) Plantar reflex 
0= Normal 
I= Equivocal 
2= One extensor 
3= Bilateral extensor 
SCORE 
k) Limb ataxia 
Finger-nose and heel-shin tests performed; ataxia is only scored if out of proportion to weakness. 
score as absent. 
0= Absent 
Ia= Present in arm 
lb= Present in leg 
2= Present in arm and leg 
r-i 





Tested with pin; only hemisensory loss scored. If comprehension or consciousness reduced, only score if obvious 
evidence. 
0= Normal 
1= Partial loss, subjectively different but still felt 
2= Dense loss, unaware of being touched 
m) Neglect 
0= No neglect 
1= Partial neglect, visual, tactile or auditory 
2= Complete neglect, affecting more than one modality 
n) Dysarthria 
0 Normal articulation 
I Mild to moderate dysarthria, slurring some words 









o) Best language 
Assessed from responses during evaluation. 
0= No aphasia 
I= Mild to moderate aphasia; naming errors, paraphrasias, etc. 





TOTAL NIH SCORE 
Ll D 
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Star Cancellation Test 
Place the star chart flat in front of the subject so that the central arrow of the page is in the subject's midline. 
Explain that this is a page full of small stars, big stars and letters. 
You are going to ask them to cross out all the small stars that they can see on the page. 
Demonstrate by crossing out the two small stars immediately above the arrow. 
Give the pen to the subject, or if they are unable to hold the pen ask them to point to the small stars so that you 
can then cross them out. 
Continue to cross out stars until the subject confirms that they cannot see any more. 
There is no time limit, but do not prompt subject or move the page once it has been put in the midline. 
Score : number of stars subject crossed out =_ (max = 54) 
PASS (52 - 54) FAIL (0 - 51) 
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Measurement of humeral external rotation (goniometer) 
Measure with the patient's elbow flexed and the shoulder internally rotated so that the forearm is across the chest. 
Place the goniometer below the arm in a horizontal position with its circle beneath the elbow. Move one prong of 
the goniometer with the forearm whilst passivel externally rotating the patient's arm at the shoulder. Keep the 
other prong in its original position whilst doing this. Read off the range of movement from the goniometer in 
degrees. Repeat with active humeral external rotation. 
Passive range of pain-free movement (degrees) 
Active range of pain-free movement (degrees) 
Basic testing of sharp-dull and hot-cold discrimination 
Use 2 empty plain blood tubes. Fill one tube with hot water from the tap (this should feel hot to your own skin but 
not painful and will be approximately 40-50C) and the other with cold water (room temperature). Ensure that it is 
obvious to you which is hot and which is cold to the touch. Test the affected upper arm, forearm and hand (with 
the patient's eyes closed), and mark as deficit if the patient cannot tell the difference between hot and cold in any 
or all of the areas. 
Hot-cold discrimination deficit No 11 YesEl 
Use a neurotip to test the affected upper arm, forearm and hand (with the patient's eyes closed), and mark as 
deficit if the patient cannot tell the difference between the sharp and dull ends of the neurotip in any or all of the 
areas. 
Sharp-dull discrimination deficit NoEJ YesF] 
Measurement of upper arm girth 
On the affected arm, measure the upper arm girth with a tape measure wrapped around the upper arm from the 
axillary fold. Measure the distance from the acromial process to the tape to aid accuracy of repeat measurements. 
Upper arm girth (in cm) 
Distance from acromion to tape (in cm) 
CT head scan 
Notdone F-I 
Assumed infarct (no clinically relevant infarct on CT) 
11 
Clinically relevant infarct on CT Fý 
Intracerebral haemorrhage El 
CT head scan report (if necessary) 








2.8 GP Letter 
Dear Dr 
Re. 'Does surface neuromuscular electrical stimulation (NMES) to the upper limb following acute stroke improve 
outcomeT 
Your patient has agreed to participate in the above study taking place at North Tyneside General Hospital, 
Wansbeck Hospital and Morpeth Cottage Hospital. 
Loss of upper limb function is a common and distressing problem following stroke. Electrical stimulation with 
surface electrodes is a popular therapy for stroke patients with upper limb pain but further research is needed to 
evaluate the effect of this treatment on recovery and pain. 
We are currently undertaking a rand ornised-controlled trial to evaluate surface NMES in acute stroke. We are 
randomising patients within 10 days of stroke to receive either surface NMES or placebo for a four-week 
intervention period. 
The intervention comprises a standard programme of NMES to the upper limb. Two surface electrodes placed 
over supraspinatus and posterior deltoid on the stroke-affected side are used and the basic stimulation frequency 
is low (30 Hz). The duration of treatment is increased slowly during the 1" week until 3x1 hour treatment 
sessions per day are achieved. This is then administered daily for the next three weeks. Where possible, patients 
who leave hospital before the end of the four-week intervention period will continue to receive surface NMES in 
their own home. Training will be given to patients, carers and support workers to enable them to use the 
equipment. 
Control subjects receive 'sham' electrical stimulation according to the same schedule as the intervention group. 
The 'sham' equipment identical to the surface NMES equipment, but an internal disconnection prevents any 
current being delivered. 
We will assess outcome at the end of the intervention period and at 3 months after stroke in terms of arm function, 
disability and pain. Patients may notice tingling of the arm and some involuntary muscle movement during the 
treatment. However, as we have experience in electrical stimulation and are using a recognised protocol, we do 
not anticipate any significant problems. 
If you would like further information, please contact Dr. Catherine Church, Teaching and Research Fellow in Stroke 
Medicine. Telephone 0191 293 2593 (direct line) or air pager via North Tyneside Hospital switchboard. 
Yours sincerely, 
Dr. Helen Rodgers 
Reader in Stroke Medicine 
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2.9 Information for General Practitioners 
Does surface neuromuscular electrical stimulation (sNMES) to the upper limb following acute stroke 
improve outcome? 
INFORMATION FOR GENERAL PRACTITIONERS 
Your patient has agreed to participate in the above study taking place at North Tyneside General Hospital and 
Wansbeck Hospital. 
Loss of upper limb function is a common and distressing problem following stroke. The literature is unclear about 
the effectiveness of upper limb rehabilitation strategies and there is need to identify interventions that will improve 
upper limb function and reduce the incidence of shoulder pain. 
Electrical stimulation with surface electrodes is a popular therapy for stroke patients with upper limb pain but 
further research is needed to evaluate the effect of this treatment on recovery and pain. 
We are currently undertaking a random ised-controlled trial to evaluate surface neuromuscular electrical stimulation 
(NMES) in acute stroke. We are randomising patients within 10 days of stroke to receive either surface NIMES or 
placebo for a four-week intervention period. 
The intervention will comprise of a standard programme of sNMES to the upper limb. Two surface electrodes 
placed over supraspinatus and posterior deltoid on the stroke-affected side will be used and the basic stimulation 
frequency will be 30 Hz. The duration of treatment will be steadily increased over the first week until 3x1 hour 
treatment sessions per day are achieved. This will then be administered daily for the next three weeks. Where 
possible, patients who leave hospital before the end of the four-week intervention period will continue to receive 
surface NMES in their own home. Training will be given to patients, carers and support workers to enable them to 
use the equipment. 
Control subjects will receive 'sham' electrical stimulation according to the same schedule as the intervention group. 
The 'sham' equipment will be identical to the surface NMES equipment, but an internal disconnection will prevent 
any current being delivered. 
We will assess outcome at the end of the intervention period and at 3 months after stroke in terms of arm function, 
disability and pain. 
Patients may notice tingling of the arm and some involuntary muscle movement during the treatment. However, as 
we have experience in electrical stimulation and are using a recognised protocol, we do not anticipate any 
significant problems. 
If you would like further information, please contact Dr. Catherine Church, Teaching and Research Fellow in Stroke 
Medicine, North Tyneside General Hospital, Rake Lane, North Shields, NE29 8NH. Telephone 0191293 2593 
(direct line). 
78 
2.10 Barthel ADL Index 7 days post stroke 
Function Description Score 
Bowels Incontinent (or needs to be given enema) 0 
L] 
Occasional accidence (once a week) I 
Continent 2 
Bladder Incontinent, or catheterised and unable to manage 0 
Occasional accident (max. once per 24 hours) 1 
Continent (for more than 7 days) 2 
Grooming Needs help with personal care: face, hair, teeth, shaving 0 F-1 
Independent (implements provided) I 
Toilet Use Dependent 0 
Needs some help but can do some things alone I 
Independent (one and off, wiping, dressing) 2 
LJ 
Feeding Unable 0 
Needs help in cutting, spreading butter etc. 1 
Independent (food provided within reach) 2 
Ll 
Transfer Unable - no sitting balance 0 
Major help (physical, I or 2 people), can sit 1 
Minor help (verbal or physical) 2 
Independent 3 
Mobility Immobile 0 
Wheelchair independent, including corners etc. I 
Walks with help of one person (verbal or physical) 2 
Independent 3 
Dressing Dependent 0 
Needs help but can do about half unaided I 
Independent (including buttons, zips, laces etc. ) 2 
Stairs Unable 0 
Needs help (verbal, physical, carrying aid) 1 
Independent up and down 2 
Bathing Dependent 0 
Independent (Bath: must get in and out unsupervised 1 




2.11 Patient Records Label 
THIS PATIENT IS PARTICIPATING IN A STUDY 
EVALUATING THE EFFECTS OF ELECTRICAL 
STIMULATION TO THE UPPER LIMB AFTER 
STROKE. 
Completion Date: 31/05/2004 
For further details, please contact: 
Dr. Cath Church at 
North Tyneside General Hospital on 
0191293 2593 (direct line). 
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2.12 Instruction Sheet 
Does surface neuromuscular electrical stimulation (NMES) to the upper limb following acute stroke improve 
outcome? 
























-1 10 UVEL 
MICROS11141? 
1. Take the box, wires and electrodes out of the packet and ensure that the box number corresponds with the 
number written in the patient's diary. 
2. if this is the patient's first treatment session: 
Write the patient's name on a blank white sticker from the study file and stick it onto their box. 
Open the battery compartment - if there is a green sticker present, the box is a real stimulator (the dummy 
stimulators do not have a sticker here). 
Replace the battery with a new one and discard the old one. 
3. Ensure that the box is switched off (knobs A& B) and that the mode (blue knob) is set at no. 2 (continuous 
mode). 
Ill 
4. Place the patient's arm in the position shown in the above picture with a pillow under the arm for support. 
5. The 1s' electrode site (supraspinatus) is found by locating the mid-point of the clavicle (collarbone) and then 
placing the electrode on the top of the muscle directly above this point. Stick an electrode pad on this site in a 
horizontal position. 
The 2nd electrode site (deltoid) is found on the outside of the arm between the tip of the shoulder and the tip 
of the elbow. Locate the point on this part of the arm a third of the way down from the shoulder and this is the 
2 nd site. Stick an electrode pad on this site in a horizontal position. 
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7. It may be helpful to mark the sites on the arm by drawing around the electrode pads with a waterproof pen. 
8. Attach the red end of the wire to the is' site (red on top) and the black end to the 2 nd site. 
9. Attach the other end of the wire into the hole on the box marked 'N. 
10. Very slowly, turn the knob labelled 'A!. This will turn on the stimulation and a beep will sound. Turn this up 
until muscle movement is seen at the shoulder (the patient is likely to mention some tingling just before this 
happens). The movement will be a 'shrug' of the shoulder. It is best to do all this very slowly to allow the 
patient to get used the sensation. Stop turning knob 'A! once the muscle movement occurs. If no movement is 
seen by intensity level 5, stop turning 'A' anyway (see below). 
11. In the placebo ('dummy) group, the box is identical to those in the intervention group but an internal 
disconnection prevents any current being delivered. In this case, there should be no shoulder movement seen 
and the intensity level (knob 'A') should not be turned up to more than 5. It is important not to indicate to the 
patient that this is the case so that they remain unaware of the group that they are in. 
12. Now turn the mode knob to number 3 (alternate mode). 
13. Write down the intensity level (knob 'A! ) in the patient's diary, as this should remain approximately the same for 
each session (if not, it may be that the battery is running low and needs replacing). 
14. Please record the time the treatment session starts in the patient's diary and sign for the treatment in the 
patient's drug kardex. 
15. A timer is provided with each box to be used for each session and will be a reminder to turn off the equipment 
once the treatment session is complete. This timer needs to be set to time either 30 mins or 1 hour depending 
on the session being given. 
16. The protocol for the timing of the NMES is the same in both the intervention group and the control group and is 
detailed in the patient's diary and on the drug kardex. 
17. During treatment sessions, the equipment must not get wet. 
18. At the end of the session, turn off the stimulator (knob A) and turn the mode (blue knob) back to no. 2 ready for 
the next session. Record the stop time in the patient's diary. 
19. In between sessions, the box is unplugged from the electrodes. The electrodes can be left in place all day 
unless the patient is to have a bath/shower. If this is the case, the electrodes should be removed, moistened 
slightly with tap water, and stuck back on their original pad. They should then be put back in their plastic bag 
and the bag resealed to prevent evaporation of moisture from the electrode gel. 
What if there are problems? 
Below is a list of possible problems with likely solutions: 
NOTE that faults maybe difficult to detect, as some of the stimulators are 'dummys'. For this reason, a green 
sticker is present in the battery compartment of each real stimulator whereas there is no sticker in the dummy 
ones. This means that a member of staff can determine the nature of a particular stimulator should there be 
concerns that there may be a fault. It is however important that the patient is not told which stimulator they have. 
No output and no indicator lights (for real/dummys): 
- Battery incorrectly installed - reconnect battery. 
. Exhausted battery - replace battery. 
- Faulty stimulator - inform Cath Church 
No output but the indicator lights oi)erate (real stims): 
- Broken stimulation lead - replace lead. 
- Fault with channel A -try the stimulation using channel B instead. 
- Faulty stimulator - inform Cath Church 
The stimulator's output produces the wrong movement (real stims): 
Incorrect electrode positions - check with diagram and/or consult other staff (e. g. ward physio/doctor, 
Cath Church). 
Incorrect level of stimulation - the level may be too high or too low. 
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- Poor electrode contact - re-apply or replace electrodes. 
The movement produced is weaker than normal (real stims): 
- Insufficient stimulation - increase the stimulation level. 
- Electrode condition may be poor - replace the electrodes. 
The stimulation is painful: 
- Incorrect electrode positions - In particular, if the patient has pain around the 2nd electrode site, try 
moving the electrode pad slightly higher up the arm and try the treatment again following the above 
guidelines. 
- Poor electrode contact - clean and re-apply electrodes. 
- Excessively high stimulation intensity - adjust the intensity level (knob A). 
- If the treatment remains painful, try again with the red and black leads the other way round so that the 
black is on top. 
- If none of the above measures are successful, contact Cath Church. 
The stimulator bleeps for 30 seconds and then switches itself off (real/dummys): 
- Low battery - replace the battery. 
Precautions 
" Avoid handling the electrodes while the stimulator is on. Always remember to turn OFF the stimulator before 
you remove the electrodes. 
" Do not immerse the electrodes in water. Clean them using a damp cloth. 
" Always wash and dry the skin carefully when the electrodes have been removed. Do not use skin creams near 
the electrode sites. 
"A slight reddening of the skin under the electrode is normal. This should fade after about an hour once the 
electrodes are removed. If stimulation causes long-term marking of the skin, discontinue use and contact Cath 
Church. 
" Do not place electrodes over broken skin or shave the area under the electrodes as this may cause skin 
irritation. 
" Spastic tone may be affected by electrical stimulation. If you notice any adverse change in the spasticity, 
discontinue use and contact Cath Church. 
" Do not use the stimulator within 3 metres of physiotherapy short wave diathermy equipment. 
" The stimulator is not to be used by people who have implanted electronic devices (e. g. pacemakers). 
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2.13 Patient Diary 
WEEK I DAY I DAY 2 DAY 3 DAY 4 DAY 5 DAY6 DAY 7 
Date 
Intensity level 
30 mins NMES 30 mins NMES 30 mins NMES 30 mins WES I hour NMES I hour NIVIES I hour NIVIES 
Session I 
Start time Start time Start time Start time Start time Start time Start time 
8am 
Stop time Stop time Stop time Stop time Stop time Stop time Stop time 
None given None given F-1 None given None given None given None given None given 
No NIVIES No NMES 30 mins NMES 30 mins WES 1 hour NMES I hour NIVIES I hour NIVIES 
Session 2 
Start time Start time Start time Start time Start time 
12prn 
Stop time Stop time Stop time Stop time 
None given 
Stop time 
None given El None given EJ None given El EJ 
None given 
30 mins NMES 30 mins NMES 30 mins NMES 30 mins NIVIES 30 mins NMES 30 mins NMES 1 hour NIVIES 
Session 3 
Start time Start time Start time Start time Start time Start time Start time 
6prn 
Stop time Stop time Stop time Stop time Stop time Stop time Stop time_ 
None given None given None given El None given El None give EJ None given 0 None gi en ID 
Difficulties 
encountered/ 
reasons for non- 




Issue 1 Apnl 2002 NHS Tikist 
NMES Study - Hospital Newsletter 
Does surface neuromuscular electrical stimulation (NMES) to the upper limb following acute 
stroke improve outcome? 
Loss of arm function is a common and distressing problem following a stroke. Electrical stimulation 
is a popular therapy for stroke patients with arm pain but further research is needed to evaluate the 
effect of this treatment on arm recovery and pain. The NMES study began in January 2002 and is 
taking place in Wansbeck, North Tyneside and Morpeth I lospitals. The input of ward staff is crucial 
to the success of this study and the purpose of sending out regular newsletters will be to keep 
everyone up to date on the progress of the study. 
A quick reminder of the airris of the study: 
To Compare the arm ftmction and impairment of stroke patients who receive a programme of surface NMRS to the arm (the 
intervention group) with those receiving placebo (the control group). 
To compare the prevalence of post stroke arm pain between the intervention and control group. 
To compare disability and global health status of the intervention and control group. 
To seek the experiences and views of patients about surface NMES. 
Methods 
All patient-, admitted to North Tvneside and Wansbeck HospitaLs within 10 days of acute stroke are assessed to determine 
whether or not they are eligible for entry into the study. Written consent is taken from eligible patients and ba-whne assessments 
are performed. 'llie patients are then 'randomised' to receive either electrical stimulation or placebo for a 4-week period. Out- 
con-Ae assessments are undertaken at 4 weeks and 3 months following the stroke. -11114" 
NMES 
'llie stimulation ý% given 3 times daily for a 4-week period. Detailed instructions for use 
are found in the studv files on the wards and it is vital that the sessions are recorded in 
the patient's diary. If patients are to be discharged within the 4-week period, 
please contact Cath Church who will review them on the ward prior to discharge. 
Progress 
171 patients have been screened so far and 25 eligible patients entered into the study. 16 four-week assessments are complete 
and the three-month assessments will commence at the beginning of April. 
Lunchtime meefiM! 
In order to update you all further on the study and, in particular, to provide further training for staff in the use of the NMF-S 
equipment, lunchtime meetings have been arranged in each of the 3 hospitals. They will take place fi-om I-2prn on the following 
dates and a sandwich lunch will be available from 1230pm. 
" Friday 19th April in the Lecture'llieatre, Education Centre at Wansheck Hospital. 
" Tuesday 23, d Apra in Classrooms 5&6, Education Centre at North Tyneside Hospital. 
" Friday 26th April in the Committee Room on Ward 2 at Morpeth Cottage Hospital. 
If you would like to attend, please return the shp below tO Cath Church at Wansbcck HoTital or North Tweside 
I lospital. 'I'his will give an idea of numbers for catering puq? oses. 
RETURN SLIP NMES STUDY 
I shall/shall not be able to attend the lunchtime meeting on Tuesday 23, d April (Delete as applicable) 
Name Ward - 
Please reply to Dr. Cath Church, Teaching and Research Fello- in Stroke Medicine, Education Centre, 
North Tyneside General Hospital, Rake Lane, North Shields NE29 8NH 
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2.15 Four-week Assessment Form 
Does surface neuromuscular electrical stimulation (sNMES) to the upper limb following acute 
stroke Improve outcome? 
4-WEEK PATIENT DETAILS 
4-week assessment due: 
Name of patient 
Dead 
Date of death (if applicable) 
Patient discharged 
Date of discharge (if applicable) 
Ward and hospital of death/discharge 
NoEl Yes El 
NoEl Yes 
Patient readmitted to hospital No Yes 
Details of readmission 
Current contact address 





Current Tel. No. 
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Other interventions for UL pain since last stroke 
New medical problems 
None F-I 
Oral analgesia F-I 
Steroid injectionD 
TENS F-I 




New UL problems 
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DOES SURFACE NEUROMUSCULAR 
ELECTRICAL STIMULATION (sNMES) TO THE 
UPPER LIMB FOLLOWING ACUTE STROKE 
IMPROVE OUTCOME? 
<<<<<<<<<<<<<<>>>>>>>>>>>>>> 




Date of Assessment: 
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How would you describe this pain? (mark one only) 






If 0 (zero) Is no pain at all and 10 (ten) means as painful as it could be, then how painful was It? 
(Please give a number between 1 and 10). 






Oxford Handicap Scale -4 week 
Please tick one box onlv 
Which one of the following best describes you: 
01 have no symptoms at all and cope well with life .............................. 
II have a few symptoms but these do not interfere with my 
everyday life 
21 have symptoms which have caused some changes in my 
life but I am still able to look after myself 
31 have symptoms which have significantly changed my life 
and prevented me from coping fully, and I need some help in 
looking after myself 
41 have quite severe symptoms which mean that I need to have 
LI 
help from other people but I am not so bad as to need 
attention day and night 
51 have major symptoms which severely handicap me and 
LI 
I need constant attention day and night 
Score F-I 
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Barthel ADL Index -4 week 
Function Description Score 
F-1 Bowels Incontinent (or needs to be given enema) 0 
Occasional accidence (once a week) I 
Continent 2 
L] 
Bladder Incontinent, or catheterised and unable to manage 0 
Occasional accident (max. once per 24 hours) 1 
Continent (for more than 7 days) 2 
G rooming Needs help with personal care: face, hair, teeth, shaving 0 
Independent (implements provided) 1 
T oilet Use Dependent 0 
Needs some help but can do some things alone 1 
Independent (one and off, wiping, dressing) 2 
Feeding Unable 0 
Ll 
Needs help in cutting, spreading butter etc. I 
Independent (food provided within reach) 2 
Transfer Unable - no sitting balance 0 
El 
Major help (physical, 1 or 2 people), can sit 1 
Minor help (verbal or physical) 2 
Independent 3 
Mobility Immobile 0 
D 
Wheelchair independent, including corners etc. 1 
Walks with help of one person (verbal or physical) 2 
Independent 3 
Dressing Dependent 0 
Ll 
Needs help but can do about half unaided I 
Independent (including buttons, zips, laces etc. ) 2 
Stairs Unable 0 
Needs help (verbal, physical, carrying aid) 1 
Independent up and down 2 
Bathing Dependent 0 F-1 
Independent (Bath: must get in and out unsupervised 1 
and wash self. Shower: unsupervised/unaided. 
Total (0-20) FIFA 
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Star Cancellation Test -4 week 
" Place the star chart flat in front of the subject so that the central arrow of the page is in the 
subject's midline. 
" Explain that this is a page full of small stars, big stars and letters. 
" You are going to ask them to cross out all the small stars that they can see on the page. 
41 Demonstrate by crossing out the two small stars immediately above the arrow. 
" Give the pen to the subject, or if they are unable to hold the pen ask them to point to the small 
stars so that you can then cross them out. 
" Continue to cross out stars until the subject confirms that they cannot see any more. 
" There is no time limit, but do not prompt subject or move the page once it has been put in the 
midline. 
Score : number of stars subject crossed out (max = 54) 
PASS (52-54) FAIL (0 - 51) 
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Motricity Index -4 week 
Arm (in sitting position) 
A. Pinch grip; 2.5cm cube between thumb and forefinger 
B. Elbow flexion; from 90 degrees, voluntary contraction/movement 
C. Shoulder abduction; from against chest 
A- Pinch grip 
0 No movement 
11 Beginnings of prehension (any movement of finger or thumb) 
19 Grips cube, but unable to hold against gravity 
22 Grips cube, held against gravity, but not against weak pull 
26 Grips cube against pull, but weaker than other side 
33 Normal pinch grip 
Score R arm 
Fl Ll 
Score L arm 
B. Elbow flexion 
0 No movement 
9 Palpable contraction in muscle, but no movement 
14 Movement seen, but not full range/not against gravity 
19 Movement; full range against gravity, not against resistance 
25 Movement against resistance, but weaker than other side 
33 Normal power 
Score R arm F-I F-I Score L arm F-11-1 
C. Shoulder abduction 
0 No movement 
9 Palpable contraction in muscle, but no movement 
14 Movement seen, but not full range/not against gravity 
19 Movement; full range against gravity, not against resistance 
25 Movement against resistance, but weaker than other side 
33 Normal power 
Score R arm FIF] Score L arm F-I F-I 
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Leg (in sitting position) 
D. Ankle dorsiflexion; from plantar flexed position 
E. Knee extension; from 90 degrees, voluntary contraction/movement 
F. Hip flexion; usually from 90 degrees 
E. Ankle Dorsiflexion 
0 No movement 
9 Palpable contraction in muscle, but no movement 
14 Movement seen, but not full range/not against gravity 
19 Movement; full range against gravity, not against resistance 
25 Movement against resistance, but weaker than other side 
33 Normal power 
Score R leg FID Score L leg 1-11-1 
E. Knee Extension 
0 No movement 
9 Palpable contraction in muscle, but no movement 
14 Movement seen, but not full range/not against gravity 
19 Movement; full range against gravity, not against resistance 
25 Movement against resistance, but weaker than other side 
33 Normal power 
Score R leg 
LI LI 
Score L leg 
LI LI 
F. Hip Flexion 
0 No movement 
9 Palpable contraction in muscle, but no movement 
14 Movement seen, but not full range/not against gravity 
19 Movement; full range against gravity, not against resistance 
25 Movement against resistance, but weaker than other side 
33 Normal power 
Score R leg FILI Score L leg F-I 0 
Arm score = scores (1) + (2) + (3) +I (to make 100) Leg scores (4) + (5) + (6) +1 (to make 100) 
TOTAL RIGHT LEG 
TOTAL RIGHT ARM 
FIFILI 
FIDLJ 
TOTAL LEFT LEG 
TOTAL LEFT ARM 
F-I F-I D 
F-I 1-1 Ll 
Side score = (ARM + LEG)12 
RIGHT SIDE 
Ll D El 
LEFT SIDE F-1 Ll D 
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Shoulder Shrug Test -4 week 
" Subject should be sitting up straight. 
" Ask subject to shrug both shoulders together. 
" Observer watches for symmetry and then attempts to push down the shoulders. 
" Normally it is not possible to force someone's shoulders down with moderate 
effort. 
0 Score each side in turn : 
Scoring 
0= no shoulder elevation at all 
1= elevation of the shoulder, but less marked or weaker than the other side 






Frenchay Arm Test -4 week 
Instnictions 
The patient sits at a table with his/her hands on his/her lap. Each task starts 
from this position. The patient scores one for each task completed 
successfully (and nought if he/she fails), and is asked to use each 
hand to: 
RL 
6. Stabilise a ruler while drawing aline with a pencil held in the 
other hand. To pass, the ruler must be held firmly. 
7. Grasp a cylinder (12mm diameter, 5cm long) set on its end 
approximately 15cm from the table edge, lift it about 30cm 
and replace it without dropping. 
8. Pick up a glass half-full of water positioned 15-30cm from 
the table edge, drink some water and replace the glass without 
spilling any water. 
9. Remove and replace a sprung clothes peg from a1 Omm 
diameter dowel, 15cm long, set in a1 Ocrn square base, placed 
15-30cm from the table edge. He/she is not to drop the peg 
or knock the dowel over. 
10. Comb his/her hair (or imitate); he/she must comb 









Action Research Arm Test -4 week 
Instructions - There are four subtests : Grasp, Grip, Pinch and Gross movement. 
If a subject passes the first the first task in each subtest then they score top marks and move onto the next subtest. If 
a subject fails the first and the second task in a subtest, then they score zero overall for that subtest and move onto 
the next. The patient must be able to sit unaided in order to attempt the test. If not, the patient scores 0. 
Score 0= can perform no part of the test 
1= performs test partially 
2= completes test, but takes abnormally long time 
3= performs test normally. 
Start with the least impaired arm first. 
ARAT done 
Unable to sit (score 0) 




7.10cm cube (if score =3 then total = 18 & go to Grip 
8.2.5cm cube (if Grasp score =0 so far then Grasp total =0& go to Grip 
9.5cm cube 
10.7.5cm cube 




5. Pour water glass to glass (if score =3 then total = 12 & go to Pinch) 
6.2.25cm tube (if Grip score =0 so far then Grip total =0& go to Pinch) 
7.1cm tube 
8. washer over bolt 
Grip total 
Pinch 
7.6mm bearing 3rd finger & thumb (if score =3 then total = 18 & go to Gross) 
8. marble index & thumb (if Pinch score =0 so far then Pinch total 0& go to Gross) 
9.6mm bearing 2nd finger & thumb 
10.6mm bearing 1 st finger& thumb 
11. marble 2nd finger & thumb 
12. marble 3rd finger & thumb 
Pinch total 
d) Gross 
5. Place hand behind head (if score 3 then total 9& finish) 
6. Place hand on top of head 





Measurement of humeral external rotation (goniorneter) 
Measure with the patient's elbow flexed and the shoulder internally rotated so that the forearm is 
across the chest. Place the goniometer below the arm in a horizontal position with its circle beneath 
the elbow. Move one prong of the goniometer with the forearm whilst passivel externally rotating the 
patient's arm at the shoulder. Keep the other prong in its original position whilst doing this. Read off 
the range of movement from the goniometer in degrees. Repeat with active humeral external rotation. 
Passive range of pain-free movement (degrees) 
Active range of pain-free movement (degrees) 
Measurement of upper arm girth 
On the affected arm, measure the upper arm girth with a tape measure wrapped around the upper 
arm from the axillary fold. Measure the distance from the acromial process to the tape to aid accuracy 
of repeat measurements. 
Upper arm girth (in cm) 
Distance from acrornion to tape (in cm) 
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2.16 Three-month Assessment Form 
Does surface neuromuscular electrical stimulation (sNMES) to the upper limb following acute 
stroke Improve outcome? 
THREE-MONTH PATIENT DETAILS 
3-month assessment due: 
Name of patient 
Dead 
Date of death (if applicable) 
Patient discharged 
Date of discharge (if applicable) 
Ward and hospital of death/discharge 
Patient readmitted to hospital 





Current contact address 





Current Tel. No. 
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Other interventions for UL pain since last stroke 
None F-I 







New medical problems (since I month assessment) 
New UL problems (since 1 month assessment) 





DOES SURFACE NEUROMUSCULAR 
ELECTRICAL STIMULATION (sNMES) TO THE 







Date of Assessment: 
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Does surface neuromuscular electrical stimulation (sNMES) to the 
upper limb following acute stroke improve outcome? 










How would you describe this pain? Excruciating (very severe) 






If 0 (zero) Is no pain at all and 10 (ten) means as painful as it could be, then how 
painful was it? (Please give a number between 1 and 10). 






Oxford Handicap Scale -3 month 
Please tick one box onl 
Which one of the following best describes you: 
01 have no symptoms at all and cope well with life .............................. 
LI 
II have a few symptoms but these do not interfere with my 
everyday life ...................................................................................... 
ID 
21 have symptoms which have caused some changes in my 
life but I am still able to look after myself ....................................... 
31 have symptoms which have significantly changed my life 
and prevented me from coping fully, and I need some help in 
looking after myself ......................................................................... F-I 
41 have quite severe symptoms which mean that I need to have 
help from other people but I am not so bad as to need 
attention day and night ................................................................... 
71 
51 have major symptoms which severely handicap me and 




Barthel ADL Index 3 months post stroke 
Function Description Score 
L] 
Bowels Incontinent (or needs to be given enema) 0 
Occasional accidence (once a week) 1 
Continent 2 
LJ 
Bladder Incontinent, or catheterised and unable to manage 0 
Occasional accident (max. once per 24 hours) 1 
Continent (for more than 7 days) 2 
L] 
Grooming Needs help with personal care: face, hair, teeth, shaving 0 
Independent (implements provided) 1 
F-1 Toilet Use Dependent 0 
Needs some help but can do some things alone 1 
Independent (one and off, wiping, dressing) 2 
L] 
Feeding Unable 0 
Needs help in cutting, spreading butter etc. 1 
Independent (food provided within reach) 2 
ID 
Transfer Unable - no sitting balance 0 
Major help (physical, I or 2 people), can sit 1 
Minor help (verbal or physical) 2 
Independent 3 
Mobility Immobile 0 F-1 
Wheelchair independent, including corners etc. 1 
Walks with help of one person (verbal or physical) 2 
Independent 3 
Dressing Dependent 0 
Ll 
Needs help but can do about half unaided I 
Independent (including buttons, zips, laces etc. ) 2 
Stairs Unable 0 
L] 
Needs help (verbal, physical, carrying aid) 1 
Independent up and down 2 
Bathing Dependent 0 
L] 
Independent (Bath: must get in and out unsupervised 1 
and wash self. Shower: unsupervised/unaided. 
Total (0-20) FILI 
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Nottingham Extended-ADL Index -3 month 
Are you living alone? 
a) Mobility 
In the last month, did you: 
walk around outside?. 
climb stairs? 
get in and out of the car? 
walk over uneven ground? 
cross roads? 
travel on public transport? 
b) In the kitchen 
In the last month, did you: 
manage to feed yourself? 
manage to make yourself a hot drink? 
take hot drinks from one room to another? 
do the washing up? 
make yourself a hot snack? 
q) Domestic tasks 
In the last month, did you: 
manage your own money when you were 
out? 
wash small items of clothing? 
do your own shopping? 
do your own housework? 
do a full clothes wash? 
d) Leisure Activities 
In the last month, did you: 
read newspapers or books? 
use the telephone? 
write letters? 
go out socially? 
manage your own garden? 
drive a car? 
No El Yes F-I Don't knowEl 
Not at With Alone Alone 
all help with easily 
difficulty 
1: 1 1: 1 F-1 El 
El El 
El El 
0 F-I 11 
El F-I F-I El 
El 0 El 
0 El El 
Fý D El El 
F-1 F-1 Fý El 
El F-I F-I El 
Fý 11 7 El 
0 F-I F-I F-1 
El 11 F1 
F-I m El 
F-I m m F-1 
El El F-I El 
El F-I 7 F-1 
El F-1 F-I 
F-I 0 F-I 
11 Fý El El 
El F-1 F-I 0 
F-1 El Fý El 
Scoring 
0= Not at all I =With help 2= On my own with difficulty 3= Alone easily 
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Star Cancellation Test -3 month 
" Place the star chart flat in front of the subject so that the central arrow of the page is in the 
subject's midline. 
" Explain that this is a page full of small stars, big stars and letters. 
" You are going to ask them to cross out all the small stars that they can see on the page. 
" Demonstrate by crossing out the two small stars immediately above the arrow. 
" Give the pen to the subject, or if they are unable to hold the pen ask them to point to the small 
stars so that you can then cross them out. 
" Continue to cross out stars until the subject confirms that they cannot see any more. 
" There is no time limit, but do not prompt subject or move the page once it has been put in the 
midline. 
Score : number of stars subject crossed out (max = 54) 
PASS (52 - 54) FAIL (0 - 51) 
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Motricity Index -3 month 
Arfn (in sitting position) 
A. Pinch grip; 2.5cm cube between thumb and forefinger 
B. Elbow flexion; from 90 degrees, voluntary contraction/movement 
C. Shoulder abduction; from against chest 
A. Pinch grip 
0 No movement 
II Beginnings of prehension (any movement of finger or thumb) 
19 Grips cube, but unable to hold against gravity 
22 Grips cube, held against gravity, but not against weak pull 
26 Grips cube against pull, but weaker than other side 
33 Normal pinch grip 
Score R arm 
L] ID 
Score L arm 
LIL) 
B. Elbow flexion 
0 No movement 
9 Palpable contraction in muscle, but no movement 
14 Movement seen, but not full range/not against gravity 
19 Movement; full range against gravity, not against resistance 
25 Movement against resistance, but weaker than other side 
33 Normal power 
Score R arm F-I F-I Score L arm FID 
C. Shoulder abduction 
0 No movement 
9 Palpable contraction in muscle, but no movement 
14 Movement seen, but not full range/not against gravity 
19 Movement; full range against gravity, not against resistance 
25 Movement against resistance, but weaker than other side 
33 Normal power 
Score R arm FIF] Score L arm F] 1-1 
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Leg (in sitting position) 
D. Ankle dorsiflexion; from plantar flexed position 
E. Knee extension; from 90 degrees, voluntary contraction/movement 
F. Hip flexion; usually from 90 degrees 
F. Ankle Dorsiflexion 
0 No movement 
9 Palpable contraction in muscle, but no movement 
14 Movement seen, but not full range/not against gravity 
19 Movement; full range against gravity, not against resistance 
25 Movement against resistance, but weaker than other side 
33 Normal power 
Score R leg F-I F-I Score L leg FILJ 
E. Knee Extension 
0 No movement 
9 Palpable contraction in muscle, but no movement 
14 Movement seen, but not full range/not against gravity 
19 Movement; full range against gravity, not against resistance 
25 Movement against resistance, but weaker than other side 
33 Normal power 
Score R leg FID Score L leg FID 
F. Hip Flexion 
0 No movement 
9 Palpable contraction in muscle, but no movement 
14 Movement seen, but not full range/not against gravity 
19 Movement; full range against gravity, not against resistance 
25 Movement against resistance, but weaker than other side 
33 Normal power 
Score R leg 
1-1 D 
Score L leg 
1-1 L) 
Arm score = scores (1) + (2) + (3) +I (to make 100) Leg scores (4) + (5) + (6) +1 (to make 100) 
TOTAL RIGHT LEG 
TOTAL RIGHT ARM 
F-I F-I F-I 
F-I F-I F-I 
TOTAL LEFT LEG 
TOTAL LEFT ARM 
F-I F] Ll 
F-I D F-I 
Side score = (ARM + LEG)12 
RIGHT SIDE 
Ll El Ll 
LEFT SIDE FIFID 
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Shoulder Shrug Test -3 month 
" Subject should be sitting up straight. 
" Ask subject to shrug both shoulders together. 
" Observer watches for symmetry and then attempts to push down the shoulders. 
" Normally it is not possible to force someone's shoulders down with moderate 
effort. 
0 Score each side in turn : 
Scoring 
0= no shoulder elevation at all 
I= elevation of the shoulder, but less marked or weaker than the other side 
2= unable to force down the shoulder. 
RIGHT SIDE F-1 LEFT SIDE Ll 
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Frenchay Arm Test -3 month 
Instnictions 
The patient sits at a table with his/her hands on his/her lap. Each task starts 
from this position. The patient scores one for each task completed 
successfully (and nought if he/she fails), and is asked to use each 
hand to: 
RL 
11. Stabilise a ruler while drawing a line with a pencil held in the 
other hand. To pass, the ruler must be held firmly. 
12. Grasp a cylinder (12mm diameter, 5cm long) set on its end 
approximately 15cm from the table edge, lift it about 30cm 
and replace it without dropping. 
13. Pick up a glass half-full of water positioned 15-30cm from 
the table edge, drink some water and replace the glass without 
spilling any water. 
14. Remove and replace a sprung clothes peg from a1 Omm 
diameter dowel, 15cm long, set in a1 Ocrn square base, placed 
15-30cm from the table edge. He/she is not to drop the peg 
or knock the dowel over. 
15. Comb his/her hair (or imitate); he/she must comb 









Action Research Arm Test -3 month 
Instructions - There are four subtests : Grasp, Grip, Pinch and Gross movement. 
If a subject passes the first the first task in each subtest then they score top marks and move onto the next 
subtest. If a subject fails the first and the second task in a subtest, then they score zero overall for that subtest and 
move onto the next. The patient must be able to sit unaided in order to attempt the test. If not, the patient scores 0. 
Score 0= can perform no part of the test 
I= performs test partially 
2= completes test, but takes abnormally long time 
3= performs test normally. 
Start with the least impaired arm first. 
ARAT done 
Unable to sit (score 0) 




13.10cm cube (if score =3 then total = 18 & go to Grip 
14.2.5cm cube (if Grasp score =0 so far then Grasp total =0& go to Grip 
15.5cm cube 
16.7.5crn cube 




9. Pour water glass to glass (if score =3 then total = 12 & go to Pinch) 
10.2.25cm tube (if Grip score =0 so far then Grip total =0& go to Pinch) 
11.1 cm tube 
12. washer over bolt 
Grip total 
c) Pinch 
13.6mm bearing 3rd finger & thumb (if score =3 then total = 18 & go to Gross) 
14. marble index & thumb (if Pinch score =0 so far then Pinch total 0& go to Gross) 
15.6mm bearing 2nd finger & thumb 
16.6mm bearing 1 st finger & thumb 
17. marble 2nd finger & thumb 
18. marble 3rd finger & thumb 
Pinch total 
d) Gross 
9. Place hand behind head (if score 3 then total 9& finish) 
10. Place hand on top of head 





Measurement of humeral external rotation (goniometer) 
Measure with the patient's elbow flexed and the shoulder internally rotated so that the forearm is across the chest. 
Place the goniometer below the arm in a horizontal position with its circle beneath the elbow. Move one prong of 
the gonlometer with the forearm whilst passively externally rotating the patient's arm at the shoulder. Keep the 
other prong in its original position whilst doing this. Read off the range of movement from the goniometer in 
degrees. Repeat with active humeral external rotation. 
Passive range of pain-free movement (degrees) 
Active range of pain-free movement (degrees) 
Measurement of upper arm girth 
On the affected arm, measure the upper arm girth with a tape measure wrapped around the upper arm from the 
axillary fold. Measure the distance from the acromial process to the tape to aid accuracy of repeat measurements. 
Upper arm girth (in cm) 
Distance from acrornion to tape (in cm) 
Patient views about sNMES 
Which stimulator were you given? 
Did you have symptoms from the stirn (e. g. tingling) 
Was the stim painful? 
How did you find the stim? 
Real D DummyEl UncertainEl 
NoEl Yes 0 
NoEl YesO 
Please review the Nottingham Health Profile questionnaire (see Appendix 1.20) with 
participant to ensure that all questions completed. 
Questionnaire completed 
If no, please give reason 
NoEl Yes El 
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2.17 Gantt Chart 
Month Research Activity, "-- Teaching Activity Other 
Nov-Dec 2001 Discussions with clinicians about Teaching sessions on the 
study. Register for MD. Obtain ethical Clinical Skills course. 
and trust approval for study. Apply for 
funding. Establish study - develop 
protocols. Test sNMES equipment and 
train ward staff. 
Nov 2001 - Sept Monthly project meetings. Final year teaching, dental Weekly clinic and 1 In 14 
2004 student teaching, stage on call. SpR training 
visits, accelerated visits days. BGS meetings bi- 
(throughout thty! ýar). Lýýnýon . _nonthly_L Jan 2002 - Feb 2004 Recruit 186 patients. 
Jan 2002 Critical appraisal course. 
Feb 2002 - May 2004 4 week and 2m nth follow ups -or----- 
BASP/BSRG 
March - May 2002 Statistics course Hospital Clinical Practice Spring BGS Meeting 
Course - preparation, (April) 
teaching and OSCE 
June 2002 Final OSLER and OSCE. RITA 
Tea=ýLKiN.. 
July 2002 Write methods section of thesis. MD Dental OSCE examiner. 
assessment 1 due. 1$t a praisal. 
August 2002 2 weeks in the USA 
Sept - Nov 2002 Clinical Skills course - Autumn BGS meeting 
preparation, teaching and (Oct) 
OSCE. Cert Med Ed. Away 
days (Oct/Nov 
Dec 2002 Poster presentation at Trust R&D day. Stage 4 OSCE 
_Leý! 
g LTLarlýir . 
Jan 2003 Poster resentation at BSRG BASP/BSRG 
Feb - Apr 2003 Critical appraisal of relevant papers for FOCP preparation. Hospital Trust away days. Access 
thesis introduction. Plan outline of Clinical Practice course - course (March). 
thesis chapters. Revise methods preparation, teaching & Spring BGS (April). 
section. 2 nd appraisal. Posters for OSCE 
BGS and ESC. 
May - June 2003 MD assessment 1 (submit report I Write and submit portfolio for ESC (May) 
month prior to this) Cert Med Ed 
June 2003 Final OSLER and OSCE. RITA 
Team rnýing. 
June-Sept 2003 Further preparation for 
FOCP 
Sept - Dec 2003 FOCP course - preparation, Autumn BGS (Oct) 
teachin and OSCE 
Nov 2003 Submit MD assessment 3 
Dec 2003 Design results tables for thesis. Write FOCP teaching. Stage 4 
plan/read papers for review. Plan/read OSCE. FOCP OSCE. Team 
for Stroke prevention paper. marking. Accelerated visit. 
Jan-June 2004 Work on review and Stroke prevention Teaching on the CIDR and 
_pgper. 
ID couLses o nightly) 
Jan 2004 Submit MD assessment 3. Complete Stage visit BASP/BSRG 
recruitment. 
Feb 2004 MD assessment 3 
March 2004 Com lete 4 week assessments 
March-Ma. 2004 Finalise thesis introduction 
_ýLay 
2004 Complete 3 month assessments Spring BGS 
June 2004 Final OSCE and OSLER. RITA 
TýamMarkiýg. 
May-Dec 2004 Analysis and writing of results and 
(Extended until June complete thesis. Submission of paper 
05 due to sick leave) to peer reviewed journal. 
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2.18 Inter-observer Assessment Form 
Does surface neuromuscular electrical stimulation (sNMES) to the upper 
limb following acute stroke improve outcome? 
INTER-OBSERVER FORM 
Motricity Index - Inter-observer 
Arm (in sitting position) 
A. Pinch grip; 2.5cm cube between thumb and forefinger 
B. Elbow flexion; from 90 degrees, voluntary contraction/movement 
C. Shoulder abduction; from against chest 
A- Pinch grip 
0 No movement 
11 Beginnings of prehension (any movement of finger or thumb) 
19 Grips cube, but unable to hold against gravity 
22 Grips cube, held against gravity, but not against weak pull 
26 Grips cube against pull, but weaker than other side 
33 Normal pinch grip 
Score R arm 
1-1 Ll 
Score L arm 
B. Elbow flexion 
0 No movement 
9 Palpable contraction in muscle, but no movement 
14 Movement seen, but not full range/not against gravity 
19 Movement; full range against gravity, not against resistance 
25 Movement against resistance, but weaker than other side 
33 Normal power 
Score R arm 
F-I F-I 
Score L arm F-IF-I 
C. Shoulder abduction 
0 No movement 
9 Palpable contraction in muscle, but no movement 
14 Movement seen, but not full range/not against gravity 
19 Movement; full range against gravity, not against resistance 
25 Movement against resistance, but weaker than other side 
33 Normal power 
Score R arm FIFI Score L arm F-11-1 
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Leg (in sitting position) 
D. Ankle dorsiflexion; from plantar flexed position 
E. Knee extension; from 90 degrees, voluntary contraction/movement 
F. Hip flexion; usually from 90 degrees 
G. Ankle Dorsiflexion 
0 No movement 
9 Palpable contraction in muscle, but no movement 
14 Movement seen, but not full range/not against gravity 
19 Movement; full range against gravity, not against resistance 
25 Movement against resistance, but weaker than other side 
33 Normal power 
Score R leg F-I F-I Score L leg F-I LI 
E. Knee Extension 
0 No movement 
9 Palpable contraction in muscle, but no movement 
14 Movement seen, but not full range/not against gravity 
19 Movement; full range against gravity, not against resistance 
25 Movement against resistance, but weaker than other side 
33 Normal power 
Score R leg 
DD 
Score L leg 
DD 
F. Hip Flexion 
0 No movement 
9 Palpable contraction in muscle, but no movement 
14 Movement seen, but not full range/not against gravity 
19 Movement; full range against gravity, not against resistance 
25 Movement against resistance, but weaker than other side 
33 Normal power 
Score R leg 
F-I F-I 
Score L leg F-I 1-1 
Arm score = scores (1) + (2) + (3) +1 (to make 100) Leg scores (4) + (5) + (6) +1 (to make 100) 
TOTAL RIGHT LEG 
TOTAL RIGHT ARM 
r-inr-1 
r-Inn 
TOTAL LEFT LEG 
TOTAL LEFT ARM 
FIFIL) 
FIFY-] 
Side score = (ARM + LEG)12 
RIGHT SIDE FIFALI LEFT SIDE LII-in 
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Shoulder Shrug Test - Inter-observer 
" Subject should be sitting up straight. 
" Ask subject to shrug both shoulders together. 
" Observer watches for symmetry and then attempts to push down the shoulders. 
Normally it is not possible to force someone's shoulders down with moderate 
effort. 
Score each side in turn 
Scoring 
0= no shoulder elevation at all 
1= elevation of the shoulder, but less marked or weaker than the other side 
2= unable to force down the shoulder. 
RIGHT SIDE LEFT SIDE 
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Frenchay Arm Test - Inter-observer 
Instructions 
The patient sits at a table with his/her hands on his/her lap. Each task starts 
from this position. The patient scores one for each task completed 
successfully (and nought if he/she fails), and is asked to use each 
hand to: 
RL 
16. Stabilise a ruler while drawing a line with a pencil held in the 
other hand. To pass, the ruler must be held firmly. 
17. Grasp a cylinder (12mm diameter, 5cm long) set on its end 
approximately 15cm from the table edge, lift it about 30cm 
and replace it without dropping. 
18. Pick up a glass half-full of water positioned 15-30cm from 
the table edge, drink some water and replace the glass without 
spilling any water. 
19. Remove and replace a sprung clothes peg from a 10mm 
diameter dowel, 15cm long, set in a1 Ocrn square base, placed 
1 5-30cm from the table edge. He/she is not to drop the peg 
or knock the dowel over. 
20. Comb his/her hair (or imitate); he/she must comb 










Action Research Arm Test - Inter-observer 
Instructions - There are four subtests : Grasp, Grip, Pinch and Gross movement. 
If a subject passes the first the first task in each subtest then they score top marks and move onto the next 
subtest. If a subject fails the first and the second task in a subtest, then they score zero overall for that subtest and 
move onto the next. The patient must be able to sit unaided in order to attempt the test. If not, the patient scores 0. 
Score 0= can perform no part of the test 
1= performs test partially 
2= completes test, but takes abnormally long time 
3= performs test normally. 
Start with the least impaired arm first. 
ARAT done 
Unable to sit (score 0) 




19.10cm cube (if score =3 then total = 18 & go to Grip 
20.2.5cm cube (if Grasp score =0 so far then Grasp total 0& go to Grip 
21.5cm cube 
22.7.5cm cube 




13. Pour water glass to glass (if score =3 then total = 12 & go to Pinch) 
14.2.25cm tube (if Grip score =0 so far then Grip total =0& go to Pinch) 
15.1 cm tube 
16. washer over bolt 
Grip total 
q) Pinch 
19.6mm bearing 3rd finger & thumb (if score =3 then total = 18 & go to Gross) 
20. marble index & thumb (if Pinch score =0 so far then Pinch total 0& go to Gross) 
21.6mm bearing 2nd finger & thumb 
22.6mm bearing 1 st finger & thumb 
23. marble 2nd finger & thumb 
24. marble 3rd finger & thumb 
Pinch total 
d) Gross 
13. Place hand behind head (if score 3 then total 9& finish) 
14. Place hand on top of head 






Measurement of humeral external rotation (goniometer) 
Measure with the patient's elbow flexed and the shoulder internally rotated so that the forearm is across the chest. 
Place the goniometer below the arm in a horizontal position with its circle beneath the elbow. Move one prong of 
the goniometer with the forearm whilst passivel externally rotating the patient's arm at the shoulder. Keep the 
other prong in its original position whilst doing this. Read off the range of movement from the goniometer in 
degrees. Repeat with active humeral external rotation. 
Passive range of pain-free movement (degrees) 
Active range of pain-free movement (degrees) 
Measurement of upper arm girth 
On the affected arm, measure the upper arm girth with a tape measure wrapped around the upper arm from the 
axillary fold. Measure the distance from the acromial process to the tape to aid accuracy of repeat measurements. 
Upper arm girth (in cm) 




3.1 Search Strategy for RCTs and Reviews of ES 
Medline (Ovid) 1966-2004, CINAHL (Ovid) 1982-2004, Embase (Ovid) 1980-2004, and the Cochrane Controlled 
Trials Register. 
The following terms were searched: 
I. electric stimulation/ 
2. electric$ stimulation. tw 
3.1 or 2 
4. cerebrovasc$. tw 
5. stroke. tw 
6. herniplegia/ 
7. (hemipleg$ or hemipar$). tw 
8.4 or 5 or 6 or 7 
9. upper limb 
10. arm 
11. shoulder 
12. (upper limb$ or arm$ or shoulder$). tw 
13.9 or 10 or 11 or 12 
14.3 and 8 and 13 
132 articles found on Medline (Ovid) 1966-2004; 77 found on CINAHL (Ovid) 1982-2004; 124 found on Embase 
(Ovid) 1980-2004; and 40 found on the Cochrane Controlled Trials Register. 
RCTs and review articles (in English) of upper limb ES in stroke patients were selected. 
Initially 12 RCTs and 8 review articles were assessed in detail. Other relevant articles were identified by a manual 
search following this. 
Methodological quality of articles was assessed using the SIGN guidelines (168) (Appendix 3.2). 
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3.2 SIGN guidelines: Methodology Checklist for RCTs 
(168) 
Guideline 50 Notes on the use of Methodology Checklist 2: Randomised Controlled T... Page I of 3 
SIGN SO: A guideline developers' handbook 
Notes on the use of Methodology Checklist 2: Randomised 
(9 
Controlled Trials 
Section I identifies the study, the reviewer, the guideline for which the paper is being 
considered as evidence, and the key question(s) it is expected to address. The 
reviewer is asked to consider a series of aspects of RCT design and to make a 
judgement as to how well the current study meets this criterion. Each relates to an 
aspect of methodology that research has shown makes a significant difference to the 
conclusions of a study. 
For each question in this section you should use one of the following to indicate how 
well it has been addressed in the study: 
o Well covered 
o Adequately addressed 
0 Poorly addressed 
0 Not addressed (i. e. not mentioned, or indicates that this aspect of study design 
was ignored) 
0 Not reported (i. e. mentioned, but insufficient detail to allow assessment to be 
made) 
0 Not applicable. 
1.1 The study addresses an appropriate and cleady focused question 
Unless a clear and well defined question is specified, it will be difficult to assess how 
well the study has met its objectives or how relevant it is to the question you are trying 
to answer on the basis of its conclusions. 
1.2 The assignment of subjects to treatment groups randomised 
Random allocation of patients to receive one or other of the treatments under 
investigation, or to receive either treatment or placebo, is fundamental to this type of 
study. If there is no indication of randomisation, the study should be rejected. If 
the description of randomisation is poor, the study should be given a lower quality 
rating. Processes such as alternate allocation, allocation by date of birth, or day of the 
week attending a clinic are not true randomisation processes and it is easy for a 
researcher to work out which patients received which treatment. These studies should 
therefore be classed as Controlled Clinical Trials rather than RCTs. 
1.3 An adequate concealment method is used 
Allocation concealment refers to the process used to ensure that researchers are 
unaware which group patients are being allocated to at the time they enter the study. Research has shown that where allocation concealment is inadequate, investigators 
can overestimate the effect of interventions by up to 40%. Centralised allocation, 
computerised allocation systems, or the use of coded identical containers would all be 
regarded as adequate methods of concealment, and may be taken as indicators of a 
well conducted study. If the method of concealment used is regarded as poor, or 
relatively easy to subvert, the study must be given a lower quality rating, and can be 
rejected if the concealment method is seen as inadequate. 
http: //www. sign. ac. uk/guidclinestfulltext/50/notes2. html 18/10/2005 
122 
Guideline 50 Notes on the use of Methodology Checklist 2: Randomised Controlled T... Page 2 of 3 
1.4 Subjects and investigators are kept 'blind'to treatment allocation 
Blinding refers to the process whereby people are kept unaware of which treatment 
an individual patient has been receiving when they are assessing the outcome for that 
patient. It can be carded out up to three levels. Single blinding is where patients are 
unaware of which treatment they are receiving. In double blind studies neither the 
doctor nor the patient knows which treatment is being given, In very rare cases 
studies may be triple blinded, where neither patients, doctors, nor those conducting 
the analysis are aware of which patients received which treatment. The higher the 
level of blinding, the lower the risk of bias in the study. 
1.5 The treatment and control groups were similar at the start of the trial 
Patients selected for inclusion in a trial must be as similar as possible. The study 
should report any significant differences in the composition of the study groups in 
relation to gender mix, age, stage of disease (if appropriate), social background, 
ethnic origin, or comorbid conditions. These factors may be covered by inclusion and 
exclusion criteria, rather than being reported directly. Failure to address this question, 
or the use of inappropriate groups, should lead to the study being downgraded. 
1.6 The only difference between the groups is the treatment under investigation 
If some patients received additional treatment, even if of a minor nature or consisting 
of advice and counselling rather than a physical intervention, this treatment is a 
potential confounding factor that may invalidate the results. If groups were not 
treated equally, the study should be rejected unless no other evidence is 
available. If the study is used as evidence it should be treated with caution. 
1.7 All relevant outcomes measured in a standard, valid and reliable way 
The primary outcome measures used should be clearly stated in the study. If the 
outcome measures are not stated, or the study bases its main conclusions on 
secondary outcomes, the study should be rejected. Where outcome measures 
require any degree of subjectivity, some evidence should be provided that the 
measures used are reliable and have been validated prior to their use in the study. 
1.8 What percentage of the individuals or clusters recruited into each treatment arm of 
the study dropped out before the study was completed? 
The number of patients that drop out of a study should give concern if the number is 
very high. Conventionally, a 20% drop out rate is regarded as acceptable, but this 
may vary. Some regard should be paid to why patients dropped out, as well as how 
many. It should be noted that the drop out rate may be expected to be higher in 
studies conducted over a long period of time. A higher drop out rate will normally lead 
to downgrading, rather than rejection of a study. 
1.9 All the subjects are analysed in the groups to which they were randomly allocate 
(intention to treat analysis) 
In practice, it is rarely the case that all patients allocated to the intervention group 
receive the intervention throughout the trial, or that all those in the comparison group 
do not. Patients may refuse treatment, or contra-indications arise that lead them to be 
switched to the other group. If the comparability of groups through randomisation is to 
http: //www. sign. ac. uk/guidelines/fulltext/50/ýotes2. htmi 18/10/2005 
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Guideline 50 Notes on the use of Methodology Checklist 2: Randomised. Controlled T... Page 3 of 3 
be maintained, however, patient outcomes must be analysed according to the group 
to which they were originally allocated irrespective of the treatment they actually 
received. (This is known as intention to treat analysis. ) If it is clear that analysis was 
not on an intention to treat basis, the study may be rejected. If there is little other 
evidence available, the study may be included but should be evaluated as if it were a 
non-randomised cohort study. 
1.10 Mere the study is carried out at more than one site, results are comparable for 
all sites 
In multi-site studies, confidence in the results should be increased if it can be shown 
that similar results were obtained at the different participating centres. 
Section 2 relates to the overall assessment of the paper. It starts by rating the 
methodological quality of the study, based on your responses in Section 1 and using 
the following coding system: 
++ 
All or most of the criteria have been fulfilled. Where they have not been fulfilled 
the conclusions of the study or review are thought very unlikely to alter. 
+ 
Some of the criteria have been fulfilled. Those criteria that have not been fulfilled 
or not adequately described are thought unlikely to alter the conclusions. 
Few or no criteria fulfilled. The conclusions of the study are thought. likely, or. very 
likely to alter. 
The code allocated here, coupled with the study type, will decide the level of 
evidence that this study provides. 
The aim of the other questions in this section is to summarise your view of the quality 
of this study and its applicability to the patient group targeted by the guideline you are 
working on. 
Section 3 asks you to summarise key points about the study that will be added to an 
evidence table at the next stage of the process. It is important that you complete this section as fully as possible, and Include actual data from the study 
wherever relevant. 
[Annex C] [Checklist] 
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Methodology Checklist 2: Randornised Controlled Trials 
SIGN 
Study identification (include author, title, year of publication, journal title, pages) 
Guideline topic: 
TKey Question No: 
Checklist completed byý 
ýCTIDN I.. INTERNAL VALIDITY 
In a well conducted RCT study ..... In this study this criterion 
is:: 
11 The study addresses an appropriate and clearly Well covered Not addressed 
focused question Adequately addressed Not reported 
Poorly addressed Not applicable 
1.2 The assignment of subjects to treatment groups is Well covered Not addressed 
randomised Adequately addressed Not reported 
Poorly addressed Not applicable 
1.3 An adequate concealment method is used Well covered Not addressed 
Adequately addressed Not reported 
Poorly addressed Not applicable 
1.4 Subjects and investigators are kept'blind' about Well covered Not addressed 
treatment allocation Adequately addressed Not reported 
Poorly addressed Not applicable 
15 The treatment and control groups are similar at the Well covered Not addressed 
start of the trial Adequately addressed Not reported 
Poorly addressed Not applicable 
The only difference between groups is the treatment i Well covered Not addressed 
under investigation Adequately addressed Not reported 
Poorly addressed Not applicable 
1.7 All relevant outcomes are measured in a standard, 
-- I-Well covered Not addressed 
valid and reliable way Adequately addressed Not reported 
Poorly addressed Not applicable 
1.8 What percentage of the individuals or clusters recruited 
into each treatment arm of the study dropped out 
before the study was completed? 
1.9 All the subjects are analysed in the groups to which Well covered Not addressed they were randomly allocated (often referred to as 




Not a licable pp 
1.10 Where the study is carried out at more than one site, Well covered Not addressed 
results are comparable for all sites Adequately addressed Not reported 
Poorly addressed Not applicable 
h6ýýFNT OF THE 4TUDY. 
21 How well was the study done to minimise bias? 
- 
Code ++, +, or - i--- --- 
22 If coded as +, or what is the likely direction in which 
-- ----------- 
bias might affect the study results? 
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23 Taking into account clinical considerations, your 
evaluation of the methodology used, and the statistical 
power of the study, are you certain that the overall 
effect is due to the study intervention? 
2.4 Are the results of this study directly applicable to the 
patient group targeted by this guideline? 
1 ' ý ý. 0 - 
31 How many patients are tricluded in this study? 
Please indicate number in each arm of the study, at 
the time the study began 
3,2 What are the main characteristics of the patient 
population? 
Include all relevant characteristics - e. g. age, sex, 
ethnic origin, comorbidity. disease status, 
communitylbospital based 
3.3 What intervention (treatment, procedure) is being 
investigated in this study? 
List all interventions covered by the study. 
3.4 What comparisons are made in the study? 
Are comparisons made between treatments, or 
between treatment and placebo /no treatment? 
3.5 How long are patients followed-up in the study? 
Length of time patients are followed from beginning 
participation in the study Note specified end points 
used to decide end of follow-up (e. g. death, complete 
cure) Note if follow-up period is shorter than originally 
planned 
3.6 ii What outcome measure(s) are used in the study? 
List all outcomes that are used to assess effectiveness 
of the interventions used. 
37 What size of effect is identified in the study? 
List all measures of effect in the units used in the study 
-eg absolute or relative risk, NNT etc. Include p 
values and any confidence intervals that are provided. 
38 How was this study funded? 
List all sources of funding quoted in the article, whether 
Government, voluntary sector. or industry. 
3.9 Does this study help to answer your key question? 
Summanse the main conclusions of the study and 
indicate how it relates to the key question. 
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